EP4188469A1 - Composite scaffold for the repair, reconstruction, and regeneration of soft tissues - Google Patents
Composite scaffold for the repair, reconstruction, and regeneration of soft tissuesInfo
- Publication number
- EP4188469A1 EP4188469A1 EP21854425.2A EP21854425A EP4188469A1 EP 4188469 A1 EP4188469 A1 EP 4188469A1 EP 21854425 A EP21854425 A EP 21854425A EP 4188469 A1 EP4188469 A1 EP 4188469A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- scaffold
- composite scaffold
- approximately
- composite
- microporous matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002131 composite material Substances 0.000 title claims abstract description 522
- 230000008439 repair process Effects 0.000 title claims abstract description 79
- 210000004872 soft tissue Anatomy 0.000 title description 21
- 230000008929 regeneration Effects 0.000 title description 11
- 238000011069 regeneration method Methods 0.000 title description 11
- 238000000034 method Methods 0.000 claims abstract description 137
- 238000004519 manufacturing process Methods 0.000 claims abstract description 64
- 239000011159 matrix material Substances 0.000 claims description 327
- 239000011148 porous material Substances 0.000 claims description 193
- 239000004753 textile Substances 0.000 claims description 184
- 239000011800 void material Substances 0.000 claims description 167
- 102000008186 Collagen Human genes 0.000 claims description 86
- 108010035532 Collagen Proteins 0.000 claims description 86
- 229920001436 collagen Polymers 0.000 claims description 86
- 239000000243 solution Substances 0.000 claims description 66
- 125000006850 spacer group Chemical group 0.000 claims description 65
- 239000000463 material Substances 0.000 claims description 57
- 229920000642 polymer Polymers 0.000 claims description 56
- 239000000835 fiber Substances 0.000 claims description 48
- -1 poly(ortho esters) Polymers 0.000 claims description 46
- 229920001223 polyethylene glycol Polymers 0.000 claims description 34
- 239000012530 fluid Substances 0.000 claims description 33
- 210000002435 tendon Anatomy 0.000 claims description 32
- 239000002202 Polyethylene glycol Substances 0.000 claims description 30
- 230000008569 process Effects 0.000 claims description 28
- 210000003041 ligament Anatomy 0.000 claims description 27
- 229920001610 polycaprolactone Polymers 0.000 claims description 27
- 230000009102 absorption Effects 0.000 claims description 26
- 238000010521 absorption reaction Methods 0.000 claims description 26
- 239000000654 additive Substances 0.000 claims description 26
- 239000004632 polycaprolactone Substances 0.000 claims description 26
- 239000000017 hydrogel Substances 0.000 claims description 25
- 229920000954 Polyglycolide Polymers 0.000 claims description 18
- 230000003592 biomimetic effect Effects 0.000 claims description 18
- 238000004132 cross linking Methods 0.000 claims description 18
- 230000000996 additive effect Effects 0.000 claims description 17
- 230000008859 change Effects 0.000 claims description 17
- 238000001746 injection moulding Methods 0.000 claims description 16
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims description 16
- 239000000622 polydioxanone Substances 0.000 claims description 16
- 230000008021 deposition Effects 0.000 claims description 15
- 238000004108 freeze drying Methods 0.000 claims description 15
- 238000010146 3D printing Methods 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 14
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 14
- 229910052753 mercury Inorganic materials 0.000 claims description 14
- 230000035699 permeability Effects 0.000 claims description 14
- 238000009940 knitting Methods 0.000 claims description 13
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 13
- 239000004626 polylactic acid Substances 0.000 claims description 13
- 210000003484 anatomy Anatomy 0.000 claims description 12
- 230000003542 behavioural effect Effects 0.000 claims description 12
- 238000000110 selective laser sintering Methods 0.000 claims description 12
- 239000006260 foam Substances 0.000 claims description 10
- 238000006073 displacement reaction Methods 0.000 claims description 8
- 238000001125 extrusion Methods 0.000 claims description 7
- 229920005615 natural polymer Polymers 0.000 claims description 7
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 230000008961 swelling Effects 0.000 claims description 5
- 206010061223 Ligament injury Diseases 0.000 claims description 4
- 208000021945 Tendon injury Diseases 0.000 claims description 4
- 238000000149 argon plasma sintering Methods 0.000 claims description 4
- 238000010894 electron beam technology Methods 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 238000001053 micromoulding Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229920002732 Polyanhydride Polymers 0.000 claims description 3
- 229920001710 Polyorthoester Polymers 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 3
- 238000005187 foaming Methods 0.000 claims description 3
- 229920001519 homopolymer Polymers 0.000 claims description 3
- 229910052743 krypton Inorganic materials 0.000 claims description 3
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 claims description 3
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 3
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims description 3
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 3
- 239000004633 polyglycolic acid Substances 0.000 claims description 3
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims description 3
- 229920002959 polymer blend Polymers 0.000 claims description 3
- 229920001299 polypropylene fumarate Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 238000000807 solvent casting Methods 0.000 claims description 3
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 claims description 3
- 238000009941 weaving Methods 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 239000013590 bulk material Substances 0.000 claims 3
- 230000002787 reinforcement Effects 0.000 abstract description 15
- 239000010410 layer Substances 0.000 description 95
- 210000001519 tissue Anatomy 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 37
- 239000007943 implant Substances 0.000 description 34
- 230000017423 tissue regeneration Effects 0.000 description 32
- 229920001432 poly(L-lactide) Polymers 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 22
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 22
- 230000006835 compression Effects 0.000 description 21
- 238000007906 compression Methods 0.000 description 21
- 239000004744 fabric Substances 0.000 description 20
- 210000000481 breast Anatomy 0.000 description 19
- 210000000513 rotator cuff Anatomy 0.000 description 19
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 17
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 17
- 206010019909 Hernia Diseases 0.000 description 17
- 210000002744 extracellular matrix Anatomy 0.000 description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- 229920001661 Chitosan Polymers 0.000 description 14
- 101001072202 Homo sapiens Protein disulfide-isomerase Proteins 0.000 description 14
- 102100036352 Protein disulfide-isomerase Human genes 0.000 description 14
- 238000005266 casting Methods 0.000 description 14
- 229920002791 poly-4-hydroxybutyrate Polymers 0.000 description 14
- RBMHUYBJIYNRLY-UHFFFAOYSA-N 2-[(1-carboxy-1-hydroxyethyl)-hydroxyphosphoryl]-2-hydroxypropanoic acid Chemical compound OC(=O)C(O)(C)P(O)(=O)C(C)(O)C(O)=O RBMHUYBJIYNRLY-UHFFFAOYSA-N 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 13
- 229920001434 poly(D-lactide) Polymers 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 12
- 230000003416 augmentation Effects 0.000 description 12
- 238000013461 design Methods 0.000 description 12
- 238000002513 implantation Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 230000008595 infiltration Effects 0.000 description 11
- 238000001764 infiltration Methods 0.000 description 11
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000035876 healing Effects 0.000 description 10
- 238000011068 loading method Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000001186 cumulative effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000005499 meniscus Effects 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000515 collagen sponge Substances 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 210000003423 ankle Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000010339 dilation Effects 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 229920004943 Delrin® Polymers 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000005273 aeration Methods 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 230000003190 augmentative effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000009954 braiding Methods 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 239000000512 collagen gel Substances 0.000 description 4
- 210000004439 collateral ligament Anatomy 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 210000002832 shoulder Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012867 bioactive agent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000002967 posterior cruciate ligament Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000009991 scouring Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 208000030922 Tibial Meniscus injury Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000005313 bioactive glass Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001523 electrospinning Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012792 lyophilization process Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 230000000278 osteoconductive effect Effects 0.000 description 2
- 230000002138 osteoinductive effect Effects 0.000 description 2
- 210000003903 pelvic floor Anatomy 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 229920006210 poly(glycolide-co-caprolactone) Polymers 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 239000012209 synthetic fiber Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 239000002407 tissue scaffold Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010060954 Abdominal Hernia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102000004954 Biglycan Human genes 0.000 description 1
- 108090001138 Biglycan Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 208000027536 Femoral Hernia Diseases 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 208000034991 Hiatal Hernia Diseases 0.000 description 1
- 206010020028 Hiatus hernia Diseases 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010021620 Incisional hernias Diseases 0.000 description 1
- 208000029836 Inguinal Hernia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- LKFHUFAEFBRVQX-UHFFFAOYSA-N decanedioic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)CCCCCCCCC(O)=O LKFHUFAEFBRVQX-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 238000002389 environmental scanning electron microscopy Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 1
- 238000009998 heat setting Methods 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000005297 material degradation process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002074 melt spinning Methods 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000002459 porosimetry Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 206010045458 umbilical hernia Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/08—Muscles; Tendons; Ligaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
- B29C64/40—Structures for supporting 3D objects during manufacture and intended to be sacrificed after completion thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/12—Mammary prostheses and implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0063—Implantable repair or support meshes, e.g. hernia meshes
- A61F2002/0068—Implantable repair or support meshes, e.g. hernia meshes having a special mesh pattern
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
- A61F2002/0086—Special surfaces of prostheses, e.g. for improving ingrowth for preferentially controlling or promoting the growth of specific types of cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0061—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof swellable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
- A61F2240/002—Designing or making customized prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Definitions
- the disclosure relates to tissue repair and reconstruction, and, more specifically, to a composite scaffold useful for stabilizing tissue injuries or defects while facilitating the regeneration of new tissue.
- Biologic and synthetic scaffolds for use in tissue engineering applications and surgical repairs and reconstructions are known, however, few are capable of providing the optimal combination of a sufficient: porosity for cellular ingrowth, biologic matrix and surface area for cell migration and proliferation, interconnected void volume and dimensions for meaningful extracellular matrix deposition and tissue regeneration, composite mechanical properties and mechanical load sharing with local tissues to encourage functional tissue maturation while resisting collapse or compression under said mechanical loading, and bio-resorption timeline which supports the tissue repair through complete healing while facilitating the regeneration of functional tissue.
- Some scaffolds such as hernia mesh have sufficient mechanical properties to complete a surgical repair, but lack the behavioral characteristics which are not optimally suited for healing and regeneration of soft tissues of the knee, ankle, shoulder elbow and hand, and non- musculoskeletal soft tissue.
- Many such scaffolds are made of permanent synthetic polymers which can elicit acute or chronic adverse inflammation, pain, or complications.
- many meshlike scaffolds are essentially two-dimensional with insufficient surface area for cell ingrowth and insufficient void volume for bulk tissue regeneration, and, therefore are not conducive to regenerating functional tissue.
- biologic scaffolds for the repair and reconstruction of soft tissues are derived from bulk tissues harvested and processed from either allogenous or xenogeneous sources, and often have slow or incomplete healing due to any combination of bulk architecture, tissue source, and processing method.
- Highly processed biologic materials that are reconstructed into entirely new architectures, such as collagen gels or sponges, can be produced with suitable porosity for tissue ingrowth but lacking suitable strength and resistance to collapse for use for ligament or tendon repair.
- a scaffold which provides a secondary support matrix capable of encouraging cell growth spaced apart from the scaffold to encourage tendon or ligament tissue ingrowth.
- the composite scaffold comprises a support structure which defines a void volume.
- a porous material or hydrogel is disposed within a void volume of the support structure.
- the support structure reinforces and supports the porous material/hydrogel, enhance the tensile strength of the scaffold and resists compression as the scaffold is extended or subject to elongation forces.
- the porous material/ hydrogel has a porosity and void volume that allows adequate extracellular matrix deposition and new functional tissue regeneration.
- the void volume is contiguous or essentially contiguous along the long axis of the scaffold, which allows cells to fully migrate within the device and for new tissue to form with an orientation in the axial direction of the scaffold, while being protected from significant collapse, compression or excessive dilation during mechanical loading or tensioning of the scaffold.
- all or part of the scaffold may be hydrated with biologic fluids such as blood, bone marrow aspirate, platelet rich plasma, autologous or allogeneic cells to modulate or direct the immune response and further facilitate and accelerate healing and tissue regeneration.
- the disclosed composite scaffold possesses a large surface area for cellular proliferation and migration, but also a sufficiently large, interconnected void space to allow tissue ingrowth, extracellular matrix deposition, and biomechanical remodeling into functional tissue. Further, the scaffold possesses the ability to maintain a highly porous structure under tension, e.g. resisting collapse, during a surgical procedure and following implantation thereby maintaining the ability for cell infiltration and new tissue ingrowth throughout the entire scaffold under physiological loadings. These loadings are mechanically shared between the device and local tissue due to the composite mechanical properties of the device, i.e., prevents stress shielding of proximal, repaired, or native tissues, as well as the developing neotissue within the scaffold itself.
- composite mechanical properties encourage the mechanobiological signaling of cells within the scaffold to differentiate and form load-bearing, oriented extracellular matrix and connective tissues.
- the disclosed composite scaffold can be manufactured using various different textile and composite manufacturing methods, and is not limited to a singular manufacturing technology.
- the disclosed composite scaffold provides a highly porous and flexible structure that substantially maintains its three-dimensional shape under tension and provides mechanical reinforcement of the repair or reconstruction-first via scaffold mechanical properties, and subsequently, through newly regenerated functional tissue as the scaffold is resorbed.
- the disclosed scaffold may have distinct regions with different mechanical properties to facilitate fixation or differential tissue regeneration.
- the composite scaffold may be impregnated with cells, biologic aspirates or bio-active agents prior to implantation to create a biological “band-aid”.
- the bio-inductive scaffold is seeded with auto-, allo- , or xeno-genous derived cells for a temporary pre-culture period to allow the cells to elaborate a collagen-rich extracellular matrix within the scaffold.
- the scaffold may then be processed and/or decellularized to leave a fiber-reinforced tissue scaffold that can be subsequently implanted, or may be implanted “as is”.
- the disclosed scaffold may be compatible with a variety of currently available fixation methods, e.g. suture, suture anchors, tacks, staples, etc.
- the disclosed composite scaffold provides a mechanism to space tissue fibers apart from each other within the scaffold to provide room for ingrowth for higher quality tissue not disrupted by polymer or the corresponding inflammation.
- the microporous matrix acts as a stabilizer that helps to maintain such space and allows for a larger surface for cells to grow so tissue can mature while the primary fiber of the scaffold still retains strength. If the microporous matrix resorbs at a faster rate than the support structure, a complete mass loss of the microporous matrix can occur so that tissue can reclaim and remodel within the newly created volume in vivo, while the primary support structure retains strength, allowing cells to first invade and encapsulate the structure but also create functional tissue over time. Additionally, if a natural material is used to create the secondary matrix, such as collagen, a reduction in scaffold inflammation may result and further encourage cell ingrowth into the scaffold while not in contact with any of the synthetic fibers comprising the support structure.
- a composite scaffold comprises a first matrix and an optional second matrix which may be integrally formed with one another to maximize the surface area to volume ratio of the scaffold while still maintaining mechanical and structural integrity.
- the first matrix may be implemented with the three- dimensional textile structure comprising first and a second support layers spaced apart to define an interior space or void therebetween. Multiple spacer elements extend between the first and second support layers to maintain the support layers separate.
- the first and second support layers may have different geometries, fibers, or material compositions.
- the first and second support layers and spacer elements may be implemented as a three dimensional textile comprising multi-layer knitted or woven surfaces of multifilament fibers or monofilament fibers, or any combination thereof, formed of any combination of synthetic bioresorbable polymers, natural polymers and/or additives.
- the second matrix is disposed within the void space between and proximate the first and second support layers of the first support matrix.
- the second matrix may be implemented with a low-density, high surface area material comprising any of a sponge, foam, felt, textured fibers or yarns, collagen or tissue-derived material, or any combination thereof.
- the first and second matrices of the composite scaffold may have the same or different structure, composition, and bioabsorbable characteristics to facilitate optimal regeneration of functional tissue.
- the composite scaffold may have a minimum thickness of approximately greater than or equal to 1 mm.
- the thickness of the scaffold may be uniform along a length thereof or may vary in a repeating or non-repeating manner, depending on the particular application for which the scaffold will be utilized.
- the disclosed composite scaffold may have length dimensions between approximately 2 to 1000 mm, depending on the particular application for which the scaffold will be utilized.
- the disclosed scaffolds may be manufactured in different incremental lengths or may be manufactured in lengths which may be cut or customized by practitioner as desired or as appropriate for a specific procedure.
- a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space; and a structure supporting the microporous matrix; wherein a surface area of the composite scaffold is between approximately 0.6 m 2 /gram and 1.2 m 2 /gram.
- a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space having a measurable volume; and a structure supporting the microporous matrix; wherein the volume of void space is between approximately 3.5 cm 3 /gram and 7 cm 3 /gram.
- a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space having a measurable volume, and wherein the void space volume is between approximately 80% and 90% of a measurable volume of the biomimetic scaffold.
- a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space having a measurable volume, and wherein the scaffold has a permeability of between approximately 1400 and 2600 millidarcy.
- a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space having a measurable volume, wherein the multitude of interconnected pores have a tortuosity of approximately between 5 pm/pm and 45 pm/pm, wherein the tortuosity defines a ratio of actual flow path length to straight distance between first and second ends of the microporous matrix.
- a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space having a measurable volume, a structure supporting the microporous matrix; and wherein the void space surface area to volume support structure volume is between approximately 7,000 cm 2 /cm 3 and 14,000 cm 2 /cm 3 .
- a composite scaffold comprises: a support structure defining an interior space; and a microporous matrix disposed within the interior space of the support structure, wherein the microporous matrix comprises a plurality of interconnected pores having a median pore size of between approximately 12 pm to 50 pm.
- a composite scaffold comprises: a support structure defining an interior space; and a microporous matrix disposed within the interior space of the support structure, the microporous matrix having a multitude of interconnected pores collectively defining void space; wherein at least approximately 60% of the void space comprises pores having a size dimension of 10 pm or greater.
- a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the biomimetic scaffold having a measurable dry weight value representing a weight of the biomimetic scaffold in a substantially dry state and a measurable dry volume value representing a volume of the biomimetic scaffold in a substantially dry state, wherein an increase of between approximately 200% and 600% of the weight value of the biomimetic scaffold from fluid absorption changes the dry volume value of the biomimetic scaffold between approximately 0% and 10%.
- a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the composite scaffold having a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state and a measurable dry length value representing a dimensional parameter of the composite scaffold in a substantially dry state, wherein an increase of between approximately 200% and 600% of the weight value of the composite scaffold from fluid absorption changes the dry length value of the composite scaffold by less than between approximately 0% and 3%.
- a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the composite scaffold having a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state and a measurable cross sectional profile value representing a dimensional parameter of the composite scaffold in a substantially dry state, wherein an increase of between approximately 200% and 600% of the weight value of the composite scaffold from fluid absorption changes the cross sectional profile value of the composite scaffold by between approximately 0% and 10%.
- a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; wherein a smallest dimension of the composite scaffold is a thickness dimension approximately greater than or equal to 1 mm, and wherein the composite scaffold has a swelling profile measurable by a less than or equal to 10% change in measured wet thickness of the composite scaffold in comparison to a measured dry thickness of the composite scaffold.
- a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the composite scaffold having a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state, wherein the microporous matrix is less than approximately 6% of the dry weight value of the composite scaffold.
- a scaffold comprises: a three-dimensional support structure having a length dimension extending between first and second ends of support structure, the support structure comprising first and second outer layers spaced apart by a distance therebetween defining a thickness dimension normal to the length dimension, and a plurality of spacer elements connecting the first and second outer layers to maintain separation therebetween; wherein the thickness dimension of the support structure changes less than approximately 35% upon elongation of the length dimension by approximately 13%.
- a scaffold comprises: a three-dimensional support structure having a length dimension extending between first and second ends of support structure and defining a cross-sectional area normal to the length dimension, the support structure comprising first and second outer layers spaced apart to define an interior space volume therebetween, and a plurality of spacer elements extending through the interior space volume between the first and second layers and attached therebetween to maintain separation of the first and second layers; wherein the cross-sectional area changes less the approximately 5% upon elongation of the length dimension by approximately 13%.
- a scaffold comprises: a three-dimensional support structure having a length dimension extending between first and second ends of support structure and defining a width dimension normal to the length dimension, the support structure comprising first and second outer layers spaced apart by a distance therebetween defining a thickness dimension normal to the length dimension and the width dimension, and a plurality of spacer elements connecting the first and second outer layers to maintain separation therebetween; wherein the width dimension of the support structure changes less than approximately 5% upon elongation of the length dimension by approximately 13%.
- a scaffold structure comprises: first and second outer layers having length dimensions defined by respective first and second ends thereof and defining an interior space therebetween, each of the first and second outer layers comprising a plurality of interconnected wales extending substantially parallel to the respective length dimensions; a plurality of spacer elements extending substantially normal to the respective length dimensions through the interior space and attached to each of the first and second outer layers proximate one of the plurality of wales, the plurality of spacer elements at least partially partitioning the interior space into a plurality of channels extending along the respective length dimensions of the first and second outer layers.
- a composite scaffold having a measurable volume comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space, wherein the composite scaffold has a density of approximately between 0.05 g/ccand 0.75 g/cc, wherein the density is defined as the mass per unit volume of the composite scaffold.
- a composite scaffold having a measurable volume comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; wherein the composite scaffold has a ratio of total surface area to volume of approximately between 160,000:1 and 190,000:1 , wherein the ratio defines the surface area of the scaffold to the volume the composite scaffold excluding the void space.
- a scaffold comprises: a three-dimensional support structure extending along an axis between first and second ends of support structure, the support structure comprising first and second layers spaced apart to define an interior space volume therebetween, and a plurality of spacer elements extending through the interior space volume between the first and second layers and attached therebetween to maintain separation of the first and second layers and defining a cross-sectional normal the axis; and a microporous matrix in the interior space and having a multitude of interconnected pores collectively defining void space between first and second ends of the support structure; wherein at least approximately 60% of the void space comprises pores having a size dimension of at least 10 pm or greater; and wherein a volume of the void space is between approximately 3.0 cm 3 /gram and 9.0 cm 3 /gram.
- a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space; and a structure supporting the microporous matrix; the composite scaffold having a substantially rectangular cross-section defined by exterior sides wherein a plurality of the interconnected pores are open to one of the exterior sides and have a largest dimension oriented relative to the one exterior side.
- the plurality of the interconnected pores have a largest dimension oriented between approximately between 45° and 135° relative to the one exterior side.
- a scaffold comprises: a three-dimensional support structure having a length dimension defined by first and second ends thereof and a thickness dimension, normal to the length dimension, defined by first and second outer layers separated by a space, and a plurality of spacer elements extending through the space and connecting the first and second outer layers; wherein the void space surface area to measurable volume is between approximately 500 cm 2 /cm 3 and 7,000 cm 2 /cm 3
- a composite scaffold occupying a measurable volume and comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space having a surface area; and a structure supporting the microporous matrix; wherein the void space surface area to measurable volume is between approximately 5,000 cm 2 /cm 3 and 16,000 cm 2 /cm 3
- a composite scaffold comprising: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space; and a structure supporting the microporous matrix; herein a surface area of the composite scaffold is between approximately 0.3 m 2 /gram and 15 m 2 /gram.
- a method of ligament or tendon injury repair with a composite scaffold comprises: A) providing a composite scaffold comprising: i) first and second layers spaced apart to define an interior space therebetween and a plurality of spacer elements extending through the interior space and attached to the first and second layers; and ii) a microporous matrix having a multitude of interconnected pores disposed within the interior space, and B) pre-tensioning the composite scaffold along a length dimension thereof; C) attaching the composite scaffold to an allograft or autograft tendon or a damaged or torn ligament or tendon.
- a method of ligament or tendon injury repair with a composite scaffold comprises: A) providing a composite scaffold comprising:! first and second layers spaced apart to define an interior space therebetween and a plurality of spacer elements extending through the interior space and attached to the first and second layers; and ii) a microporous matrix having a multitude of interconnected pores disposed within the interior space, and B) pre-tensioning the composite scaffold along a length dimension thereof; C) attaching the composite scaffold to an allograft or autograft tendon or other tissue graft or a damaged or torn ligament or tendon.
- a method of making a composite scaffold comprises: A) constructing a three-dimensional support structure extending along a length dimension between first and second ends thereof and defining an interior surface within the support structure; and B) forming a microporous matrix within the interior surface, the microporous matrix having a multitude of interconnected pores in fluid communication with exterior surfaces of the support structure, wherein a plurality of the interconnected pores are oriented relative to the dimensional characteristics of the support structure.
- the plurality of interconnected pores are oriented radially inward into the interior space from exterior surfaces of the support structure.
- the plurality of interconnected pores are oriented towards the length dimension of the support structure.
- a composite scaffold comprises: a support structure having an exterior profile defining an interior space and extending along a length dimension between first and second ends thereof; a microporous matrix disposed within the interior space having a multitude of interconnected pores opening exteriorly of the support structure; wherein a plurality of the interconnected pores are oriented relative to the dimensional characteristics of the support structure.
- a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the composite scaffold having a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state, wherein the microporous matrix is less than approximately 6% of the dry weight value of the composite scaffold.
- the second support matrix e.g. the sponge
- the composite scaffold may have a degradation profile with greater than or equal to 50% strength retention for at least approximately two weeks after implantation and a mass loss of 100% mass loss between approximately six and twelve months or longer after implantation.
- a higher density or mass of the support matrix provides the primary and bulk structure of the disclosed scaffold, in comparison to the more porous matrix disposed therein. More specifically, the first and second support matrixes have different densities or mass components relative to each other. In one embodiment, the first support matrix, e.g., the textile, has a measurable mass or density which is greater than or equal to one times that of the mass or density of the second support matrix, e.g. the sponge.
- the pore structure of the microporous matrix is designed to facilitate cellular attachment, proliferation, and ingrowth throughout the scaffold dimensions.
- the faces of the device, the secondary matrix, or pore structure could be engineered in architecture to encourage cellular migration in a certain direction, or to encourage the formation of aligned tissues such as connective tissues.
- the surfaces of the device might differ from each other in physical or chemical characteristics to reflect use in specific anatomic locations - i.e. one side to encourage integration with bone while the other to encourage tendon; or one side to encourage abdominal wall regeneration but the other side to prevent adhesions of internal organs.
- the composite scaffold disclosed herein provides a measurably high surface area to volume ratio, compared to existing commercially available devices, to facilitate more rapid and greater quantity of cell infiltration and tissue ingrowth within the composite scaffold. More specifically, based predominantly on the first support matrix, e.g., the textile, surface area of the fiber to volume of the device ratio, calculated using scaffold denier, polymer density and dimensions, greater than 10 times.
- the first support matrix e.g., the textile
- the scaffold may have ends that narrow and transition into suture-like dimensions or are modified, e.g. stitched or knotted, to attach to conventional suture used in the procedures described herein.
- the first support matrix e.g., the textile
- the first support matrix has ends or edges that are modified to be heat set or embroidered or impregnated with other materials to facilitate better handling, better integration with existing tissue and to further reduce dimensional distortion of the scaffold under pressure, tensile, or shear forces.
- a monofilament or multifilament suture of any material may pass through the scaffold lengthwise and exit both ends, and be attached or fixed to the scaffold.
- selected sections of the scaffold may be repeated, either randomly or with fixed frequency to increase or decrease the density of the scaffold by increasing or decreasing the density of the textile, for example, by a change in the textile pattern of the first support matrix.
- such repeating regions may be chosen to alter the surface finish of the scaffold by altering the smoothness or roughness, of the exterior surface of the scaffold to enhance acceptance of the scaffold once implanted.
- the composite scaffold comprises just a single three-dimensional support matrix which may be the same or different than either of the first or second support matrices described herein and may have any of the characteristics of the composite scaffold described herein.
- any of the scaffolds as disclosed herein are attached to an allograft or autograft tendon and used to replace a damaged ligament or tendon, or, the scaffold is used to augment a damaged or torn ligament or tendon.
- Methods of use may include preparation of the scaffold with a solution to enhance its performance, pretensioning of the scaffold, and/or fixing the femoral end and independently tensioning and fixing a tendon and graft in the tibial tunnel.
- the composite scaffold may be utilized in a wide array of medical procedures including to reinforce a suture repair, stand alone repair or reconstruction, or reconstruction using a tissue graft and for fixation purposes. Reinforcement of a repair or reconstruction using the composite scaffold may be applicable to the knee, ankle, shoulder, hip, elbow, foot, and hand, and non-musculoskeletal soft tissue.
- a graft preparation table provides a surface and fixation mechanisms that allow for independent tensioning of tissue, e.g. tendon or ligament, and composite scaffold either prior to or during an implantation procedure.
- a fixation device allows tissue, e.g. tendon or ligament, and composite scaffold to be attached to each other avoiding the need for whip stitching.
- tissue e.g. tendon or ligament
- composite scaffold may be attached to each other avoiding the need for whip stitching.
- Such device may comprise a clip with legs that go through graft and tendon.
- a method of making a composite scaffold comprises: A) constructing a three-dimensional support structure defining an interior surface within the support structure; B) modifying the three-dimensional support structure, and C) forming a microporous matrix within the interior surface.
- the three- dimensional support structure may be formed in (B) by an additive manufacturing techniques such as any of 3D printing or injection molding of a polymer scaffold, and modified in (C) by dimensionally or mechanically manipulating, e.g. drawing, the scaffold to align the polymer structure and improve behavioral characteristics, such as any of increase stiffness, yield point, ultimate strength, etc.
- a method of making a composite scaffold comprises: A) constructing a three-dimensional support structure by an additive manufacturing techniques a scaffold defining both an exterior support matrix and an interior microporous matrix interiorly of the exterior support matrix; and B) modifying the three- dimensional support structure by dimensionally or mechanically manipulating, e.g. drawing, the scaffold to align the polymer structure and improve behavioral characteristics of one or both of the exterior support matrix and the interior microporous matrix.
- Such method in (A) may comprise any of 3D printing or injection molding, the exterior support matrix and the interior microporous matrix using the same or different materials, and at the same or different times.
- Suitable manufacturing technologies suitable for use with the disclosed composite scaffolds include, but are not limited to, Injection Molding, Micro Molding, Stereolithography (SLA), Selective Laser Sintering (SLS), Fused Deposition Modeling (FDM), Digital Light Process (DLP), Multi Jet Fusion (MJF, Material Jetting (MJ), Direct Metal Laser Sintering (DMLS), Electron Beam Melting (EBM), and Drop on Demand (DOD).
- SLA Stereolithography
- SLS Selective Laser Sintering
- FDM Fused Deposition Modeling
- DLP Digital Light Process
- MJF Digital Light Process
- MJF Multi Jet Fusion
- MJF Material Jetting
- DMLS Direct Metal Laser Sintering
- EBM Electron Beam Melting
- DOD Drop on Demand
- Figure 1A is a conceptual illustration of a composite scaffold in accordance with the disclosure
- Figure 1 B is a photograph of a composite scaffold in accordance with the disclosure.
- Figure 1C is a photograph of a composite scaffold in accordance with the disclosure.
- Figure 2A is a conceptual illustration of knit pattern usable for exterior layers of the composite scaffold in accordance with the disclosure
- Figure 2B is a conceptual illustration of an alternative knit pattern usable for exterior layers of the composite scaffold in accordance with the disclosure
- Figure 2C is a conceptual illustration of the yarn components patterns comprising the exterior layers of Figures 2A-B in accordance with the disclosure
- Figure 2D is a conceptual illustration of a perspective view of textile patterns for a pair of of composite scaffolds useful for ACL and rotor cuff procedures in accordance with the disclosure
- Figure 3A is a photograph of a plan view of a composite scaffold having at least on exterior layer made in accordance with the pattern of Figure 2A in accordance with the disclosure;
- Figure 3B is a photograph of a side view of the composite scaffold of Figure 3A;
- Figure 4A is an SEM photograph of a plan view of a composite scaffold having at least on exterior layer made in accordance with the pattern of Figure 2A in accordance with the disclosure;
- Figure 4B is an SEM photograph of a side view of the composite scaffold of Figure 4A;
- Figure 4C is an SEM photograph of a perspective, cross-sectional view of the composite scaffold of Figure 4A as seen along axis 4A-4A in Figure 4A;
- Figure 5A is a perspective view of a mold useful in making a composite scaffold in accordance with the disclosure.
- Figures 5B-C are top and side plan views, respectively, of another mold useful in making a composite scaffold in accordance with the disclosure.
- Figure 5D illustrates graphically the relationship of temperature, time and pressure during the lypholization process in accordance with the disclosure
- Figures 6A-6C are SEM photograph of a sagittal cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line A-A within the in accordance with the disclosure;
- Figure 6D is an SEM photograph of a coronal cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line B-B within the in accordance with the disclosure;
- Figures 6E is an SEM photograph of a transverse cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line B-B within the in accordance with the disclosure;
- Figures 6F is an SEM photograph of a sagittal cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line A-A within the in accordance with the disclosure
- Figure 6G is an SEM photograph of a coronal cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line B-B within the in accordance with the disclosure;
- Figure 6H is an SEM photographs of a transverse cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line B-B within the in accordance with the disclosure;
- Figure 6I is an SEM photographs of a sagittal cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line A-A within the in accordance with the disclosure;
- Figure 7A is an SEM photograph of a typical microporous matrix attached to a fiber support structure of a composite matrix in accordance with the disclosure
- Figure 7B is an SEM photograph of a typical microporous matrix attached to a fiber support structure of a composite matrix in accordance with the disclosure
- Figure 7C is an SEM photograph of the exterior surface of the typical microporous matrix of a composite scaffold in accordance with the disclosure.
- Figure 8 illustrates graphically test data defining the relationship of the cumulative total pore surface area relative to pore diameter in accordance with the disclosure
- Figure 9 illustrates graphically the relationship of the cumulative total pore volume relative to pore diameter for a number of composite scaffold samples as well as only the textile only support structure in accordance with the disclosure
- Figure 10 illustrates graphically the relationship of the composite scaffold in relation to Mercury pressure for a number of composite scaffold samples as well as only the textile only support structure in accordance with the disclosure
- Figure 11 illustrates graphically the relationship of the distribution of pore diameter relative to the logarithmic differential volume in accordance with the disclosure
- Figure 12 illustrates graphically the relationship of load versus extension for both a solo tendon and a tendon augmented with a composite scaffold in accordance with the disclosure
- Figure 13A is a cross sectional microscopic view of the composite scaffold of Figure 1C illustrating the porous matrix relative to the support matrix in accordance with the disclosure;
- Figure 13B is a cross sectional microscopic view of the composite scaffold of Figure 1C hydrated with blood and illustrating how red blood cells fully infiltrate a collagen sponge porous matrix in accordance with the disclosure;
- Figure 14 is a photograph of the composite scaffold for MPFL repair or reconstruction in accordance with the disclosure
- Figure 15 illustrates conceptually lapsed image of a circular textile structure a circular textile structure in various stages of manufacture in accordance with the disclosure
- Figure 16 illustrates conceptually how a disclosed composite may be utilized for augmented ACL repair, stabilization or reconstruction in accordance with the disclosure
- Figure 17 illustrates graphically the relationship of the distribution of pore diameter relative to percentage of pores as measured in accordance with the disclosure
- Figures 18A-B are conceptual partial, perspective illustrations of a scaffold support structure of an implant useful for a meniscus repair in accordance with the disclosure
- Figure 18C is a partial, side cross-sectional illustration of the support scaffolds of Figures 18A-B in accordance with the disclosure
- Figure 19A is a conceptual partial, perspective illustrations of a scaffold support structure of an implant useful for rotator cuff repair in accordance with the disclosure
- Figures 19B-C are partial, side cross-sectional illustrations of the support scaffold of Figure 19A in accordance with the disclosure.
- Figure 20A is a conceptual partial, perspective illustrations of a scaffold support structure of an implant useful for breast reconstruction in accordance with the disclosure
- Figures 20B-C are partial, side cross-sectional illustrations of the support scaffold of Figure 20A in accordance with the disclosure.
- Figure 21 A is a conceptual partial, perspective illustrations of a scaffold support structure formed by additive manufacturing prior to drawing in accordance with the disclosure
- Figure 21 B is a conceptual partial, perspective illustrations of a scaffold support structure of Figure 21A post drawing in accordance with the disclosure
- Figures 22 is a photograph of a pattern useful in the manufacture of the scaffold faces of implants in accordance with the disclosure.
- Figure 23 is a photograph of a pattern useful in the manufacture of the scaffold faces of implants in accordance with the disclosure.
- Figure 24 is a photograph of a pattern useful in the manufacture of the scaffold faces of implants in accordance with the disclosure.
- Figure 25 is computer simulated sample polymer scaffold with a double baseline 5 wale panel, with 2 yarns per wale, and 1 layin sponge in accordance with the disclosure;
- Figure 26 is a perspective conceptual view of a composite scaffold and attachment devices sponge in accordance with the disclosure
- Figure 27 is a conceptual perspective, cross-sectional view of a composite scaffold and microporous sponge in accordance with the disclosure
- Figure 28A is perspective conceptual view of a composite scaffold bound to a tissue graft in accordance with the disclosure.
- Figure 28B is perspective, conceptual view of a composite scaffold bound to a tissue graft being positioned during an ACL repair procedure in accordance with the disclosure
- Figure 28C is perspective, conceptual view of a composite scaffold bound to a tissue graft in position during an ACL repair procedure in accordance with the disclosure.
- Figure 29 is a conceptual cross-sectional view of composite scaffold and microporous sponge in accordance with the disclosure.
- a composite scaffold 10 comprises a first three-dimensional support matrix, and a second matrix integrally formed with one another to form the composite scaffold 10 which maximize the surface area to volume ratio and surface area per weight ratios of the scaffold.
- the first matrix in embodiments, may be implemented with a support structure 5 comprising a first outer layer 12 and a second outer layer 14 spaced apart to define an interior void space 16 therebetween.
- a plurality of spacer elements 18 extend between first outer layer 12 and a second outer layer 14 to maintain separation of the layers.
- each of layers 12, 14, and spacer elements 18 may be implemented as a three- dimensional textile structure, each having different geometries, fibers, or material compositions.
- any of outer layers 12, 14, and spacer elements 18 may be implemented with a textile of multifilament fibers and/or monofilament fibers.
- Support layers 12 and 14 may be implemented as substantially planar three dimensional textile comprising multi-layer knitted surfaces and spacer elements 18 may be implemented with interconnecting yarns in the “Z” direction normal to the planes of layers 12 and 14 provide support to prevent collapse.
- the support structure 5 is intended to provide mechanical support to the growing neo tissue and to provide resistance to compression such that the area intended for new tissue formation is maintained during patient movement and activity. As such the support structure 5 provides extensional strength in its long axis and stiffness to resist compression in the “z direction”.
- support structure 5 may be formed from any of 30-150 denier multifilament fiber, 30-150 denier monofilament fiber, or 30-150 denier composite yarn, or any combination thereof, e.g., a combination of multifilament and monofilament fibers, and may be optionally coated with an anti-adhesion material. Unfinished edges of the scaffold 10 maybe sealed or secured using methods inclusive, but not limited to, heat setting or embroidery.
- support structure 5 is fabricated from 75-denier 30-filament Poly-L-Lactic Acid (PLLA) with a polymer density of 1.25g/cc. Yarns may be braided over a twisted fiber yarn to provide higher stiffness yarns for use as a lay in as described below.
- PLLA Poly-L-Lactic Acid
- one or both of outer layers 12 and 14 of support structure 5 may be implemented with a warp knit open pillar stitch 22 using double yarns, as illustrated in Figure 2A and 2C, resulting in the textile layers illustrated in Figure 3A.
- the exterior layer comprises a series of wales connected by single weft lay-in 26 yarn and having double 0° straight lay-in yarns 24 on both sides inserted in the pillar structure, as illustrated in Figure 2A.
- the pattern of the first outer layer 12 and second outer layer 14 may be the same or different.
- both outer layers 12 and 14 may have the same number of wales with spacer elements 18 connecting similar corresponding wales in each of layers 12 and 14.
- outer layers 12 and 14 may have different number of wales with spacer elements 18 connecting wales in each of layers 12 and 14.
- a wale is "a column of loops” lying lengthwise in the fabric.
- Each wale may be a single or double fiber to increase strength, but consequently increasing bulk.
- Increasing the number of wales, or the number of yarns per wale will result in increasing the ultimate tensile strength of the fabric.
- the width of the fabric can changed, which allows the same textile design to be applied to narrow applications, such as for ACL augmentation, e.g. 5mm wide, to moderately wide applications, such as for Rotator Cuff, e.g. 23mm wide, to very wide applications, such as for Hernia, e.g. 200mm wide.
- a method of increasing ultimate tensile strength, resistance to elongation and initial stiffness can be achieved by the addition of 0° straight lay-in yarns to the technical faces of the fabric. These lay-in yarns are incorporated into each wale in a linear fashion.
- a machine that has been used to manufacture the scaffold 10 is a Karl Mayer Double Needle Bar Warp Knitting Machine. These machines are computer controlled and allow modification of many parameters to effect changes to the textile properties. Key variables include the number of wales, the number of yarns per wale, addition of In-lay yarns to wales, In-lay yarn design, and number of yarns per in-lay. The ability of the fabric to stretch under tensile load can be influenced by, for example, knitting together every two wales rather than every three wales together.
- spacer elements 18 may be implemented with a plurality of yarns in the “Z” direction, normal to the planes in which layers 12 and 14 exist, that connect layers 12 and 14 and provide support to prevent collapse.
- each of layers 12 and 14 may have the same number of wales and spacer elements 18 may connect corresponding wales in each of layers 12 and 14.
- spacer elements 18 may cross diagonally between different wales of layers 12 and 14.
- Spacer elements 18 may comprise yarns which may be monofilament, multifilament, or multifilament and/or textured.
- layers 12 and 14 may be implemented using the textile pattern illustrated in Figure 2B.
- Other textile patterns suitable for layers 12 and 14 may include including Full Tricot, Locknit, and Queenscord, Single Atlas, Jersey, reverse jersey, miland interlock, Milano, half Milano, etc.
- Variations of warp knit surface design can be utilized to adjust the dimensions, density and mechanical properties of the layers 12 and 14 including any of: surface design, number of wales, number of yarns per wale, addition of in-lay yarns to wales, in-lay yarn design, number of yarns per in-lay, lengthening or decreasing quality (machine parameter), or lengthening or decreasing gap (machine parameter).
- An alternative method to warp knitting is the use of a V-Bed knitting machine, such as a Whole Garment Knitting machine, or use of a double rapier loom or a fly-shot loom to generate a woven 3D spacer fabric.
- a support structure number five, implemented with a three- dimensional textile may have the physical parameters as illustrated in Figure 1 below.
- a scaffold having the above physical values, and defining a void space between the first and second outer layers 12 and 14, respectively, through which plurality of spacer elements 18 extend, may be calculated to have a measurable void space surface area to volume ratio of between approximately 500 cm 2 /cm 3 and 7,000 cm 2 /cm 3
- the scaffold textile may be scoured to clean it and remove any finishes that may have been used.
- the method of scouring can include the use of water, solvent and water solvent mixtures.
- the fabric may be washed constrained or unconstrained.
- the fabric may also be treated with an agent to modify its surface characteristics, for example, to influence its hydrophilicity. Various agents can be used for this including polyethylene glycols.
- the surface may also be treated to improve cell adhesion by agents such as fibrin.
- the surface of the fibers may be coated with a calcium phosphate, hydroxyapatite or bioactive glass or growth factor such as a bone morphogenetic protein, and demineralized bone matrix.
- the composite scaffold 10, or any portion thereof, including layers 12 and 14 or spacer elements 18, may comprise any combination of synthetic bioresorbable polymers, natural polymers and/or additives.
- Synthetic bioresorbable polymers suitable for use as part of the composite scaffold may include, homopolymers, copolymers, or polymer blends of any of the following: polylactic acid, polyglycolic acid, polycaprolactone, polydioxanone, polyhydroxyalkanoates, polyanhydrides, poly(ortho esters), polyphosphazenes, poly (amino acids), polyalkylcyanoacrylates, polypropylene fumarate, trimethylene carbonate), poly(glycerol sebacate), poly(glyconate), poly(ethylene glycol), poly(vinyl alcohol) and polyurethane, or any combination thereof.
- Natural polymers suitable for use as part of the composite scaffold may include silk, collagen, chitosan, hyaluronic acid, alginate, and an amnion-derived matrix
- the composite scaffold 10 may have a thickness, i.e. the vertical height dimension of the scaffold as opposed to the larger length and width dimensions, between approximately .5 mm to 5 mm, and, even more preferably between approximately 1 mm to 3 mm. Even more preferably, the scaffold may have a minimum thickness of approximately greater than or equal to 1 mm. In embodiments, the thickness of the scaffold 10 may be uniform along a length thereof or may vary in a repeating or non-repeating manner, depending on the particular application for which the scaffold will be utilized.
- the disclosed composite scaffold 10 may have width dimensions between approximately 2 mm to 1000 mm, depending on the particular application for which the scaffold will be utilized.
- the width of the disclosed scaffold may be uniform or may vary in a repeating or non-repeating manner, depending on the particular application for which the scaffold will be utilized.
- a scaffold 10 may have ends were in the width of the scaffold narrows and dimensionally transitions into a suture-like dimension or is modified to attach to conventional suture used in the procedures described herein.
- the disclosed composite scaffold may have length dimensions between approximately 2 to 1000 mm, and, even more preferably greater than or equal to approximately 10 inches, again, depending on the particular application for which the scaffold will be utilized.
- the disclosed scaffolds may be manufactured in different incremental lengths or may be manufactured in lengths which may be cut or customized by practitioner as desired.
- Figure 4B is an SEM photograph of a side view of the composite scaffold 10 having a length dimension and formed from a pair of outer layers 12 and 14 separated by a plurality of spacer elements 18.
- FIG. 4B The photograph of Figure 4B was taken with a Philips/FEI XL30 ESEM Scanning Electron Microscope (SEM) with a 1 mm scale legend shown on the image and distances along the axis of the length dimension between spacer yarn, indicated by reference lines 1 - 23.
- Table 1 displays each reference line and its respective distance value in micrometers as well as an average distance. As can be seen from Table 1 , the average distance along the axis of the length dimension between spacer yarns is between approximately 200 pm and 300 pm.
- Figure 4C is an SEM photograph of a perspective, cross-sectional view of the composite scaffold of Figure 4A.
- the photograph of Figure 4C was taken with a SEM with a 1 mm scale legend shown on the image and distances along a width axis, normal to the axis of the length dimension, between spacer yarns, indicated by reference lines 1 - 17.
- Table 2 displays each reference line and its respective distance value in micrometers as well as an average distance. As can be seen from Table 2, the average distance along the width axis between spacer yarns is between approximately 300 pm and 400 pm (along axis);
- the respective distances between spacer elements 18, e.g. the spacer yarns, create a series of substantially parallel, similarly sized channels 19 extending through the void between outer layers 12 and 14.
- These channels provide space within the interior of the support structure into which the microporous matrix 15 may be formed, as described herein.
- these channels form along the axis of the device such that a contiguous channel exists between the two ends of the scaffold.
- the neo tissue Upon replacement by neo tissue, the neo tissue is substantive along the axis of the device and is hence load bearing and thus a functional tissue.
- these channels may have widths of between approximately 200-300 microns and the 300-400 micron.
- channels 19 may be irregular in the shape of their cross-section, the actual dimensions could be quantified with an effective diameter, i.e. the diameter of a circle of the same cross sectional area as the channel 19.
- channels 19 may have an effective cross sectional diameter of between approximately 50 -1000 microns, but more specifically between approximately 200 - 400 microns.
- a composite scaffold 10 made of any of the foregoing materials may be combined with additives to enhance various characteristics of the scaffold including to encourage regeneration of cell growth.
- Additives suitable for use as part of the composite scaffold may include biologies including seeded cells, biological aspirates, and bio-active agents.
- Seeded cells suitable for use as part of the composite scaffold may include adipose derived stem cells, mesenchymal stem cells, and induced pluripotent stem cells, or any combination thereof.
- Biological aspirates suitable for use as part of the composite scaffold may include whole blood, platelet rich plasma and bone marrow aspirate concentrate, or any combination thereof.
- Bio-active agents suitable for use as part of the composite scaffold 10 may include growth factors, extracellular matrix molecules and peptides, therapeutics, and osteoinductive or osteoconductive agents, or any combination thereof, and may be added to the support structure 5 before formation of the microporous matrix 15 or thereafter.
- Growth factors suitable for use as part of the composite scaffold may include transforming growth factor-beta superfamily (e.g. transforming growth factor-beta, bone morphogenetic proteins), insulin-derived growth factor, platelet-derived growth factor epidermal growth factor, Interleukin 1- receptor antagonist, fibroblast growth factor and vascular endothelial growth factor, or any combination thereof.
- transforming growth factor-beta superfamily e.g. transforming growth factor-beta, bone morphogenetic proteins
- insulin-derived growth factor e.g. transforming growth factor-beta, bone morphogenetic proteins
- platelet-derived growth factor epidermal growth factor e.g., platelet-derived growth factor epidermal growth factor
- Interleukin 1- receptor antagonist e.g., Interleukin 1- receptor antagonist
- fibroblast growth factor e.g., vascular endothelial growth factor, or any combination thereof.
- Extracellular matrix molecules and peptides suitable for use as part of the composite scaffold may include tenascin-C, hyaluronic acid, glycosaminoglycans (e.g. chondroitin sulfate, dermatan sulfate, and heparan sulfate), fibrin, thrombin, small leucine rich peptides (e.g. decorin and biglycan), fibronectin, elastin and arginine-glycine-aspartate (RGD) peptide, or any combination thereof.
- glycosaminoglycans e.g. chondroitin sulfate, dermatan sulfate, and heparan sulfate
- fibrin e.g. chondroitin sulfate, dermatan sulfate, and heparan sulfate
- fibrin e.g. chondroitin sulfate, dermatan sul
- Therapeutics suitable for use as part of the composite scaffold may include non-steroidal anti-inflammatories (NSAIDs) (e.g., aspirin, ibuprofen, indomethacin, nabumetone, naproxen, and diclofenac), steroidal anti-inflammatories (e.g., cortisone and hydrocortisone), antibiotics or antimicrobial agents, or any combination thereof.
- NSAIDs non-steroidal anti-inflammatories
- ibuprofen e.g., aspirin, ibuprofen, indomethacin, nabumetone, naproxen, and diclofenac
- steroidal anti-inflammatories e.g., cortisone and hydrocortisone
- antibiotics or antimicrobial agents or any combination thereof.
- Osteoinductive or osteoconductive agents suitable for use as part of the composite scaffold may include tricalcium phosphate, hydroxyapatite, and bioactive glass, or any combination thereof.
- An optional microporous matrix 15 may be formed within the interior void space 16 of composite scaffold 10.
- the microporous matrix 15 is supported and retained by support structure 5 and provide a support for cells to populate, proliferate.
- the microporous matrix 15 is resorbable or degradable and is designed to be rapidly replaced by neo tissue.
- a microporous matrix made from the materials described herein, on its own would not have the mechanical strength characteristics to be usable, both in terms of tensile strength and resistance to compression.
- a method of making a composite scaffold comprising constructing a three-dimensional support structure extending along a length dimension between first and second ends thereof and defining an interior surface within the support structure; and forming a microporous matrix within the interior surface, the microporous matrix having a multitude of interconnected pores 60 in fluid communication with exterior surfaces of the support structure.
- the microporous matrix is formed so that a plurality of the interconnected pores 60 are oriented relative to the dimensional characteristics of the support structure. For example, those pores closest to exterior surfaces of the composite matrix may be oriented substantially normal, or radially inward extending, relative to the closest exterior surface of the support structure.
- other of the plurality of interconnected pores 60 may be oriented towards the length dimension of the support structure in a manner that mimics the orientation of spacer elements 18, e.g. spacer yarns, separating the outer layers 12 and 14.
- microporous matrix 15 may be implemented with a high surface area material such as any of a sponge, foam, or textured fibers or yarns, or any combination thereof.
- Methods for fabrication of the microporous matrix 15 may comprise any of lyophilization, particulate leaching, open cell extrusion, solvent casting, solid-state foaming, and cross-linking.
- sponges/foams useful as the microporous matrix may comprise any of freeze-dried sponge, open cell extrusion foam and particulate leached sponge, or any combination thereof.
- a material suitable to implement microporous 15 is collagen, including bovine type 1 collagen.
- Other materials that can be used for porous matrix 15, in place of or in addition to collagen, include hydrogels based on Polyethylene Glycol (PEG ), Polycaprolactone (PCL), or Poly (glycolide-co-caprolactone) (PGCL), or a combination thereof.
- a collagen solution can be infiltrated into support structure 5 with the help of a mold to hold the scaffold.
- the secondary scaffold material may also coat the exterior surfaces of support structure 5 in an encapsulating manner.
- the mold, with textile and collagen solution may be placed into a shelf lyophilizer, also known as a freeze dryer that uses temperature-controlled shelves to freeze the contents of the mold to a very cold temperature, e.g.
- the porosity of the collagen within the microporous matrix 15 can be influenced during this process in multiple ways. Bulk porosity can be increased or decreased by decreasing or increasing the collagen solution weight percentage, respectively.
- the size of the pores can be adjusted by changing the rate of freezing in the mold. Increasing the rate of freezing decreases the average size, and decreasing the rate of freezing increases the average size.
- FIG. 5D is a graph illustrating the relationship of temperature, pressure and time during the during the lypholization process.
- mold material including Delrin, Aluminum, Stainless Steel, or other materials
- a mold made of Delrin a thermoplastic used in precision parts manufacturing, transfers heat more slowly causing larger pore sizes to form within the collagen solution.
- a mold formed of aluminum transfers heat very quickly resulting in a microporous matrix with relatively small size pores.
- a mold made of stainless steel transfers heat more slowly than aluminum and results in larger pores than those generated with an aluminum mold, but smaller than those generated with a Delrin mold.
- adjusting the thickness of the mold, between the bottom surface of the mold and the bottom of the cavity has a similar effect of increasing or decreasing heat transfer speed, which can result in different microporous matrix structures.
- the molds shown in Figures 5A and 5B are made from stainless steel and have the cavity dimensions listed in Table 6 below, wherein the 5 x 260mm column of dimensions refers to the mold 50 illustrated in Figure 5A and the 23 x 30mm column of dimensions refers to the mold 57 illustrated in Figure 5B.
- Mold 50 defines a plurality rectangular cavities 52 and has clamps 54 with pins 55 securable at the ends thereof.
- Mold 57 includes an array of rectangular cavities 59 and threw holes 53. Table 6
- the mold illustrated in Figure 5A utilizes end clips made of Delrin, which are securable to the main mold body and which may be used to clamp the textile scaffolds during the lypholization process.
- the cavity 52 of mold 50 have a substantially rectangular cross-sectional shape.
- Other cross-sectional shapes may be utilized to maximize the contact between surface area of the support structure five during the process of forming the microporous matrix therein.
- scaffolds having any of a D - shape, II - shape, O - shape, or C - shape may be utilized during the lypholization to maximize the surface area of the shape of the scaffold and further facilitate orientation of the pores with the microporous matrix the lypholization process.
- tube shaped molds whether oriented horizontally or vertically may be utilized during the the lypholization process.
- Alignment of pores relative to a dimension of the scaffold can be created via contact with the mold surfaces.
- pores within the microporous matrix 15 form, proximate the mold surface perpendicularly to the plane of contact with the mold.
- pores may be oriented between proximally 45° and 135° to the plane of contact with the mold.
- a substantial number of pores will orient normal to the contact surfaces with the mold interior towards the center of the support structure 5. Such orientation further facilitates the ingrowth of cells into the composite scaffold 10 more rapidly.
- An alternative mold design utilizes a similar cavity as above, but with the addition of a securely fashioned and air-tight top lid. Vacuum, or pressure, or other means may be used to fill the mold with collagen solution from one end, similar to injection molding, and release trapped gasses at another end, helping to further align the collagen fibers during the injection process.
- An additional alternative mold design uses cavities that place the textile on its side, so that the faces of the textile are perpendicular to the bottom face of the mold.
- An additional alternative mold design may use cavities that have a “II” shaped cross-sectional profile or another shape, which will create a finished scaffold shaped more applicably for a specific type of implantation.
- the resorption and mechanical characteristics of the microporous matrix may be further modified by crosslinking.
- materials used for crosslinking have potential cyctotoxicity so being able to use lower levels is greatly beneficial. It is a benefit of the disclosed procedure that the use of the support structure 5 allows the microporous matrix 15 to utilize a low level of crosslinking.
- the 3D textile, infilled with a dry, highly porous and low-density collagen microporous matrix is removed from the mold cavities and placed into a sealed chamber on a permeable shelf, such as a wire rack. A formaldehyde and ethanol solution is poured into a tray, and this tray is placed under the rack of scaffold, and the chamber door sealed.
- the tray fully encompasses the base dimensions of the chamber (L x W) and the vapor from the solution is used to crosslink the collagen within the 3D textile.
- the tray is removed, and the product is moved into an aeration chamber, in which clean, dry air, or alternatively, another gas such as Nitrogen, is pumped through and out of the chamber, which effectively stops the crosslinking process.
- Crosslinking of the collagen can be increased by increasing the time in the chamber, increasing concentration of formaldehyde in the ethanol solution, or reducing the aeration.
- crosslinking can be decreased by decreasing time in the chamber, decreasing concentration of formaldehyde in the ethanol solution.
- a chemical cross linking agent may be added to the collagen solution.
- These agents may include, but are not limited to, various concentrations of aldehydes such as glutaraldehyde, genipin, 1-ethyl-3-(3-dimethylaminoipropyl) carbodiimide (EDC), and EDC/N- hydroxysuccinimide (EDC/NHS).
- EDC 1-ethyl-3-(3-dimethylaminoipropyl) carbodiimide
- EDC/N- hydroxysuccinimide EDC/N- hydroxysuccinimide
- An additional alternative mode of crosslinking may come in the form of photochemically activated crosslinking, which may involve the use of UV or visible light to trigger a crosslinking process with or without a crosslinking initiator.
- Composite Scaffold Mechanical Characteristics The mechanical characteristics of the composite scaffolds 10 disclosed herein, result in a composite scaffold optimized for use in a wide array of medical procedures including to reinforce a suture repair, stand alone repair or reconstruction, or reconstruction using a tissue graft and for fixation purposes.
- Composite scaffolds 10 made in accordance with the description herein as well as Examples 1, 2 and 3 were tensile tested using a Mark-10 Tensile Tester with a crosshead speed of 20mm/min, with the results listed in Table 3.
- An advantage of the composite scaffold 10, and particularly, the support structure 5, as disclosed herein, is its ability to resist compression upon elongation.
- the width, height and cross-sectional area of the three- dimensional textile comprising support structure 5 resists compression upon substantial forces.
- a support structure 5 having a cross-sectional area of approximately 9.92 mm 2 a thickness (height) of approximately 2.17 mm and a width of approximately 4.57 mm
- extension of the support structure 5 along its length axis by force of 35 N causes an approximately 13% extension of the length dimension of the support structure 5.
- the thickness dimension of the support structure changes less than approximately 31 % upon elongation of the length dimension by approximately 13%.
- the cross-sectional area changes less the approximately 35% upon elongation of the length dimension by approximately 13%.
- the width dimension of the support structure changes less than approximately 5% upon elongation of the length dimension by approximately 13%.
- a length of a support structure 5, implemented with a three-dimensional textile scaffold as disclosed herein may have an ultimate load at a percentage of elongation of the length dimension between approximately 30% and 125%.
- the scaffold may have a yield at a percentage of elongation of the length dimension between approximately 5% and 15%.
- the scaffold may have a tenacity of between approximately 0.073 grams-force/denier and 1.102 grams-force/denier.
- the scaffold may have a stiffness of approximately between 2.5 N/mm and 25 N/mm, wherein the stiffness defines an extent to which the scaffold resists deformation in response to an applied force.
- the scaffold may have a strain at failure of approximately between 20 % and 70 %.
- the scaffold may have a tenacity at failure approximately between 0.3 grams- force/denier and 2 grams-force/denier.
- the support structure 5, implemented with a three- dimensional textile scaffold 5 mm in width and 40 mm in length and having a thickness approximately 1 mm, or as disclosed herein, may have an ultimate load displacement of approximately between 5 mm and 50 mm, wherein the ultimate load displacement defines a change in displacement at an amount of load applied to the biomimetic scaffold beyond which the biomimetic scaffold will fail.
- the scaffold may have a yield displacement of approximately between 1 mm and 8 mm, wherein the yield displacement defines a change in displacement at which the biomimetic scaffold begins to deform.
- the scaffold may have a yield force of approximately between approximately between 20 N and 70 N, wherein the yield force defines a force at which the biomimetic scaffold begins to deform.
- the scaffold may have a stiffness of approximately between 2.5 N/mm and 25 N/mm, wherein the stiffness defines an extent to which the biomimetic scaffold resists deformation in response to an applied force.
- the scaffold may have an ultimate strain of approximately between 20 % and 70 %, wherein the ultimate strain defines the deformation of the biomimetic scaffold due to stress.
- the scaffold may have an ultimate load approximately between 100 N and 200 N wherein the ultimate load is defined as the amount of load applied to the biomimetic scaffold beyond which amount the scaffold fails.
- the scaffold may have an ultimate strength approximately between 2.5 MPa and 20 MPa wherein the ultimate strength is defined as a capacity of the biomimetic scaffold to withstand loads tending to elongate the biomimetic scaffold.
- the scaffold may have an ultimate stress approximately between 2.5 MPa and 20 MPa wherein the ultimate stress is defined as a maximum value of stress that the structure can resist beyond which maximum value the structure fails.
- the scaffold may have a modulus of approximately between 2.5 MPa and 70 MPa, wherein the modulus defines measure of stiffness of the biomimetic scaffold with the void space.
- the scaffold may have a modulus of approximately between 150 MPa and 600 MPa, wherein the modulus defines measure of stiffness of the biomimetic scaffold without the void space, where the modulus is calculated using a cross-sectional area of only material comprising the composite scaffold.
- the composite scaffold disclosed herein provides greater support for a larger quantity of regenerated tissue through staggered degradation rates of the scaffold components.
- the first and second support matrixes 5 and 15 of scaffold 10 have different degradation rates.
- the second support matrix 15, e.g. the sponge degrades 2 to 12 times faster than the first support structure 5 based on mass loss or molecular weight loss.
- the sponge comprising the second support matrix may have a mass loss by 3 to 6 months following implementation whereas the textile weave comprising first support matrix may have mass loss at 12 months following implantation.
- Such difference in the rate of degradation enables the considerable tissue ingrowth facilitated by the interior void of the scaffold 10 to continue to be supported by the textile fabric for a longer period of time.
- the parameter of material degradation may be measured via loss of mass or molecular weight loss.
- the composite scaffold may have a degradation profile of greater than or equal to 50% strength retention for at least approximately four weeks after implantation and a mass loss of 100% mass loss between approximately six and twelve months after implantation.
- the composite scaffold disclosed herein may have features which enhance usability and better performance once implanted.
- the scaffold 10 may have ends that narrow and transition into suture-like dimensions or are modified, e.g. stitched or knotted, to attach to conventional suture used in the procedures described herein.
- the support structure 5, e.g., the textile has ends or edges that are modified to be heat set or embroidered or impregnated with other materials to facilitate better handling, better integration with the existing tissue and to further reduce dimensional distortion of the scaffold 10 under pressure, tensile, or shear forces.
- selected sections of the scaffold 10 may be repeated, either randomly or with fixed rapidity to increase or decrease the density of the scaffold by increasing or decreasing the density of the textile, for example, by a change in the textile pattern of the first support structure 5.
- such repeat regions may be chosen to alter the surface finish of the scaffold by altering the parameters of lyophilization, smoothness or roughness, of the exterior surface of the scaffold to enhance acceptance of the scaffold once implanted.
- the spacer elements18 may be located in only part of the interior space 16 of scaffold 10, e.g. a hollow lumen, as illustrated in Figure 2D. In other embodiments, the spacer elements 18 may have any of a regular or irregular repeating placement pattern within the interior space 16 between the layers 12 and 14 of the scaffold 10. In other embodiments, the spacer elements 18 themselves may be implemented with a textile, such as felt, or tissue or tissue derived materials, or as otherwise described herein.
- the composite scaffold could also be seeded with cells for a temporary pre-culture period to allow the cells to elaborate a collagen-rich extracellular matrix on the sponge and textile components.
- the scaffold could then optionally be decellularized to leave a matrix template having native extracellular matrix proteins on the textile structure and the scaffold subsequently implanted to repair a tendon or ligament in vivo.
- the microporous matrix in each sample composite scaffold has a multitude of interconnected pores opening to an exterior surface of the microporous matrix and the composite scaffold.
- Various characteristics of the pores within the microporous matrix, and, accordingly, the composite scaffold are measurable by Mercury Intrusion Porosimtery (MIP) or gas adsorption.
- MIP Mercury Intrusion Porosimtery
- Mercury is a non-wetting liquid that will not actively infill into porous structures.
- pressure using MIP
- mercury can be forced into the pores of the microporous matrix, with higher pressures allowing the mercury to enter smaller pores.
- pore size (diameter) and pore volume can be accurately measured. The pore size and volume measurements can be used to determine multiple properties of the microporous matrix and the composite scaffold generally.
- the disclosed composite scaffold due to the extensive multitude of interconnected pores within the microporous matrix supported by the 3D textile support structure, has a large surface area onto which cell migration and subsequent neotissue development may occur.
- the total surface area of the interconnected pores and the exterior of the composite scaffold is more accurately measurable using MIP, instead of just geometric dimensions and image quantification. Surface area may be calculated from the known diameter of the pores, measured via MIP, by assuming the pores are spheres using the following formula:
- the surface area parameter represents an amount of surface area of the composite scaffold per unit weight of the composite scaffold area, measurable in meters squared per gram (m 2 /g).
- Figure 8 is a graph 80 of test data showing the relationship of the cumulative total pore surface area relative to pore diameter, measured in micrometers, for a number of composite scaffold samples as well as a sample comprising only the 3D textile comprising support structure 5.
- the 3D textile support structure 5, whether alone or populated with a microporous matrix 15, comprised PLLA fibers. All samples were produced in accordance with the methods and Examples 1 and 2 described herein.
- a disclosed composite scaffolds may have a surface area per weight unit which range from between approximately 0.3 m 2 /gram and 1.5 m 2 /gram.
- the disclosed composite scaffolds may have a surface area per weight unit which range from between approximately 0.6 m 2 /gram and 1.2 m 2 /gram.
- the disclosed composite scaffolds may have a surface area per weight unit, from between approximately 0.71 m 2 /gram and 1.0 m 2 /gram.
- the total surface area of the interconnected pores and the exterior of the composite scaffold is also more accurately measurable using gas adsorption, instead of just geometric dimensions and image quantification, such as with krypton gas.
- the Table 7 below illustrates two samples having a 5 mm width and a 40 mm length.
- the surface area of the composite scaffold is between approximately 0.3 m 2 /gram and 15 m 2 /gram, as measured by krypton gas adsorption for pores having a diameter less than 1 pm.
- the composite scaffold Another important characteristic of the composite scaffold is the high volume of void space due, in part, to the number, size, orientation and interconnectivity of the pores which collectively define void space within the microporous matrix. Such high total pore volume facilitates more rapid blood absorption, cell migration and subsequent neo-tissue development.
- the total volume of pores collectively forming the void space within the microporous matrix may be measured directly using MIP by monitoring the change in Mercury volume during the MIP process.
- the pore volume parameter of the composite scaffold represents a total cumulative void volume per unit weight of the composite scaffold, e.g. cm 3 /g.
- Figure 9 is a graph 90 showing the relationship of the cumulative total pore volume as measurable in centimeters cubed per gram relative to pore diameter, as measured in micrometers for a number of composite scaffold samples as well as only the textile only support structure.
- the textile support structure whether alone or populated with a microporous matrix, comprises PLLA fibers. All samples were produced in accordance with the methods described herein.
- the disclosed composite scaffold may have a total pore volume which ranges from between approximately 3.0 cm 3 /gram and 9.0 cm 3 /gram.
- the disclosed composite scaffolds may have a volume which ranges from between approximately 3.5 cm 3 /gram and 7.0 cm 3 /gram.
- the disclosed composite scaffolds may have a total pore volume which ranges from between approximately 4.0 cm 3 /gram and 5.0 cm 3 /gram.
- porosity is the measurement of the void space volume within the microporous matrix as a percentage of the measurable volume of the composite scaffold itself. Such calculation may be done using measurements taken during MIP. During the Ml P process, the mass of each sample is known, as is the occupied volume of the sample by monitoring mercury volume. At the lowest applied pressure during MIP, there should be no mercury infill into the scaffold, so bulk density of the composite scaffold can be calculated. At the higher applied pressures during MIP, the composite scaffold should be near-complete mercury infill. Accordingly, the scaffold skeletal density can be calculated as follows:
- Porosity 100 * 1 - (density at low pressure/density at high pressure)
- Figure 10 is a graph 100 of the relationship of the composite scaffold density in grams per cubic centimeter in relation to Mercury pressure, as measured in pounds per square inch absolute, i.e. in a vacuum, measured in micrometers, for a number of composite scaffold samples as well as only the textile only support structure.
- the textile support structure whether alone or populated with a microporous matrix, comprises PLLA fibers. All samples were produced in accordance with the methods described herein.
- the disclosed composite scaffold may have a porosity which ranges from between approximately 75% to 98%.
- the disclosed composite scaffold may have a porosity which ranges from between approximately 80% to 90%.
- the disclosed composite scaffold may have a porosity which ranges from between approximately 80% to 85%.
- the permeability of the microporous matrix which facilitates more rapid absorption of fluids, particularly blood, both during and after implantation, to accelerate the process of cell migration and subsequent neo-tissue development.
- the microporous structure e.g. collagen
- inside the textile support structure facilitates a more uniform and well-defined pore structure compared to a collagen sponge alone, with a permeability of approximately 200% of the permeability of a collagen sponge by itself. This is due, at least in part, to the more uniform and well-defined structure of interconnected pores.
- Reproducible permeability values can be calculated from Mercury Intrusion Porosimetry (MIP) data using the Katz-Thompson equation set forth below:
- cp porosity from MIP data (subtract inaccessible void space in fibers)
- the disclosed composite scaffold may have a permeability which ranges from between approximately 1200 and 3000 millidarcy. In embodiments, the disclosed composite scaffold may have a porosity which ranges from between approximately from between approximately 1400 and 2600 millidarcy. In embodiments, the disclosed composite scaffold may have a porosity which ranges from between approximately from between approximately 1600 and 2000 millidarcy. Total Surface Area/Scaffold Volume
- the surface area per given sample is determinable from MIP.
- the skeletal density can be calculated as explained above with reference to the porosity parameter. Surface area is reported in units of square meters per sample weight unit (m 2 /g) and can be converted to meters cubed by multiplying by the sample mass. Scaffold volume is equal to the sample mass divided by the skeletal density.
- the disclosed composite scaffold may have a void space surface area to scaffold volume between approximately 5,000 cm 2 /cm 3 and 16,000 cm 2 /cm 3 .
- the disclosed composite scaffold may have a void space surface area to scaffold volume between approximately 7,000 cm 2 /cm 3 and 14,000 cm 2 /cm 3 . In embodiments, the disclosed composite scaffold may have a void space surface area to scaffold volume between approximately 9,000 cm 2 /cm 3 and 12,000 cm 2 /cm 3 .
- FIG. 12 is a graph 120 illustrating graphically the relationship of the distribution of pore diameter, as measured in micrometers relative to the logarithmic differential volume as measured in cubic centimeters per grams.
- the microporous matrix may have a plurality of interconnected pores having a median pore size of between approximately 10 pm to 70 pm. In embodiments, the microporous matrix may have a plurality of interconnected pores having a median pore size of between approximately 12 pm to 50 pm. In embodiments, the microporous matrix may have a plurality of interconnected pores having a median pore size of between approximately 20 pm to 35 pm.
- Another important characteristic of the composite scaffold is distribution of pore sizes within the void space of the microporous matrix of the composite scaffold, as measured in micrometers. Cumulative pore volume is determinable from MIP. The fractional contribution of pores over a certain size to the void space can be calculated as cumulative void space at a given pore size divided by total void space. The distribution of pore sizes within the void space of the microporous matrix is also illustrated in Figure 12. As can be seen from Figure 12, the majority of the collective void space within a microporous matrix comprises pores having a size parameter greater than 10 pm.
- the microporous matrix has a multitude of interconnected pores collectively defining void space wherein at least approximately 99% of the void space comprises pores having a size dimension of 10 pm or greater. In embodiments, the microporous matrix has a multitude of interconnected pores collectively defining void space wherein at least approximately 95% of the void space comprises pores having a size dimension of 10 pm or greater. In embodiments, the microporous matrix has a multitude of interconnected pores collectively defining void space wherein at least approximately 80% of the void space comprises pores having a size dimension of 10 pm or greater.
- the composite scaffold disclosed herein provides a measurably high absorptive capacity, e.g. capable of absorbing aqueous mediums, or wickability, to facilitate more rapid and greater quantity of absorbed biologic fluids and/or cells within the scaffold.
- the absorbance capacity of the composite scaffold can be measured from the following formula:
- the disclosed composite scaffold has a measurable dry weight value representing a weight of the scaffold in a substantially dry state and a measurable dry volume value representing a volume of the scaffold in a substantially dry state, with an increase of between approximately 200% and 600% of the weight value of the scaffold from fluid absorption changing the dry volume value of the scaffold between approximately 0% and 10%.
- the percent volume change of the composite scaffold can be measured from the following formula:
- the composite scaffold disclosed herein provides a reduced swelling profile, e.g. resists dimensional changes with increased absorption fluids.
- the disclosed composite scaffold has a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state and a measurable dry length value representing a dimensional parameter of the composite scaffold in a substantially dry state, with an increase of between approximately 200% and 600% of the weight value of the composite scaffold from fluid absorption changing the dry length value of the composite scaffold by less than between approximately 0% and 3%.
- the percent length change of the composite scaffold can be measured from the following formula:
- the disclosed composite scaffold a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state and a measurable cross sectional profile value representing a dimensional parameter of the composite scaffold in a substantially dry state, with an increase of between approximately 200% and 600% of the weight value of the composite scaffold from fluid absorption changing the cross sectional profile value of the composite scaffold by between approximately 0% and 10%.
- the percent cross sectional profile change of the composite scaffold can be measured from the following formula:
- % of Sample Volume filled (Sample wet mass - samples dry mass)/(Sample dry volume)
- Composite scaffold devices are weighed throughout the manufacturing process, capturing both the mass of the textile alone, the mass after being coated with PEG 400, and the mass after adding collagen solution and subsequent lyophilization.
- the mass of the collagen microporous matrix in each device can be calculated as follows:
- the % dry weight of the collagen compared to the whole composite scaffold device can then be calculated:
- the composite scaffold disclosed herein has a higher density or mass of the support matrix provides the primary and bulk structure of the disclosed scaffold, in comparison to the more porous matrix disposed therein. More specifically, the first and second support matrixes 5 and 15 of scaffold 10 have different densities or mass components relative to each other.
- the first support structure 5, e.g., the textile has a measurable mass or density which is greater than or equal to one times that of the mass or density of the second support matrix 15, e.g. the sponge, and, more preferably, between 2 to 5 times that of the mass or density of the second support matrix 15.
- the disclosed composite scaffold may have a maximum scaffold density of less than 0.5 g/cm 3 , and specifically between approximately 0.05 g/cm 3 and 0.3 g/cm 3
- Methods for manufacturing the composite scaffold in accordance with the disclosure are as follows.
- a 5mm wide, 3mm tall, and 260mm long composite scaffold for ACL repair or augmentation made from a three-dimensional PLLA textile filled with a highly porous collagen matrix is manufactured, as follows.
- a three-dimensional (3D) textile which comprises the support structure is manufactured using the double pillar pattern illustrated in Figure 2A in accordance with the technique the warp knitting technique described.
- the resulting structure has top and bottom layers of 6 wales each.
- the 3D textile is received as a continuous length textile, 5mm wide and 3mm tall and is ultrasonically scoured, e.g. washed, in solution of DI and I PA to remove particulate and yarn spin finish. Multiple washes, replacing solution in between washes, are used.
- the temperature of the wash solution may be room temperature, or up to 40C.
- the 3D textile is then air dried, and cut to length.
- An alternative method of preparing the 3-D textile prior to coating with a hydrophilic solution involves wrapping the continuous length textile, not overlapping, around a frame, also known as a tenter frame, or suture rack, with moderate tension.
- the wrapped frame is then submerged in a distilled water and isopropyl alcohol solution, and washed either ultrasonically or in a shaker bath for agitation. Multiple washes, replacing solution between washes, may be used.
- the temperature of the wash solution may be room temperature, or up to 40C.
- the 3D textile is then air dried on the rack, under tension.
- the textile is then cut to length, while under tension, on the rack, creating uniform lengths.
- the scoured and cut to length of 3D textile is then submerged in a solution of polyethylene glycol (PEG) and ethanol to increase hydrophilicity.
- PEG polyethylene glycol
- concentration of PEG in ethanol is specifically controlled to result in a controlled weight percentage of PEG on the 3D textile.
- the 3D textile is then air dried.
- An alternative method of preparing the 3-D textile prior to coating with a hydrophilic solution involves submerging the 3D textile in the PEG and Ethanol solution, after scouring, but before cutting to length.
- An additional alternative method involves submerging the 3D textile as wrapped on the frame, after scouring, but before cutting, in the PEG and ethanol solution. In the above-mentioned steps, multiple combinations of each alternative may be utilized to achieve the same outcome.
- a 0.6% collagen solution by weight is made up using low molarity acetic acid and powder-form Type-1 bovine collagen is blended and vacuum processed to remove trapped air bubbles.
- a different low molarity acid such as hydrochloric acid may be used to make the collagen solution.
- an alternative process may remove trapped air bubbles, for example, by spinning the solution in a centrifuge.
- Different weight percent collagen solutions can be used. Increasing the weight percentage of collagen increases the amount of collagen in the matrix. Decreasing the weight percentage of collagen reduces the amount of collagen in the matrix. These changes will affect the final collagen matrix density, structural characteristics, and porosity when utilized with the lyophilization process described herein.
- the stainless-steel mold 57 shown in Figure 5B is used to guide infill of collagen solution into the 3D textile and through the next step, lyophilization, to create the collagen sponge matrix structure.
- the cavities of the mold are filled with a small amount of collagen solution.
- 3D textile lengths are placed into the mold, 3D textile faces parallel to the bottom of the cavity, and clamps are used on each end to secure the 3D textiles and to prevent movement.
- These clamps have an additive benefit, in the following step, Lyophilization, by creating areas on each end that are flat without porous collagen matrix, used for product handling and suture attachment.
- the tray is removed, and the product moved into an aeration chamber, in which clean, dry air is pumped through and out of the chamber, which effectively stops the crosslinking process.
- a highly porous, low density collagen matrix is formed within the 3D textile.
- a 23mm wide, 3mm tall, and 30mm long composite scaffold for Rotator Cuff repair or augmentation made from a three-dimensional PLLA textile filled with a highly porous collagen matrix is manufactured, as follows.
- a 5mm wide, 3mm tall, and 260mm long composite scaffold for ACL repair or augmentation made from a three-dimensional PLLA textile filled with a highly porous collagen matrix is manufactured, as described hereafter.
- a three-dimensional (3D) textile which comprises the support structure is manufactured using the double pillar pattern illustrated in Figure 2A in accordance with the technique the warp knitting technique described.
- the resulting structure has top and bottom layers of approximately 25 wales each.
- the 3D textile is received as a continuous length textile, 5mm wide and 3mm tall and is ultrasonically scoured, e.g. washed, in solution of DI and IPA to remove particulate and yarn spin finish. Multiple washes, replacing solution in between washes, are used.
- the temperature of the wash solution may be room temperature, or up to 40C.
- the 3D textile is then air dried, and cut to length.
- the scoured and cut to length of 3D textile is then submerged in a solution of PEG and ethanol to increase hydrophilicity.
- the concentration of PEG in ethanol is specifically controlled to result in a controlled weight percentage of PEG on the 3D textile.
- the 3D textile is then air dried.
- a 0.6% collagen solution by weight is made up using low molarity acetic acid and powder-form Type-1 bovine collagen is blended and vacuum processed to remove trapped air bubbles.
- the stainless-steel mold shown in Figure 5B is used to guide infill of collagen solution into the 3D textile and through the next step, Lyophilization, to create the collagen sponge matrix structure.
- the cavities of the mold are filled with a small amount of collagen solution.
- 3D textile lengths are placed into the mold, 3D textile faces parallel to the bottom of the cavity, and clamps are used on each end to secure the 3D textiles and to prevent movement.
- These clamps have an additive benefit, in the following step, Lyophilization, by creating areas on each end that are flat without porous collagen matrix, used for product handling and suture attachment.
- the mold design may be such that the whole scaffold becomes encapsulated in the collagen gel this may have the benefit of shielding the body from the textile scaffold component with the more biocompatible collagen gel.
- the composite scaffolds described herein may be utilized in a wide array of medical procedures including to reinforce a suture repair, stand alone repair or reconstruction, or reconstruction using a tissue graft and for fixation purposes. Reinforcement of a repair or reconstruction using the composite scaffold may be applicable to the knee, ankle, shoulder elbow and hand, and non-musculoskeletal soft tissue.
- the knee may include any of ACL (anterior cruciate ligament), PCL (posterior cruciate ligament), LCL (lateral collateral ligament), MCL (medical collateral ligament), MPFL (medial patellofemoral ligament), ALL (anterolateral ligament), and Posterolateral Corner Injury (fibular collateral ligament, popliteus tendon, popliteofibular ligament).
- the ankle may include any of the ATFL (anterior talofibular ligament) and CFL (calcaneofibular ligament).
- the shoulder elbow and hand may include any of the rotor cuff (supraspinatus, infraspinatus, subscapularis, and teres minor tendons), acromioclavicular ligament, UCL (ulnar collateral ligament), and flexor tendon.
- Non-musculoskeletal soft tissue may include any of the breast, abdominal wall, and pelvic floor.
- the composite scaffolds described herein may be utilized for fixation of permanent and re-absorbable materials, including sutures, suture anchors, tacks, and staples.
- the physical dimensions and biomechanical characteristics of the composite scaffolds disclosed herein are optimized for use in a wide array of medical procedures including to reinforce a suture repair, standalone repair or reconstruction, or reconstruction using a tissue graft and for fixation purposes. Reinforcement of a repair or reconstruction using the composite scaffold may be applicable to the knee, ankle, shoulder elbow and hand, and non-musculoskeletal soft tissue. Such physical characteristics are measurably different than those of commercially available products such as hernia mesh and orthopedic suture tape and are more suitable for the above described procedures.
- orthopedic suture tape exists, and is measurable as a three- dimensional entity, for all intents and purposes relative to surgery it is effectively two-dimensional with little value for regenerating the volume of tissue necessary to enhance or mimic the characteristics of tendons or ligaments.
- tissue plane that is formed following total resorption of the material can be quite thin and weak; this is due to a lack of thickness and/or sufficient void volume of suitable pore size for cellular ingrowth within the scaffold. Therefore, there is a clear need to create tissue scaffolds of sufficient thickness that regenerate thicker and stronger tissue planes following polymeric degradation.
- Figure12 and Table 4 below illustrates, over the number of samples, that a tendon augmented by the disclosed composite scaffold, is consistently stronger and capable of handling greater force over similar extension than the tendon alone.
- a 75 denier 30 filament poly-L-Lactic Acid (PLLA) yarn was produced for use in manufacture of scaffold fabrics.
- a warp beam was produced for use in a Karl Mayer Double Needle Bar Machine to produce the fabric.
- a 5mm wide fabric of 6 wales across its width and a 23mm wide fabric with 27 wales across were produced, i.e. using a 22 gauge needle bed.
- the two surface layers were separated in the Z direction by spacer yarns to make fabrics 2mm thick.
- the fabric was scoured in an ultrasonic bath with a mixture of deionized water and iso propyl alcohol and dried.
- a 0.6%collagen solution (by weight) was made up using low molarity Acetic Acid and powder-form Type-1 bovine collagen. This solution was blended and vacuum processed to remove trapped air bubbles.
- a stainless-steel mold as shown in Figure 5A, its cavities filled with a small amount of collagen solution.
- the textile scaffold from Example 1 a 26 cm long and 5mm wide sample, were placed into the mold, with textile faces parallel to the bottom of the cavity, and clamps used on each end to secure the textile and prevent movement. Additional collagen solution was filled into the cavities with the textile, completely submerging the textile in collagen solution.
- the mold with textile and collagen solution was vacuum processed to remove remaining air within the textile to completely infill textile with solution.
- the mold was then placed in an SP Scientific Advantage Plus Lyophilizer and the samples lyophilized, the lyophilization process taking the interior of the Lyophilizer from room temperature to -55C over a period of 2 hrs.
- the textile infilled with a dry, highly porous and low-density collagen matrix, was removed from the mold cavities and placed into a sealed chamber on a wire rack.
- a formaldehyde and ethanol solution was poured into a tray, and the tray placed under the rack of product, and the chamber door sealed. Vapor from the solution crosslinks the collagen within the textile. After 2 hours, the tray was removed, and the product moved into an aeration chamber, in which clean, dry air was pumped through and out of the chamber, which effectively stops the crosslinking process.
- the final device was suitable for use in ACL augmentation or repair
- Example 2 Following the methodology of Example 2 a mold suitable to accommodate a 23mm wide fabric was used to impregnate 50mm by 23mm pieces of fabric from Example 1 , but instead using the mold of Figure 5B. The final device was suitable for use in rotator cuff augmentation or repair
- a 0.6%collagen solution (by weight) was made up using low molarity Acetic Acid and powder-form Type-1 bovine collagen. This solution was blended and vacuum processed to remove trapped air bubbles. The solution was then lyophilized same as in Examples 2 and 3.
- a Porcine profundus tendon was obtained from a local abbatoir.
- the composite scaffold device from Example 1 was doubled over the tissue and whip-stitched at one end with #2 suture.
- a tensile test machine was used to mimic the graft preparation table.
- the whip-stitched end secured in upper grip jaws of tensile tester.
- Pretension achieved by loading both ends of composite scaffold to appropriate force and securing lower grip jaws.
- the construct was cycled to 3.75mm extension and back to zero.
- the performance data are shown in Table 5 below, and demonstrated the ability of the composite scaffold pre tension to control the reinforcement provided by the scaffold.
- a scaffold may have a lengths up to 1000 mm and a width from 3 mm to 1000 mm to adopt to different soft-tissue sizes and applications. Further, the width may taper to suture width at the ends of the scaffold.
- the composite scaffold may utilize a tubular spacer, whether warp or weft knit, which can be used as a “sheath” over autograft, allograft, or a repaired tendon or ligament.
- a tubular spacer whether warp or weft knit, which can be used as a “sheath” over autograft, allograft, or a repaired tendon or ligament.
- One method of producing this is to take a flat spacer fabric and then attach the opposing edges, by sewing, heat sealing, or other means, to create a tube, as illustrated in Figure 14.
- a customized circular knitter can be used to knit a tubular spacer fabric without a connecting seam.
- Another alternative method of making a tubular spacer is to weave the structure by method of 3D circular woven preform, method and structure is illustrated in Figure 15.
- the textile component which serves as the structure to hold the porous matrix, may be a 3D print a structure manufactured from an elastic or non-elastic material, which will then be infilled with the porous matrix.
- both the support structure and the porous matrix can be 3D printed from one or multiple materials, either as separate but combined entities, or as a single entity that provides both strength, porosity, and resistance to compression.
- the scaffold comprises a composite structure with a textile outer cover extending at least partially thereover to provide strength and a 3D printed inner support structure to provide resistance to compression.
- Such scaffold may have either rectangular, tubular shape, customized or other shaped profile. Braiding may be used as a cost effective method of producing a tubular structure. By braiding over a 3D printed inner support structure insert the required contiguous space for tissue ingrowth is provided. Polymer fibers braided longitudinally into an exterior braid structure may be provided to further modulate the tensile characteristics of the scaffold.
- the scaffolds described herein may be designed for specific applications such as rotator cuff repair, hernia repair and breast reconstruction, with reduced polymer density and/or increased the rate of absorbance, to enable faster tissue ingrowth, and less inflammation due to lower polymer density and faster absorption.
- implants having dimensional and behavioral characteristics may be specifically designed for rotator cuff, low polymer density rotator cuff, narrow soft tissue, (e.g. 2-3mm wide), hernia, breast reconstruction, meniscus, and achilles tendon repair procedures.
- the support structure of a composite scaffold may be implemented with a knitted textile structure similar to those disclosed herein and may have a collagen matrix formed therein through lyophilization or other processes, as also described herein.
- the knit pattern influences polymer density: adding wales increases density, adding warps increases density, going from single ends to double ends add density, and adding yarns per wale increases density, while longer stitch length reduces density, and a larger gap between textile faces increases height of textile.
- One or both face patterns may have every two or three wales knitted together; two is more dense but stronger.
- Figures 22A, 23 and 24 are photographs of a pattern 220, 230, and 240, respectively, that may be utilized as scaffold faces of implants in accordance with the disclosure.
- Polymer selection may influence absorbtion rate. Ratios of composite materials may also influence density and absorbtion rate.
- a polymer such as any of Polypropylene, PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET, PDO, or PGS in various ratios, or as a copolymer in any combination thereof, or a copolymer can be extruded via a melt spinning technique or similar to create a fiber.
- the fiber may be multifilament or monofilament and may be knitted or otherwise formed into a textile structure having a 3/3 face design (3 wales stitched) or 2/2 face design (2 wales stitched) with a vertical fiber in the Z direction, featuring a short or long quality gap and either a single or double wale end, zero to two lay-ins, and between 5 to 30 wales.
- Figure 25 is computer simulated sample scaffold 250 with a double baseline 5 wale panel, with 2 yarns per wale, and 1 lay-in sponge in accordance with the disclosure;
- the final textile structure may be shaped and then infilled with lyophilization, casting or other process, with a porous matrix of a different absorbable material, such as collagen, Polyethylene glycol (PEG), Poly (Glycerol Sebacate) (PGS), Polycaprolactone (PLC), poly(lactic- co-glycolic acid) (PCLA), Polydioxanone (PDO) or chitosan or other polymeric or polymeric biologic materials, to form a scaffold which may be subsequently crosslinked via vapor or liquid phase, dehydrothermal (DHT), UV or other forms of crosslinking to increase in-vivo resistance to degradation.
- a different absorbable material such as collagen, Polyethylene glycol (PEG), Poly (Glycerol Sebacate) (PGS), Polycaprolactone (PLC), poly(lactic- co-glycolic acid) (PCLA), Polydioxanone (PDO) or chitosan or other polymeric or polymeric biologic materials
- the resulting composite scaffold with microporous matrix supports tissue ingrowth and resists mechanical forces until the scaffold and microporous matrix is fully absorbed.
- Other relevant manufacturing technologies suitable for creating the use with the disclosed composite scaffolds include, but are not limited to warp knitting, weft knitting, weaving, braiding, nonwoven methods, electrospinning and 3D printing.
- the first and second support layer can be 3D printed, injection molded or cast to form a mechanical support structure as further described herein.
- the first and second layer can be manufactured simultaneously to create small pores while also maintaining mechanical strength.
- the first layer can be manufactured using 3D printing, injection molding or cast while the second layer may be implemented to define the interior space of the scaffold with small pores to promote tissue ingrowth.
- the first matrix may be implemented such that the design is shaped specific to a patient’s own anatomy.
- the shape may be tapered, conical, tubular, rounded, or rectangular, such that the first matrix represents the anatomical shape of the anatomy that is being repaired or replaced or reconstructed.
- the first matrix may be implemented such that the faces of embodiments may form various knitted, braided, woven or otherwise interconnected fibers with various patterns based on application and function of the composite scaffold for each category of utilization.
- the composite device may be constructed to reduce the overall density of the composite scaffold relative to other embodiments.
- the reduction of density may decrease the potential for an inflammatory reaction to the polymer comprising the scaffold, and may increase the ability of tissue ingrowth and cell proliferation to occur.
- the composite device may be constructed to reduce the overall in-vivo absorption time of the composite scaffold relative to other embodiments.
- An increased rate of resorption may decrease the potential for an inflammatory reaction to the polymer comprising the scaffold, and may increase the ability of tissue ingrowth and cell proliferation to occur.
- any of the composite scaffolds embodiments described herein may comprise a microporous matrix having a multitude of interconnected pores and a three dimensional structure supporting the microporous matrix, wherein at least a portion of the three dimensional structure extends through the microporous matrix.
- Such portion of the support structure extending through the microporous matrix may be the disclosed spacer elements extending between layers of the support structure or may be integral portions of the support structure itself.
- the structure supporting the microporous matrix may have a generally geometric shape comprising any of a conical, tubular, rounded, tapered or rectangular shape, or a shape that generally mimics a shape of an anatomical structure, as described in the illustrated herein.
- the composite scaffold may provide mechanical reinforcement for meniscus repair, replacement or reconstruction.
- the composite scaffold comprises a support structure 180 which defines a void volume, such structure may be similar or different to the structure illustrated in Figures 18A-C, to allow adequate extracellular matrix deposition and new functional tissue regeneration.
- a porous material or hydrogel may be disposed of within a void volume of the support structure.
- the support structure reinforces and supports the porous material/hydrogel, enhances the tensile strength of the scaffold and resists compression as the scaffold is extended or subject to elongation forces.
- the porous material/ hydrogel has a porosity and void volume that allows adequate extracellular matrix deposition and new functional tissue regeneration.
- the void volume is contiguous or essentially contiguous along the long axis of the scaffold for a substantially linear implant, or one or more primary axes or planes of the scaffold for an irregularly shaped implant, which allows cells to fully migrate within the device and for new tissue to form with an orientation enabled by the support structure and microporous structure of the scaffold, while being protected from significant collapse, compression or excessive dilation during mechanical loading or tensioning of the scaffold.
- all or part of the scaffold may be hydrated with biologic fluids such as blood, bone marrow aspirate, platelet rich plasma, autologous or allogeneic cells to modulate or direct the immune response and further facilitate and accelerate healing and tissue regeneration.
- the scaffold may have porous material/hydrogel encompassing both faces of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration.
- the scaffold is shaped or trimmed appropriately to the application for which it is used in order to fit the anatomy of a patient, including but not limited to intrasubstance tears, radial tears, horizontal tears, flap tears, complex tears, and bucket-handle tears.
- the scaffold provides mechanical reinforcement for meniscus repair, replacement or reconstruction including but not limited to arthroscopic meniscus repair with augmentation, meniscectomy, partial meniscectomy, and meniscus reconstruction.
- the composite device may provide mechanical reinforcement for rotator cuff repair.
- the composite scaffold comprises a support structure 190 which defines a void volume, such structure may be similar or different to the structure illustrated in Figures 19A-C, to allow adequate extracellular matrix deposition and new functional tissue regeneration.
- a porous material or hydrogel may be disposed of within a void volume of the support structure.
- the support structure reinforces and supports the porous material/hydrogel, enhances the tensile strength of the scaffold and resists compression as the scaffold is extended or subject to elongation forces.
- the porous material/ hydrogel has a porosity and void volume that allows adequate extracellular matrix deposition and new functional tissue regeneration.
- the void volume is contiguous or essentially contiguous along the long axis of the scaffold, which allows cells to fully migrate within the device and for new tissue to form with an orientation in the axial direction of the scaffold, while being protected from significant collapse, compression or excessive dilation during mechanical loading or tensioning of the scaffold.
- all or part of the scaffold may be hydrated with biologic fluids such as blood, bone marrow aspirate, platelet rich plasma, autologous or allogeneic cells to modulate or direct the immune response and further facilitate and accelerate healing and tissue regeneration.
- the scaffold may have porous material/hydrogel encompassing both faces of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration.
- the scaffold may have porous material/hydrogel encompassing only one face of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration.
- the scaffold is shaped appropriately to the application for which it is used in order to fit the anatomy of a patient.
- the scaffold provides mechanical reinforcement for rotator cuff repair, replacement or reconstruction including but not limited to arthroscopic rotor cuff repair with augmentation and reconstruction.
- the composite scaffold may provide mechanical reinforcement for breast repair or reconstruction.
- the composite scaffold comprises a support structure 200 which defines a void volume, such structure may be similar or different to the structure illustrated in Figures 20A-C, to allow adequate extracellular matrix deposition and new functional tissue regeneration.
- a porous material or hydrogel may be disposed of within a void volume of the support structure.
- the support structure reinforces and supports the porous material/hydrogel, enhances the tensile strength of the scaffold and resists compression as the scaffold is extended or subject to elongation forces.
- the porous material/ hydrogel has a porosity and void volume that allows adequate extracellular matrix deposition and new functional tissue regeneration.
- the void volume is contiguous or essentially contiguous along the long axis of the scaffold for a substantially linear implant, or one or more primary axes or planes of the scaffold for an irregularly shaped implant, which allows cells to fully migrate within the device and for new tissue to form with an orientation enabled by the support structure and microporous structure of the scaffold, while being protected from significant collapse, compression or excessive dilation during mechanical loading or tensioning of the scaffold.
- all or part of the scaffold may be hydrated with biologic fluids such as blood, bone marrow aspirate, platelet rich plasma, autologous or allogeneic cells to modulate or direct the immune response and further facilitate and accelerate healing and tissue regeneration.
- the scaffold may have porous material/hydrogel encompassing both faces of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration. In some embodiments, the scaffold may have porous material/hydrogel encompassing only one face of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration. In some embodiments, the scaffold may be coated in adhesion preventing material encompassing only face of the support, as to function as a barrier between bodily organs and the scaffold.
- the scaffold is shaped appropriately to the application for which it is used in order to fit the anatomy of a patient to provide mechanical reinforcement for breast repair or reconstruction including but not limited to implant reconstruction, autologous reconstruction, flap reconstructions, nipple reconstruction, mastectomy, breast augmentation, breast reduction, breast revision, or other types of mammoplasty procedures.
- the composite scaffold may provide mechanical reinforcement for hernia repair.
- the composite scaffold comprises a support structure 190 which defines a void volume, such structure may be similar or different to the structure illustrated in Figures 19A-C, to allow adequate extracellular matrix deposition and new functional tissue regeneration.
- a porous material or hydrogel may be disposed of within a void volume of the support structure.
- the support structure reinforces and supports the porous material/hydrogel, enhances the tensile strength of the scaffold and resists compression as the scaffold is extended or subject to elongation forces.
- the porous material/ hydrogel has a porosity and void volume that allows adequate extracellular matrix deposition and new functional tissue regeneration.
- the void volume is contiguous or essentially contiguous along the long axis of the scaffold, which allows cells to fully migrate within the device and for new tissue to form with an orientation in the axial direction of the scaffold, while being protected from significant collapse, compression or excessive dilation during mechanical loading or tensioning of the scaffold.
- all or part of the scaffold may be hydrated with biologic fluids such as blood, bone marrow aspirate, platelet rich plasma, autologous or allogeneic cells to modulate or direct the immune response and further facilitate and accelerate healing and tissue regeneration.
- the scaffold may have porous material/hydrogel encompassing both faces of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration.
- the scaffold may have porous material/hydrogel encompassing only one face of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration.
- the scaffold may be coated in adhesion preventing material encompassing only one face of the support, as to function as a barrier between bodily organs and the scaffold.
- the scaffold is shaped appropriately to the application for which it is used in order to fit the anatomy of a patient.
- the scaffold provides mechanical reinforcement for hernia repair including but not limited to inguinal hernias, incisional hernias, femoral hernias, umbilical hernias, epigastric hernia, hiatal hernia, or pelvic floor hernias.
- a copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) may be formed into a three dimensional textile structure, in a manner similar or dissimilar as described herein, with two faces defining an internal open void space therebetween.
- the shapes of the faces can be any of a square, rectangular, circle or oval face or combination thereof depending on the application.
- the three dimensional textile structure may then have solvent cast within the void space, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, in a manner similar or dissimilar as described herein, resulting in the three dimensional textile structure embedded within the casted sponge-like structure thereby creating a composite scaffold.
- the resulting sponge-like structure contains the textile structure in such a manner that the sponge structure extends beyond the textile structure faces so that the composite scaffold is generally symmetrical, allowing the composite scaffold to be implanted with either face in any direction with the functionality of the implant unchanged.
- a copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) may be formed into a three dimensional textile structure with two faces, in a manner similar or dissimilar as described herein, defining an internal open void space therebetween.
- the shapes of the faces can be any of a square, rectangular, circle or oval face or combination thereof depending on the application.
- the three dimensional textile structure may then have solvent cast within the void space, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, in a manner similar or dissimilar as described herein, resulting in the three dimensional textile structure embedded within the casted sponge-like structure thereby creating a composite scaffold.
- the resulting sponge-like structure contains the textile structure in such a manner that the sponge structure extends beyond only a single face of the textile structure so that the composite scaffold generally asymmetrical allowing the composite scaffold to be implanted with a specific direction for the scaffold to be functional.
- a copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) may be formed into a three dimensional textile structure, in a manner similar or dissimilar as described herein, with two planar faces defining an internal open void space therebetween.
- the shapes of the faces can be any of a square, rectangular, circle or oval face or combination thereof depending on the application.
- the three dimensional textile structure may then have solvent cast within the void space, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, , in a manner similar or dissimilar as described herein, resulting in the three dimensional textile structure embedded within the casted sponge-like structure thereby creating a composite scaffold.
- the resulting sponge-like structure contains the textile structure in such a manner that the sponge structure envelopes the top and bottom planar faces and sides in their respective entireties so that the composite scaffold is generally symmetrical, allowing the composite scaffold to be implanted with either face in any direction with the functionality of the implant unchanged.
- Example 9A Dense sponge reinforced with fibers
- a structure can be casted via various methods using polymer or biologic polymer, such as collagen, PEG or chitosan in a manner similar or dissimilar as described herein, to create a three dimensional sponge. Adjusting the concentrations of inputs to the sponge structure may increase the density of the resulting three dimensional sponge. Further processing of the three dimensional sponge via additional casting, crosslinking, dissolution and recasting may also increase the density of the three dimensional sponge.
- a copolymer or polymer such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof
- a copolymer or polymer can be physically or chemically added to the three dimension sponge in the form of any of a fiber form, two dimensional textile form, or three dimensional textile form, resulting in a composite scaffold.
- Example 9B Dense sponge reinforced with fibers
- a structure can be casted via various methods using polymer or biologic polymer, such as collagen, PEG or chitosan in a manner similar or dissimilar as described herein, to create a three dimensional sponge. Adjusting the concentrations of inputs to the sponge structure may increase the density of the resulting three dimensional sponge. Further processing of the three dimensional sponge via additional casting, crosslinking, dissolution and recasting may also increase the density of the three dimensional sponge.
- a copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) in the form of any of a fiber form, two dimensional textile form, or three dimensional textile form, can be configured into the mold, for example by tensioning fibers in a mold, prior to casting, so that the sponge is effectively cast around the fiber patterns, the resulting in the composite scaffold.
- a copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) may be formed into a three dimensional textile structure, in a manner similar or dissimilar as described herein, with two parallel faces defining an internal open void space therebetween.
- the shapes of the faces can be any of a square, rectangular, circle or oval face or combination thereof depending on the application.
- One face may have less polymer present than another face, creating a more open face to the textile structure and an overall less dense structure.
- the three dimensional textile structure may then have solvent cast within the void space, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, in a manner similar or dissimilar as described herein, resulting in the three dimensional textile structure embedded within the casted sponge-like structure thereby creating a composite scaffold.
- the resulting sponge structure contains the textile structure in such a manner where the sponge structure takes up a majority of the scaffold volume and textile structure faces, improving the functionality of the sponge structure within the composite scaffold.
- Example 11 Shaped conical 3D spacer mesh with sponge
- a copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) may be formed into a three dimensional textile structure, in a manner similar or dissimilar as described herein, with two parallel faces defining an internal open void space therebetween.
- the shapes of the faces can be any of a square, rectangular, circle or oval face or combination thereof depending on the application.
- This textile structure can be cut or trimmed or otherwise separated and folded to create a conical shape comprising the textile structure.
- the three dimensional textile structure may then have solvent cast within the void space, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, in a manner similar or dissimilar as described herein, resulting in the three dimensional textile structure embedded within the casted sponge creating a composite scaffold which holds the folded textile structure shape in place.
- Another method of holding the shape in place would be through additional stitching of the textile structure either before or after casting additional material.
- Another method of forming the textile structure would be to directly knit, braid or weave the structure.
- the sponge structure contains the textile structure in such a manner where the sponge structure extends beyond the textile structure faces so that the composite scaffold is symmetrical.
- Example 12 Shaped tubular 3D space mesh with sponge
- a copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) may be formed into a three dimensional textile structure, in a manner similar or dissimilar as described herein, with two faces defining an internal open void space therebetween.
- the shapes of the faces can be any of a square, rectangular, circle or oval face or combination thereof depending on the application.
- This textile structure can be cut or trimmed or otherwise separated and folded or rolled to create a hollow cylindrical tube shape comprising a three dimensional textile structure with a void space down the center.
- the three dimensional textile structure may then have solvent cast within the void space, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, in a manner similar or dissimilar as described herein, resulting in the three dimensional textile structure embedded within the casted sponge creating a composite scaffold which holds the folded or rolled textile structure shape in place.
- Another method of holding the shape in place would be through additional stitching of the textile structure either before or after casting additional material.
- Another method of forming the textile structure would be to directly knit, braid or weave the structure.
- the sponge structure contains the textile structure in such a manner where the sponge structure extends beyond the textile structure faces so that the composite scaffold is symmetrical. Additional material can be placed within the tubular fabric.
- a copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) can be formed into a three dimensional textile structure providing an open void space between two parallel faces.
- the shapes of the faces can be a square, rectangular, circle or oval face or combination thereof depending on the application.
- This textile structure can be cut or trimmed or otherwise separated and folded or rolled to create a crescent moon shape comprising a three dimensional textile structure in the shape of a ‘C’.
- the three dimensional textile structure may have a solvent cast within, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, so that the three dimensional textile structure is embedded within the casted sponge creating a composite scaffold and holding the textile structure shape in place. Another method of holding the shape in place is through additional stitching of the textile structure either before or after casting additional material. Another method of forming the textile structure would be to directly knit, braid or weave the structure.
- the sponge structure contains the textile structure in such a manner where the sponge structure extends beyond the textile structure faces so that the composite scaffold is symmetrical.
- alternative manufacturing methods such as 3D printing, casting, and injection molding of a scaffold with a porous matrix made be utilized to achieve implants with varying mechanics and physical properties, as well as complex shapes for specific anatomy and tissue ingrowth requirement of procedures such as Soft tissues, cartilage, meniscus, rotor cuff repair and breast reconstruction.
- Such method may comprise any of 3D printing or injection molding of a polymer scaffold followed by formation of a microporous collagen matrix through lyophilization; 3D printing of a polymer scaffold and microporous matrix at same time, using the same or different materials; or 3D printing or injection molding of a polymer scaffold followed by dimensionally or mechanically manipulating, i.e.
- the scaffold in order to align the polymer structure and improve mechanics, such as to increase stiffness, yield point, ultimate strength, etc.
- Other relevant manufacturing technologies suitable for use with the disclosed composite scaffolds include, but are not limited to, Injection Molding, Micro Molding, Stereolithography (SLA), Selective Laser Sintering (SLS), Fused Deposition Modeling (FDM), Digital Light Process (DLP), Multi Jet Fusion (MJF), Material Jetting (MJ), Direct Metal Laser Sintering (DMLS), Electron Beam Melting (EBM), and Drop on Demand (DOD).
- a composite scaffold may comprise a first matrix and an optional second matrix which may be integrally formed with one another to maximize the surface area to volume ratio of the scaffold while still maintaining mechanical and structural integrity.
- the first matrix may be implemented with the three-dimensional textile structure comprising first and a second support layers spaced apart to define an interior space or void therebetween. Multiple spacer elements extend between the first and second support layers to maintain the support layers separate.
- the first and second support layers may have different geometries, fibers, or material compositions.
- the first and second support layers and spacer elements may be implemented as a three dimensional textile comprising multi-layer knitted or woven surfaces of multifilament fibers or monofilament fibers, or any combination thereof, formed of any combination of synthetic bioresorbable polymers, natural polymers and/or additives.
- the second matrix is disposed within the void space between and proximate the first and second support layers of the first support matrix.
- the second matrix may be implemented with a low- density, high surface area material comprising any of a sponge, foam, felt, textured fibers or yarns, collagen or tissue-derived material, or any combination thereof.
- the first and second matrices of the composite scaffold may have the same or different structure, composition, and bioabsorbable characteristics to facilitate optimal regeneration of functional tissue.
- the first matrix may be implemented with a three-dimensional printed (3D printed) structure composing first and second support layers spaced apart to define an interior space or void therbetween.
- the first and second support layers may have different geometries, diameters, or material compositions.
- the first and second support layers may be supported by spacer elements which may have different geometries, diameters, or material compositions.
- the first and second support layers and any spacer elements may be integrally formed with 3D printing using various technologies (FDM, SLS, SLA, etc.) which allow for lattice geometries to be formed, with varying lattice spacing which may change throughout, or the first and second support layers and any spacer elements may be separately 3D printed.
- the first matrix shape may be tapered, conical, tubular, rounded, or rectangular, such that the first matrix represents the anatomical shape of the anatomy that is being repaired or replaced.
- the second matrix is disposed within the void between and proximate the first and second support layers of the first support matrix.
- the second matrix may also be implemented using 3D printing at the same time as the first matrix, or in a secondary operation, and may be the same material or a different material.
- the first and second matrices of the composite scaffold may have the same or different structure, composition, and bioabsorbable characteristics to facilitate optimal regeneration of functional tissue.
- the first matrix may be implemented with injection molding or casting of the support structure comprising the first and second support layers which are spaced apart to define an interior space or void therebetween.
- the first and second support layers may have different geometries, diameters, or material compositions.
- the first and second support layers are supported by spacer elements which may have different geometries, diameters, or material compositions.
- the first matrix may be implemented by 3D printing, casting, or injection molding, and then mechanically drawn to improve mechanical strength.
- polyesters are very low in strength prior to being oriented in the process used to make fibers. This is particularly true for resorbable polymers such as poly hydroxy butyrates and Poly caprolactones.
- a 3D printed scaffold can be produced that is a net like structure that when oriented provides strength and struts.
- An illustrative structure is shown in Figures 21A and 21 B.
- the structure 210A may be a two layer one with struts between the two layers, or there could be multiple layers.
- the struts may be drawn and will increase in strength to provide the final structure 21 OB, shown in the post orientation state illustrate in Figure 21 B.
- Biaxial orientation would allow strength enhancement and opening up of the structure in two planes.
- the method used to orient the preformed structure could be similar to the method used for fiber manufacturer such as accelerating rollers. Textile processing technology such as stenters and tenters are also in existence that would allow stretching biaxially and uniaxially.
- a second microporous matrix made from a collagen gel for example may be infused in the void space of the first matrix in a manner as described herein or using other current methodologies.
- Example 14 3D printed support structure with cast and lyophilized sponge matrix
- a polymer such as PLLA, PDLA, PGA, P4HB
- a polymer can be 3D printed (such as with SLS, SLA, or FDM) into a shaped porous scaffold which creates structural integrity while maintaining open space to resist compression and tension and mechanical forces.
- the scaffold can then be infilled (such as lyophilization or casting) with a porous matrix of a different absorbable material (collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, or another absorbable polymer), which may be subsequently crosslinked.
- This composite scaffold with microporous matrix will support tissue ingrowth and resist mechanical forces until the scaffold and microporous matrix is fully absorbed.
- Example 15 3D printed support structure, drawn and cast, with lyophilized sponge matrix
- a polymer such as PLLA, PDLA, PGA, P4HB
- 3D printed such as with SLS, SLA, or FDM
- the scaffold is then mechanically drawn or manipulated biaxially and uniaxially in such a way that the polymer's crystalline structure is aligned, improving the mechanical properties.
- the drawn scaffold is then infilled (such as with lyophilization or casting) with a porous matrix of a different absorbable material (such collagen, PEG, PGS, PLC, PCLA, PDO or chitosan), which may be subsequently crosslinked.
- a porous matrix of a different absorbable material such collagen, PEG, PGS, PLC, PCLA, PDO or chitosan
- Example 16 Injection molded support structure, then cast and lyophilize sponge matrix
- a polymer such as PLLA, PDLA, PGA, P4HB
- a polymer such as PLLA, PDLA, PGA, P4HB
- the scaffold is then infilled (such as with lyophilization or casting) with a porous matrix of a different absorbable material (such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan), which may be subsequently crosslinked.
- a porous matrix of a different absorbable material such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan
- Example 17 3D print of integral support and matrix
- a polymer such as PLLA, PLDA, PGA, PEG, P4HB
- 3D printed such as with SLS, SLA, or FDM
- the 3D printed material acts as both as mechanical support while also supporting tissue ingrowth.
- the scaffold itself can be made of the polymer but can be printed alongside a water soluble polymer (such as PGA) to provide structure during manufacturing or change the degradation rate of the absorbable implant.
- the absorbable implant may also be made alongside synthetic fibers incorporated during the additive process effectively creating more surface area and strength while maintaining flexibility.
- FIGs 26-29 illustrate conceptually how any of the disclosed scaffolds, illustrated in Figure 26 as scaffold 260, may be utilized for augmented ACL repair, stabilization or reconstruction.
- the scaffold 260 is bound to an allograft or autograft tendon, ligament, or tissue graft 280 and joined together at one or both ends. e.g. whip-stitched with suture, as illustrated in Figure 28A.
- One or both of scaffold 260 and tissue graft 280 may be pre-tensioned, as described herein.
- the combination of scaffold 260 and tissue graft 280 is then doubled over joined together at one end, e.g. whip-stitched with suture, and positioned into place, as illustrated in Figures 28B and 28C.
- scaffold 260 may be implemented as similar or dissimilar to scaffold 270 of Figure 27 and may be comprises of a support matrix 292 having a microporous matrix 290 formed therein and about, as illustrated in Figure 29.
- values are disclosed in groups or in ranges. It is specifically intended that the description include each and every individual subcombination of the members of such groups and ranges and any combination of the various endpoints of such groups or ranges.
- an integer in the range of 0 to 40 is specifically intended to individually disclose 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, and 40
- an integer in the range of 1 to 20 is specifically intended to individually disclose 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, and 20.
- Real numbers are intended to be similarly inclusive, including values up to at least three decimal places.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- Mechanical Engineering (AREA)
- Optics & Photonics (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
The disclosed composite scaffolds and methods of manufacturing the same provide highly porous and flexible structures that substantially maintain three-dimensional shape under tension and provide mechanical reinforcement of the repair or reconstruction- first via scaffold mechanical properties, and subsequently, through newly regenerated functional tissue as the scaffold is resorbed.
Description
COMPOSITE SCAFFOLD FOR THE REPAIR, RECONSTRUCTION, AND REGENERATION OF SOFT TISSUES
Field of the Invention
The disclosure relates to tissue repair and reconstruction, and, more specifically, to a composite scaffold useful for stabilizing tissue injuries or defects while facilitating the regeneration of new tissue.
Background of the Invention
Biologic and synthetic scaffolds for use in tissue engineering applications and surgical repairs and reconstructions are known, however, few are capable of providing the optimal combination of a sufficient: porosity for cellular ingrowth, biologic matrix and surface area for cell migration and proliferation, interconnected void volume and dimensions for meaningful extracellular matrix deposition and tissue regeneration, composite mechanical properties and mechanical load sharing with local tissues to encourage functional tissue maturation while resisting collapse or compression under said mechanical loading, and bio-resorption timeline which supports the tissue repair through complete healing while facilitating the regeneration of functional tissue.
Some scaffolds, such as hernia mesh have sufficient mechanical properties to complete a surgical repair, but lack the behavioral characteristics which are not optimally suited for healing and regeneration of soft tissues of the knee, ankle, shoulder elbow and hand, and non- musculoskeletal soft tissue. Many such scaffolds are made of permanent synthetic polymers which can elicit acute or chronic adverse inflammation, pain, or complications. In addition, many meshlike scaffolds are essentially two-dimensional with insufficient surface area for cell ingrowth and insufficient void volume for bulk tissue regeneration, and, therefore are not conducive to regenerating functional tissue. Conversely, most biologic scaffolds for the repair and reconstruction of soft tissues are derived from bulk tissues harvested and processed from either allogenous or xenogeneous sources, and often have slow or incomplete healing due to any combination of bulk architecture, tissue source, and processing method. Highly processed biologic materials that are reconstructed into entirely new architectures, such as collagen gels or sponges, can be produced with suitable porosity for tissue ingrowth but lacking suitable strength and resistance to collapse for use for ligament or tendon repair.
Many of the commercially available scaffolds composed of fibers have appropriate mechanical properties but are inadequate for functional tissue regeneration due to shortcomings of the architecture derived from existing manufacturing processes such as knitting, weaving, braiding, and non-woven methods such electrospinning, pneumatic-spinning, melt-blowing etc.; this is because the fibers have insufficient space between filaments and/or fiber bundles (inadequate porosity or void volume or density - e.g. typical of electrospun textiles), or too little surface area, void volume and dimensions for meaningful tissue regeneration (e.g. typical planar warp knit textiles or braids, or fiber bundles), or when adequate void volumes are created, it is either not contiguous on a cellular and biologically-relevant scale, or it collapses as the structure is tensioned.
Accordingly, a need exists for a scaffold and method of repairing or regenerating ligament tissue.
Another need exists for a scaffold which is composite, i.e. mimics the mechanical properties of native tendons and ligaments.
A further need exists for a scaffold which provides adequate porosity and interconnected void volume for cellular infiltration and tissue ingrowth, while substantially maintaining its shape under loading or tension.
A still further need exists for a scaffold which is bio-absorbable over a period of time which supports healing for a number of weeks or months while facilitating the regeneration of functional tissue capable of bearing mechanical load following scaffold resorption.
Another need exists for a scaffold which minimizes synthetic polymer density and maximizes the surface area to volume ratio of the scaffold, thereby limiting the foreign body response and improving tissue regeneration.
Yet another need exists for a scaffold which has an adjustable length, width, and height for different procedures.
Another need exists for which a bioresorbable scaffold regenerates tissue of sufficient strength and thickness following complete resorption of scaffold material.
Yet another need exists for a scaffold which provides a secondary support matrix capable of encouraging cell growth spaced apart from the scaffold to encourage tendon or ligament tissue ingrowth.
Still another need exists for this scaffold to have engineered regions of variable dimensions, density, porosity, material composition, fiber type, and surface characteristics to improve the tissue regeneration and or surgical handling and implantation.
Summary of the Invention
Disclosed is a composite scaffold for ligament or tendon repair that provides mechanical reinforcement for the repaired and healing tendon or ligament. In embodiments, the composite scaffold comprises a support structure which defines a void volume. A porous material or hydrogel is disposed within a void volume of the support structure. The support structure reinforces and supports the porous material/hydrogel, enhance the tensile strength of the scaffold and resists compression as the scaffold is extended or subject to elongation forces. The porous material/ hydrogel has a porosity and void volume that allows adequate extracellular matrix deposition and new functional tissue regeneration. In embodiments, the void volume is contiguous or essentially contiguous along the long axis of the scaffold, which allows cells to fully migrate within the device and for new tissue to form with an orientation in the axial direction of the scaffold, while being protected from significant collapse, compression or excessive dilation during mechanical loading or tensioning of the scaffold. Optionally, all or part of the scaffold may be hydrated with biologic fluids such as blood, bone marrow aspirate, platelet rich plasma, autologous or allogeneic cells to modulate or direct the immune response and further facilitate and accelerate healing and tissue regeneration.
The disclosed composite scaffold possesses a large surface area for cellular proliferation and migration, but also a sufficiently large, interconnected void space to allow tissue ingrowth, extracellular matrix deposition, and biomechanical remodeling into functional tissue. Further, the scaffold possesses the ability to maintain a highly porous structure under tension, e.g. resisting collapse, during a surgical procedure and following implantation thereby maintaining the ability for cell infiltration and new tissue ingrowth throughout the entire scaffold under physiological loadings. These loadings are mechanically shared between the device and local tissue due to the composite mechanical properties of the device, i.e., prevents stress shielding of proximal, repaired, or native tissues, as well as the developing neotissue within the scaffold itself. Further, these composite mechanical properties encourage the mechanobiological signaling of cells within the scaffold to differentiate and form load-bearing, oriented extracellular matrix and connective tissues. The disclosed composite scaffold can be manufactured using various different textile and composite manufacturing methods, and is not limited to a singular manufacturing technology.
The disclosed composite scaffold provides a highly porous and flexible structure that substantially maintains its three-dimensional shape under tension and provides mechanical reinforcement of the repair or reconstruction-first via scaffold mechanical properties, and subsequently, through newly regenerated functional tissue as the scaffold is resorbed.
The disclosed scaffold may have distinct regions with different mechanical properties to facilitate fixation or differential tissue regeneration. In embodiments, the composite scaffold may be impregnated with cells, biologic aspirates or bio-active agents prior to implantation to create a biological “band-aid”. In other embodiments, the bio-inductive scaffold is seeded with auto-, allo- , or xeno-genous derived cells for a temporary pre-culture period to allow the cells to elaborate a collagen-rich extracellular matrix within the scaffold. The scaffold may then be processed and/or decellularized to leave a fiber-reinforced tissue scaffold that can be subsequently implanted, or may be implanted “as is”. The disclosed scaffold may be compatible with a variety of currently available fixation methods, e.g. suture, suture anchors, tacks, staples, etc.
The disclosed composite scaffold provides a mechanism to space tissue fibers apart from each other within the scaffold to provide room for ingrowth for higher quality tissue not disrupted by polymer or the corresponding inflammation. The microporous matrix acts as a stabilizer that helps to maintain such space and allows for a larger surface for cells to grow so tissue can mature while the primary fiber of the scaffold still retains strength. If the microporous matrix resorbs at a faster rate than the support structure, a complete mass loss of the microporous matrix can occur so that tissue can reclaim and remodel within the newly created volume in vivo, while the primary support structure retains strength, allowing cells to first invade and encapsulate the structure but also create functional tissue over time. Additionally, if a natural material is used to create the secondary matrix, such as collagen, a reduction in scaffold inflammation may result and further encourage cell ingrowth into the scaffold while not in contact with any of the synthetic fibers comprising the support structure.
According to one aspect of the disclosure, a composite scaffold comprises a first matrix and an optional second matrix which may be integrally formed with one another to maximize the surface area to volume ratio of the scaffold while still maintaining mechanical and structural integrity. According to embodiments, the first matrix may be implemented with the three- dimensional textile structure comprising first and a second support layers spaced apart to define an interior space or void therebetween. Multiple spacer elements extend between the first and second support layers to maintain the support layers separate. The first and second support layers may have different geometries, fibers, or material compositions. The first and second support layers and spacer elements may be implemented as a three dimensional textile comprising multi-layer knitted or woven surfaces of multifilament fibers or monofilament fibers, or any combination thereof, formed of any combination of synthetic bioresorbable polymers, natural polymers and/or additives. The second matrix is disposed within the void space between and proximate the first and second support layers of the first support matrix. The second matrix may
be implemented with a low-density, high surface area material comprising any of a sponge, foam, felt, textured fibers or yarns, collagen or tissue-derived material, or any combination thereof. The first and second matrices of the composite scaffold may have the same or different structure, composition, and bioabsorbable characteristics to facilitate optimal regeneration of functional tissue.
In one embodiment, the composite scaffold may have a minimum thickness of approximately greater than or equal to 1 mm. The thickness of the scaffold may be uniform along a length thereof or may vary in a repeating or non-repeating manner, depending on the particular application for which the scaffold will be utilized. In other embodiments, the disclosed composite scaffold may have length dimensions between approximately 2 to 1000 mm, depending on the particular application for which the scaffold will be utilized. The disclosed scaffolds may be manufactured in different incremental lengths or may be manufactured in lengths which may be cut or customized by practitioner as desired or as appropriate for a specific procedure.
According to one aspect of the disclosure, a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space; and a structure supporting the microporous matrix; wherein a surface area of the composite scaffold is between approximately 0.6 m2/gram and 1.2 m2/gram.
According to another aspect of the disclosure, a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space having a measurable volume; and a structure supporting the microporous matrix; wherein the volume of void space is between approximately 3.5 cm3/gram and 7 cm3/gram.
According to another aspect of the disclosure, a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space having a measurable volume, and wherein the void space volume is between approximately 80% and 90% of a measurable volume of the biomimetic scaffold.
According to another aspect of the disclosure, a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space having a measurable volume, and wherein the scaffold has a permeability of between approximately 1400 and 2600 millidarcy.
According to another aspect of the disclosure, a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of
the microporous matrix and collectively defining void space having a measurable volume, wherein the multitude of interconnected pores have a tortuosity of approximately between 5 pm/pm and 45 pm/pm, wherein the tortuosity defines a ratio of actual flow path length to straight distance between first and second ends of the microporous matrix.
According to another aspect of the disclosure, a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space having a measurable volume, a structure supporting the microporous matrix; and wherein the void space surface area to volume support structure volume is between approximately 7,000 cm2/cm3 and 14,000 cm2/cm3.
According to another aspect of the disclosure, a composite scaffold comprises: a support structure defining an interior space; and a microporous matrix disposed within the interior space of the support structure, wherein the microporous matrix comprises a plurality of interconnected pores having a median pore size of between approximately 12 pm to 50 pm.
According to another aspect of the disclosure, a composite scaffold comprises: a support structure defining an interior space; and a microporous matrix disposed within the interior space of the support structure, the microporous matrix having a multitude of interconnected pores collectively defining void space; wherein at least approximately 60% of the void space comprises pores having a size dimension of 10 pm or greater.
According to another aspect of the disclosure, a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the biomimetic scaffold having a measurable dry weight value representing a weight of the biomimetic scaffold in a substantially dry state and a measurable dry volume value representing a volume of the biomimetic scaffold in a substantially dry state, wherein an increase of between approximately 200% and 600% of the weight value of the biomimetic scaffold from fluid absorption changes the dry volume value of the biomimetic scaffold between approximately 0% and 10%.
According to another aspect of the disclosure, a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the composite scaffold having a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state and a measurable dry length value representing a dimensional parameter of the composite scaffold in a substantially dry state, wherein an increase of between approximately 200% and 600% of the weight value of the
composite scaffold from fluid absorption changes the dry length value of the composite scaffold by less than between approximately 0% and 3%.
According to another aspect of the disclosure, a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the composite scaffold having a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state and a measurable cross sectional profile value representing a dimensional parameter of the composite scaffold in a substantially dry state, wherein an increase of between approximately 200% and 600% of the weight value of the composite scaffold from fluid absorption changes the cross sectional profile value of the composite scaffold by between approximately 0% and 10%.
According to another aspect of the disclosure, a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; wherein a smallest dimension of the composite scaffold is a thickness dimension approximately greater than or equal to 1 mm, and wherein the composite scaffold has a swelling profile measurable by a less than or equal to 10% change in measured wet thickness of the composite scaffold in comparison to a measured dry thickness of the composite scaffold.
According to another aspect of the disclosure, a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the composite scaffold having a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state, wherein the microporous matrix is less than approximately 6% of the dry weight value of the composite scaffold.
According to another aspect of the disclosure, a scaffold comprises: a three-dimensional support structure having a length dimension extending between first and second ends of support structure, the support structure comprising first and second outer layers spaced apart by a distance therebetween defining a thickness dimension normal to the length dimension, and a plurality of spacer elements connecting the first and second outer layers to maintain separation therebetween; wherein the thickness dimension of the support structure changes less than approximately 35% upon elongation of the length dimension by approximately 13%.
According to another aspect of the disclosure, a scaffold comprises: a three-dimensional support structure having a length dimension extending between first and second ends of support structure and defining a cross-sectional area normal to the length dimension, the support structure
comprising first and second outer layers spaced apart to define an interior space volume therebetween, and a plurality of spacer elements extending through the interior space volume between the first and second layers and attached therebetween to maintain separation of the first and second layers; wherein the cross-sectional area changes less the approximately 5% upon elongation of the length dimension by approximately 13%.
According to another aspect of the disclosure, a scaffold comprises: a three-dimensional support structure having a length dimension extending between first and second ends of support structure and defining a width dimension normal to the length dimension, the support structure comprising first and second outer layers spaced apart by a distance therebetween defining a thickness dimension normal to the length dimension and the width dimension, and a plurality of spacer elements connecting the first and second outer layers to maintain separation therebetween; wherein the width dimension of the support structure changes less than approximately 5% upon elongation of the length dimension by approximately 13%.
According to another aspect of the disclosure, a scaffold structure comprises: first and second outer layers having length dimensions defined by respective first and second ends thereof and defining an interior space therebetween, each of the first and second outer layers comprising a plurality of interconnected wales extending substantially parallel to the respective length dimensions; a plurality of spacer elements extending substantially normal to the respective length dimensions through the interior space and attached to each of the first and second outer layers proximate one of the plurality of wales, the plurality of spacer elements at least partially partitioning the interior space into a plurality of channels extending along the respective length dimensions of the first and second outer layers.
According to another aspect of the disclosure, a composite scaffold having a measurable volume comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space, wherein the composite scaffold has a density of approximately between 0.05 g/ccand 0.75 g/cc, wherein the density is defined as the mass per unit volume of the composite scaffold.
According to another aspect of the disclosure, a composite scaffold having a measurable volume comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; wherein the composite scaffold has a ratio of total surface area to volume of approximately between 160,000:1 and 190,000:1 , wherein the ratio defines the surface area of the scaffold to the volume the composite scaffold excluding the void space.
According to another aspect of the disclosure, a scaffold comprises: a three-dimensional support structure extending along an axis between first and second ends of support structure, the support structure comprising first and second layers spaced apart to define an interior space volume therebetween, and a plurality of spacer elements extending through the interior space volume between the first and second layers and attached therebetween to maintain separation of the first and second layers and defining a cross-sectional normal the axis; and a microporous matrix in the interior space and having a multitude of interconnected pores collectively defining void space between first and second ends of the support structure; wherein at least approximately 60% of the void space comprises pores having a size dimension of at least 10 pm or greater; and wherein a volume of the void space is between approximately 3.0 cm3/gram and 9.0 cm3/gram.
According to another aspect of the disclosure, a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space; and a structure supporting the microporous matrix; the composite scaffold having a substantially rectangular cross-section defined by exterior sides wherein a plurality of the interconnected pores are open to one of the exterior sides and have a largest dimension oriented relative to the one exterior side. In one embodiment, the plurality of the interconnected pores have a largest dimension oriented between approximately between 45° and 135° relative to the one exterior side.
According to another aspect of the disclosure, a scaffold comprises: a three-dimensional support structure having a length dimension defined by first and second ends thereof and a thickness dimension, normal to the length dimension, defined by first and second outer layers separated by a space, and a plurality of spacer elements extending through the space and connecting the first and second outer layers; wherein the void space surface area to measurable volume is between approximately 500 cm2/cm3 and 7,000 cm2/cm3
According to another aspect of the disclosure, a composite scaffold occupying a measurable volume and comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space having a surface area; and a structure supporting the microporous matrix; wherein the void space surface area to measurable volume is between approximately 5,000 cm2/cm3 and 16,000 cm2/cm3
According to another aspect of the disclosure, a composite scaffold comprising: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space; and a structure supporting the microporous matrix; herein a surface area of the composite scaffold is between approximately 0.3 m2/gram and 15 m2/gram.
According to another aspect of the disclosure, a method of ligament or tendon injury repair with a composite scaffold comprises: A) providing a composite scaffold comprising: i) first and second layers spaced apart to define an interior space therebetween and a plurality of spacer elements extending through the interior space and attached to the first and second layers; and ii) a microporous matrix having a multitude of interconnected pores disposed within the interior space, and B) pre-tensioning the composite scaffold along a length dimension thereof; C) attaching the composite scaffold to an allograft or autograft tendon or a damaged or torn ligament or tendon.
According to another aspect of the disclosure, a method of ligament or tendon injury repair with a composite scaffold comprises: A) providing a composite scaffold comprising:!) first and second layers spaced apart to define an interior space therebetween and a plurality of spacer elements extending through the interior space and attached to the first and second layers; and ii) a microporous matrix having a multitude of interconnected pores disposed within the interior space, and B) pre-tensioning the composite scaffold along a length dimension thereof; C) attaching the composite scaffold to an allograft or autograft tendon or other tissue graft or a damaged or torn ligament or tendon.
According to another aspect of the disclosure, a method of making a composite scaffold comprises: A) constructing a three-dimensional support structure extending along a length dimension between first and second ends thereof and defining an interior surface within the support structure; and B) forming a microporous matrix within the interior surface, the microporous matrix having a multitude of interconnected pores in fluid communication with exterior surfaces of the support structure, wherein a plurality of the interconnected pores are oriented relative to the dimensional characteristics of the support structure. In embodiments, the plurality of interconnected pores are oriented radially inward into the interior space from exterior surfaces of the support structure. In embodiments, the plurality of interconnected pores are oriented towards the length dimension of the support structure.
According to another aspect of the disclosure, a composite scaffold comprises: a support structure having an exterior profile defining an interior space and extending along a length dimension between first and second ends thereof; a microporous matrix disposed within the interior space having a multitude of interconnected pores opening exteriorly of the support structure; wherein a plurality of the interconnected pores are oriented relative to the dimensional characteristics of the support structure.
According to another aspect of the disclosure, a composite scaffold comprises: a microporous matrix having a multitude of interconnected pores collectively defining void space
opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the composite scaffold having a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state, wherein the microporous matrix is less than approximately 6% of the dry weight value of the composite scaffold.
In embodiments, the second support matrix, e.g. the sponge, degrades between approximately two to twelve times faster than the first support matrix based on either mass loss or molecular weight loss. The composite scaffold may have a degradation profile with greater than or equal to 50% strength retention for at least approximately two weeks after implantation and a mass loss of 100% mass loss between approximately six and twelve months or longer after implantation.
In embodiments, a higher density or mass of the support matrix provides the primary and bulk structure of the disclosed scaffold, in comparison to the more porous matrix disposed therein. More specifically, the first and second support matrixes have different densities or mass components relative to each other. In one embodiment, the first support matrix, e.g., the textile, has a measurable mass or density which is greater than or equal to one times that of the mass or density of the second support matrix, e.g. the sponge.
In the disclosed embodiment, the pore structure of the microporous matrix is designed to facilitate cellular attachment, proliferation, and ingrowth throughout the scaffold dimensions. In embodiments, the faces of the device, the secondary matrix, or pore structure could be engineered in architecture to encourage cellular migration in a certain direction, or to encourage the formation of aligned tissues such as connective tissues. In other embodiments the surfaces of the device might differ from each other in physical or chemical characteristics to reflect use in specific anatomic locations - i.e. one side to encourage integration with bone while the other to encourage tendon; or one side to encourage abdominal wall regeneration but the other side to prevent adhesions of internal organs.
In embodiments, the composite scaffold disclosed herein provides a measurably high surface area to volume ratio, compared to existing commercially available devices, to facilitate more rapid and greater quantity of cell infiltration and tissue ingrowth within the composite scaffold. More specifically, based predominantly on the first support matrix, e.g., the textile, surface area of the fiber to volume of the device ratio, calculated using scaffold denier, polymer density and dimensions, greater than 10 times.
In embodiments, the scaffold may have ends that narrow and transition into suture-like dimensions or are modified, e.g. stitched or knotted, to attach to conventional suture used in the procedures described herein. In other embodiments, the first support matrix, e.g., the textile, has
ends or edges that are modified to be heat set or embroidered or impregnated with other materials to facilitate better handling, better integration with existing tissue and to further reduce dimensional distortion of the scaffold under pressure, tensile, or shear forces. In other embodiments, a monofilament or multifilament suture of any material may pass through the scaffold lengthwise and exit both ends, and be attached or fixed to the scaffold.
In other embodiments selected sections of the scaffold may be repeated, either randomly or with fixed frequency to increase or decrease the density of the scaffold by increasing or decreasing the density of the textile, for example, by a change in the textile pattern of the first support matrix. In still other embodiments, such repeating regions may be chosen to alter the surface finish of the scaffold by altering the smoothness or roughness, of the exterior surface of the scaffold to enhance acceptance of the scaffold once implanted.
In one embodiment, the composite scaffold comprises just a single three-dimensional support matrix which may be the same or different than either of the first or second support matrices described herein and may have any of the characteristics of the composite scaffold described herein.
Also disclosed is a method of treatment of ligament or tendon injury wherein any of the scaffolds as disclosed herein are attached to an allograft or autograft tendon and used to replace a damaged ligament or tendon, or, the scaffold is used to augment a damaged or torn ligament or tendon. Methods of use may include preparation of the scaffold with a solution to enhance its performance, pretensioning of the scaffold, and/or fixing the femoral end and independently tensioning and fixing a tendon and graft in the tibial tunnel.
In use, the composite scaffold may be utilized in a wide array of medical procedures including to reinforce a suture repair, stand alone repair or reconstruction, or reconstruction using a tissue graft and for fixation purposes. Reinforcement of a repair or reconstruction using the composite scaffold may be applicable to the knee, ankle, shoulder, hip, elbow, foot, and hand, and non-musculoskeletal soft tissue.
In accordance with another aspect of the disclosure, a graft preparation table provides a surface and fixation mechanisms that allow for independent tensioning of tissue, e.g. tendon or ligament, and composite scaffold either prior to or during an implantation procedure.
In accordance with another aspect of the disclosure, a fixation device allows tissue, e.g. tendon or ligament, and composite scaffold to be attached to each other avoiding the need for whip stitching. Such device may comprise a clip with legs that go through graft and tendon.
In accordance with another aspect of the disclosure, a method of making a composite scaffold comprises: A) constructing a three-dimensional support structure defining an interior
surface within the support structure; B) modifying the three-dimensional support structure, and C) forming a microporous matrix within the interior surface. In embodiments, the three- dimensional support structure may be formed in (B) by an additive manufacturing techniques such as any of 3D printing or injection molding of a polymer scaffold, and modified in (C) by dimensionally or mechanically manipulating, e.g. drawing, the scaffold to align the polymer structure and improve behavioral characteristics, such as any of increase stiffness, yield point, ultimate strength, etc.
In accordance with another aspect of the disclosure, a method of making a composite scaffold comprises: A) constructing a three-dimensional support structure by an additive manufacturing techniques a scaffold defining both an exterior support matrix and an interior microporous matrix interiorly of the exterior support matrix; and B) modifying the three- dimensional support structure by dimensionally or mechanically manipulating, e.g. drawing, the scaffold to align the polymer structure and improve behavioral characteristics of one or both of the exterior support matrix and the interior microporous matrix. Such method in (A) may comprise any of 3D printing or injection molding, the exterior support matrix and the interior microporous matrix using the same or different materials, and at the same or different times. Other relevant manufacturing technologies suitable for use with the disclosed composite scaffolds include, but are not limited to, Injection Molding, Micro Molding, Stereolithography (SLA), Selective Laser Sintering (SLS), Fused Deposition Modeling (FDM), Digital Light Process (DLP), Multi Jet Fusion (MJF, Material Jetting (MJ), Direct Metal Laser Sintering (DMLS), Electron Beam Melting (EBM), and Drop on Demand (DOD).
Description the Drawings
The various features and advantages of the present invention may be more readily understood with reference to the following detailed description taken in conjunction with the accompanying drawings, wherein like reference numerals designate like structural elements, and in which:
Figure 1A is a conceptual illustration of a composite scaffold in accordance with the disclosure;
Figure 1 B is a photograph of a composite scaffold in accordance with the disclosure;
Figure 1C is a photograph of a composite scaffold in accordance with the disclosure;
Figure 2A is a conceptual illustration of knit pattern usable for exterior layers of the composite scaffold in accordance with the disclosure;
Figure 2B is a conceptual illustration of an alternative knit pattern usable for exterior layers of the composite scaffold in accordance with the disclosure;
Figure 2C is a conceptual illustration of the yarn components patterns comprising the exterior layers of Figures 2A-B in accordance with the disclosure;
Figure 2D is a conceptual illustration of a perspective view of textile patterns for a pair of of composite scaffolds useful for ACL and rotor cuff procedures in accordance with the disclosure;
Figure 3A is a photograph of a plan view of a composite scaffold having at least on exterior layer made in accordance with the pattern of Figure 2A in accordance with the disclosure;
Figure 3B is a photograph of a side view of the composite scaffold of Figure 3A;
Figure 4A is an SEM photograph of a plan view of a composite scaffold having at least on exterior layer made in accordance with the pattern of Figure 2A in accordance with the disclosure;
Figure 4B is an SEM photograph of a side view of the composite scaffold of Figure 4A;
Figure 4C is an SEM photograph of a perspective, cross-sectional view of the composite scaffold of Figure 4A as seen along axis 4A-4A in Figure 4A;
Figure 5A is a perspective view of a mold useful in making a composite scaffold in accordance with the disclosure;
Figures 5B-C are top and side plan views, respectively, of another mold useful in making a composite scaffold in accordance with the disclosure;
Figure 5D illustrates graphically the relationship of temperature, time and pressure during the lypholization process in accordance with the disclosure;
Figures 6A-6C are SEM photograph of a sagittal cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line A-A within the in accordance with the disclosure;
Figure 6D is an SEM photograph of a coronal cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line B-B within the in accordance with the disclosure;
Figures 6E is an SEM photograph of a transverse cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line B-B within the in accordance with the disclosure;
Figures 6F is an SEM photograph of a sagittal cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line A-A within the in accordance with the disclosure;
Figure 6G is an SEM photograph of a coronal cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line B-B within the in accordance with the disclosure;
Figure 6H is an SEM photographs of a transverse cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line B-B within the in accordance with the disclosure;
Figure 6I is an SEM photographs of a sagittal cross-sectional view of the microporous matrix of the composite scaffold of Figure 1C as taken along line A-A within the in accordance with the disclosure;
Figure 7A is an SEM photograph of a typical microporous matrix attached to a fiber support structure of a composite matrix in accordance with the disclosure;
Figure 7B is an SEM photograph of a typical microporous matrix attached to a fiber support structure of a composite matrix in accordance with the disclosure;
Figure 7C is an SEM photograph of the exterior surface of the typical microporous matrix of a composite scaffold in accordance with the disclosure;
Figure 8 illustrates graphically test data defining the relationship of the cumulative total pore surface area relative to pore diameter in accordance with the disclosure;
Figure 9 illustrates graphically the relationship of the cumulative total pore volume relative to pore diameter for a number of composite scaffold samples as well as only the textile only support structure in accordance with the disclosure;
Figure 10 illustrates graphically the relationship of the composite scaffold in relation to Mercury pressure for a number of composite scaffold samples as well as only the textile only support structure in accordance with the disclosure;
Figure 11 illustrates graphically the relationship of the distribution of pore diameter relative to the logarithmic differential volume in accordance with the disclosure;
Figure 12 illustrates graphically the relationship of load versus extension for both a solo tendon and a tendon augmented with a composite scaffold in accordance with the disclosure;
Figure 13A is a cross sectional microscopic view of the composite scaffold of Figure 1C illustrating the porous matrix relative to the support matrix in accordance with the disclosure;
Figure 13B is a cross sectional microscopic view of the composite scaffold of Figure 1C hydrated with blood and illustrating how red blood cells fully infiltrate a collagen sponge porous matrix in accordance with the disclosure;
Figure 14 is a photograph of the composite scaffold for MPFL repair or reconstruction in accordance with the disclosure;
Figure 15 illustrates conceptually lapsed image of a circular textile structure a circular textile structure in various stages of manufacture in accordance with the disclosure;
Figure 16 illustrates conceptually how a disclosed composite may be utilized for augmented ACL repair, stabilization or reconstruction in accordance with the disclosure;
Figure 17 illustrates graphically the relationship of the distribution of pore diameter relative to percentage of pores as measured in accordance with the disclosure;
Figures 18A-B are conceptual partial, perspective illustrations of a scaffold support structure of an implant useful for a meniscus repair in accordance with the disclosure;
Figure 18C is a partial, side cross-sectional illustration of the support scaffolds of Figures 18A-B in accordance with the disclosure;
Figure 19A is a conceptual partial, perspective illustrations of a scaffold support structure of an implant useful for rotator cuff repair in accordance with the disclosure;
Figures 19B-C are partial, side cross-sectional illustrations of the support scaffold of Figure 19A in accordance with the disclosure;
Figure 20A is a conceptual partial, perspective illustrations of a scaffold support structure of an implant useful for breast reconstruction in accordance with the disclosure;
Figures 20B-C are partial, side cross-sectional illustrations of the support scaffold of Figure 20A in accordance with the disclosure;
Figure 21 A is a conceptual partial, perspective illustrations of a scaffold support structure formed by additive manufacturing prior to drawing in accordance with the disclosure;
Figure 21 B is a conceptual partial, perspective illustrations of a scaffold support structure of Figure 21A post drawing in accordance with the disclosure;
Figures 22 is a photograph of a pattern useful in the manufacture of the scaffold faces of implants in accordance with the disclosure;
Figure 23 is a photograph of a pattern useful in the manufacture of the scaffold faces of implants in accordance with the disclosure;
Figure 24 is a photograph of a pattern useful in the manufacture of the scaffold faces of implants in accordance with the disclosure;
Figure 25 is computer simulated sample polymer scaffold with a double baseline 5 wale panel, with 2 yarns per wale, and 1 layin sponge in accordance with the disclosure;
Figure 26 is a perspective conceptual view of a composite scaffold and attachment devices sponge in accordance with the disclosure;
Figure 27 is a conceptual perspective, cross-sectional view of a composite scaffold and microporous sponge in accordance with the disclosure;
Figure 28A is perspective conceptual view of a composite scaffold bound to a tissue graft in accordance with the disclosure;
Figure 28B is perspective, conceptual view of a composite scaffold bound to a tissue graft being positioned during an ACL repair procedure in accordance with the disclosure;
Figure 28C is perspective, conceptual view of a composite scaffold bound to a tissue graft in position during an ACL repair procedure in accordance with the disclosure; and
Figure 29 is a conceptual cross-sectional view of composite scaffold and microporous sponge in accordance with the disclosure.
Detailed Description of the Invention
Embodiments of the systems and methods are now described in detail with reference to the drawings in which like reference numerals designate identical or corresponding elements in each of the several views. Throughout this description, the phrase “in embodiments” and variations on this phrase generally is understood to mean that the particular feature, structure, system, or method being described includes at least one iteration of the disclosed technology. Such phrase should not be read or interpreted to mean that the particular feature, structure, system, or method described is either the best or the only way in which the embodiment can be implemented. Rather, such a phrase should be read to mean an example of a way in which the described technology could be implemented, but need not be the only way to do so. Further, words denoting orientation such as “top”, “bottom”, “side”, “lower” and “upper”, and the like, as well as references on a specific axis in three-dimensional space are merely used to help describe the location of components with respect to one another. No words denoting orientation are used to describe an absolute orientation, i.e. , where an “upper” part must always be on top.
Referring to Figures 1A - 6D, a composite scaffold 10 comprises a first three-dimensional support matrix, and a second matrix integrally formed with one another to form the composite scaffold 10 which maximize the surface area to volume ratio and surface area per weight ratios of the scaffold. Referring to Figure 1A, the first matrix, in embodiments, may be implemented with a support structure 5 comprising a first outer layer 12 and a second outer layer 14 spaced apart to define an interior void space 16 therebetween. A plurality of spacer elements 18 extend between first outer layer 12 and a second outer layer 14 to maintain separation of the layers. In embodiments, each of layers 12, 14, and spacer elements 18 may be implemented as a three-
dimensional textile structure, each having different geometries, fibers, or material compositions. For example, any of outer layers 12, 14, and spacer elements 18 may be implemented with a textile of multifilament fibers and/or monofilament fibers. Support layers 12 and 14 may be implemented as substantially planar three dimensional textile comprising multi-layer knitted surfaces and spacer elements 18 may be implemented with interconnecting yarns in the “Z” direction normal to the planes of layers 12 and 14 provide support to prevent collapse.
The support structure 5 is intended to provide mechanical support to the growing neo tissue and to provide resistance to compression such that the area intended for new tissue formation is maintained during patient movement and activity. As such the support structure 5 provides extensional strength in its long axis and stiffness to resist compression in the “z direction”.
In embodiments, support structure 5 may be formed from any of 30-150 denier multifilament fiber, 30-150 denier monofilament fiber, or 30-150 denier composite yarn, or any combination thereof, e.g., a combination of multifilament and monofilament fibers, and may be optionally coated with an anti-adhesion material. Unfinished edges of the scaffold 10 maybe sealed or secured using methods inclusive, but not limited to, heat setting or embroidery. In one embodiment, support structure 5 is fabricated from 75-denier 30-filament Poly-L-Lactic Acid (PLLA) with a polymer density of 1.25g/cc. Yarns may be braided over a twisted fiber yarn to provide higher stiffness yarns for use as a lay in as described below.
In embodiments, one or both of outer layers 12 and 14 of support structure 5 may be implemented with a warp knit open pillar stitch 22 using double yarns, as illustrated in Figure 2A and 2C, resulting in the textile layers illustrated in Figure 3A. As can be seen from Figures 2A and 3A, the exterior layer comprises a series of wales connected by single weft lay-in 26 yarn and having double 0° straight lay-in yarns 24 on both sides inserted in the pillar structure, as illustrated in Figure 2A. The pattern of the first outer layer 12 and second outer layer 14 may be the same or different. In embodiments, both outer layers 12 and 14 may have the same number of wales with spacer elements 18 connecting similar corresponding wales in each of layers 12 and 14. In embodiments, outer layers 12 and 14 may have different number of wales with spacer elements 18 connecting wales in each of layers 12 and 14.
As used herein, a wale is "a column of loops” lying lengthwise in the fabric. Each wale may be a single or double fiber to increase strength, but consequently increasing bulk. Increasing the number of wales, or the number of yarns per wale, will result in increasing the ultimate tensile strength of the fabric. By adjusting the number of wales, the width of the fabric can changed, which allows the same textile design to be applied to narrow applications, such as for ACL
augmentation, e.g. 5mm wide, to moderately wide applications, such as for Rotator Cuff, e.g. 23mm wide, to very wide applications, such as for Hernia, e.g. 200mm wide. A method of increasing ultimate tensile strength, resistance to elongation and initial stiffness can be achieved by the addition of 0° straight lay-in yarns to the technical faces of the fabric. These lay-in yarns are incorporated into each wale in a linear fashion.
A machine that has been used to manufacture the scaffold 10 is a Karl Mayer Double Needle Bar Warp Knitting Machine. These machines are computer controlled and allow modification of many parameters to effect changes to the textile properties. Key variables include the number of wales, the number of yarns per wale, addition of In-lay yarns to wales, In-lay yarn design, and number of yarns per in-lay. The ability of the fabric to stretch under tensile load can be influenced by, for example, knitting together every two wales rather than every three wales together.
Referring to Figures 3B and 4B, spacer elements 18 may be implemented with a plurality of yarns in the “Z” direction, normal to the planes in which layers 12 and 14 exist, that connect layers 12 and 14 and provide support to prevent collapse. In embodiments, each of layers 12 and 14 may have the same number of wales and spacer elements 18 may connect corresponding wales in each of layers 12 and 14. In other embodiments, spacer elements 18 may cross diagonally between different wales of layers 12 and 14. Spacer elements 18 may comprise yarns which may be monofilament, multifilament, or multifilament and/or textured.
One or both of layers 12 and 14 may be implemented using the textile pattern illustrated in Figure 2B. Other textile patterns suitable for layers 12 and 14 may include including Full Tricot, Locknit, and Queenscord, Single Atlas, Jersey, reverse jersey, miland interlock, Milano, half Milano, etc. Variations of warp knit surface design can be utilized to adjust the dimensions, density and mechanical properties of the layers 12 and 14 including any of: surface design, number of wales, number of yarns per wale, addition of in-lay yarns to wales, in-lay yarn design, number of yarns per in-lay, lengthening or decreasing quality (machine parameter), or lengthening or decreasing gap (machine parameter).
An alternative method to warp knitting is the use of a V-Bed knitting machine, such as a Whole Garment Knitting machine, or use of a double rapier loom or a fly-shot loom to generate a woven 3D spacer fabric.
Adding pull threads between knitted panels spreads tension and keeps panels together during the manufacturing process until the pull thread is removed, without tearing or catching. These pull threads can be either mechanically removed, or dissolved away in a scour process.
In an illustrative embodiment, a support structure number five, implemented with a three- dimensional textile may have the physical parameters as illustrated in Figure 1 below.
A scaffold having the above physical values, and defining a void space between the first and second outer layers 12 and 14, respectively, through which plurality of spacer elements 18 extend, may be calculated to have a measurable void space surface area to volume ratio of between approximately 500 cm2/cm3 and 7,000 cm2/cm3
Subsequent to manufacture the scaffold textile may be scoured to clean it and remove any finishes that may have been used. The method of scouring can include the use of water, solvent and water solvent mixtures. The fabric may be washed constrained or unconstrained. The fabric may also be treated with an agent to modify its surface characteristics, for example, to influence its hydrophilicity. Various agents can be used for this including polyethylene glycols. The surface may also be treated to improve cell adhesion by agents such as fibrin. Where a portion of the scaffold is intended to be placed into contact with a bone region the surface of the fibers may be coated with a calcium phosphate, hydroxyapatite or bioactive glass or growth factor such as a bone morphogenetic protein, and demineralized bone matrix.
In embodiments, the composite scaffold 10, or any portion thereof, including layers 12 and 14 or spacer elements 18, may comprise any combination of synthetic bioresorbable polymers, natural polymers and/or additives. Synthetic bioresorbable polymers suitable for use as part of the composite scaffold may include, homopolymers, copolymers, or polymer blends of any of the following: polylactic acid, polyglycolic acid, polycaprolactone, polydioxanone, polyhydroxyalkanoates, polyanhydrides, poly(ortho esters), polyphosphazenes, poly (amino acids), polyalkylcyanoacrylates, polypropylene fumarate, trimethylene carbonate), poly(glycerol sebacate), poly(glyconate), poly(ethylene glycol), poly(vinyl alcohol) and polyurethane, or any combination thereof. Natural polymers suitable for use as part of the composite scaffold may include silk, collagen, chitosan, hyaluronic acid, alginate, and an amnion-derived matrix.
Composite Scaffold Dimensions
In embodiments, the composite scaffold 10 may have a thickness, i.e. the vertical height dimension of the scaffold as opposed to the larger length and width dimensions, between approximately .5 mm to 5 mm, and, even more preferably between approximately 1 mm to 3 mm. Even more preferably, the scaffold may have a minimum thickness of approximately greater than or equal to 1 mm. In embodiments, the thickness of the scaffold 10 may be uniform along a length thereof or may vary in a repeating or non-repeating manner, depending on the particular application for which the scaffold will be utilized.
In embodiments, the disclosed composite scaffold 10 may have width dimensions between approximately 2 mm to 1000 mm, depending on the particular application for which the scaffold will be utilized. In embodiments, the width of the disclosed scaffold may be uniform or may vary in a repeating or non-repeating manner, depending on the particular application for which the scaffold will be utilized. For example, a scaffold 10 may have ends were in the width of the scaffold narrows and dimensionally transitions into a suture-like dimension or is modified to attach to conventional suture used in the procedures described herein.
In embodiments, the disclosed composite scaffold may have length dimensions between approximately 2 to 1000 mm, and, even more preferably greater than or equal to approximately 10 inches, again, depending on the particular application for which the scaffold will be utilized. In embodiments, the disclosed scaffolds may be manufactured in different incremental lengths or may be manufactured in lengths which may be cut or customized by practitioner as desired. Figure 4B is an SEM photograph of a side view of the composite scaffold 10 having a length dimension and formed from a pair of outer layers 12 and 14 separated by a plurality of spacer elements 18. The photograph of Figure 4B was taken with a Philips/FEI XL30 ESEM Scanning Electron Microscope (SEM) with a 1 mm scale legend shown on the image and distances along the axis of the length dimension between spacer yarn, indicated by reference lines 1 - 23. Table 1 displays each reference line and its respective distance value in micrometers as well as an average distance. As can be seen from Table 1 , the average distance along the axis of the length dimension between spacer yarns is between approximately 200 pm and 300 pm.
Table 1
Figure 4C is an SEM photograph of a perspective, cross-sectional view of the composite scaffold of Figure 4A. The photograph of Figure 4C was taken with a SEM with a 1 mm scale legend shown on the image and distances along a width axis, normal to the axis of the length dimension, between spacer yarns, indicated by reference lines 1 - 17. Table 2 displays each reference line and its respective distance value in micrometers as well as an average distance. As can be seen from Table 2, the average distance along the width axis between spacer yarns is between approximately 300 pm and 400 pm (along axis);
Table 2
In the disclosed composite scaffold 10, the respective distances between spacer elements 18, e.g. the spacer yarns, create a series of substantially parallel, similarly sized channels 19 extending through the void between outer layers 12 and 14. These channels provide space within the interior of the support structure into which the microporous matrix 15 may be formed, as described herein. Importantly, these channels form along the axis of the device such that a contiguous channel exists between the two ends of the scaffold. Upon replacement by neo tissue, the neo tissue is substantive along the axis of the device and is hence load bearing and thus a functional tissue. In embodiments, these channels may have widths of between approximately 200-300 microns and the 300-400 micron. While the channels 19 may be irregular in the shape of their cross-section, the actual dimensions could be quantified with an effective diameter, i.e. the diameter of a circle of the same cross sectional area as the channel 19. In embodiments,
channels 19 may have an effective cross sectional diameter of between approximately 50 -1000 microns, but more specifically between approximately 200 - 400 microns.
Support Structure Additives
A composite scaffold 10 made of any of the foregoing materials may be combined with additives to enhance various characteristics of the scaffold including to encourage regeneration of cell growth. Such Additives suitable for use as part of the composite scaffold may include biologies including seeded cells, biological aspirates, and bio-active agents. Seeded cells suitable for use as part of the composite scaffold may include adipose derived stem cells, mesenchymal stem cells, and induced pluripotent stem cells, or any combination thereof. Biological aspirates suitable for use as part of the composite scaffold may include whole blood, platelet rich plasma and bone marrow aspirate concentrate, or any combination thereof.
Bio-active agents suitable for use as part of the composite scaffold 10 may include growth factors, extracellular matrix molecules and peptides, therapeutics, and osteoinductive or osteoconductive agents, or any combination thereof, and may be added to the support structure 5 before formation of the microporous matrix 15 or thereafter.
Growth factors suitable for use as part of the composite scaffold may include transforming growth factor-beta superfamily (e.g. transforming growth factor-beta, bone morphogenetic proteins), insulin-derived growth factor, platelet-derived growth factor epidermal growth factor, Interleukin 1- receptor antagonist, fibroblast growth factor and vascular endothelial growth factor, or any combination thereof.
Extracellular matrix molecules and peptides suitable for use as part of the composite scaffold may include tenascin-C, hyaluronic acid, glycosaminoglycans (e.g. chondroitin sulfate, dermatan sulfate, and heparan sulfate), fibrin, thrombin, small leucine rich peptides (e.g. decorin and biglycan), fibronectin, elastin and arginine-glycine-aspartate (RGD) peptide, or any combination thereof.
Therapeutics suitable for use as part of the composite scaffold may include non-steroidal anti-inflammatories (NSAIDs) (e.g., aspirin, ibuprofen, indomethacin, nabumetone, naproxen, and diclofenac), steroidal anti-inflammatories (e.g., cortisone and hydrocortisone), antibiotics or antimicrobial agents, or any combination thereof.
Osteoinductive or osteoconductive agents suitable for use as part of the composite scaffold may include tricalcium phosphate, hydroxyapatite, and bioactive glass, or any combination thereof.
Microporous Matrix
An optional microporous matrix 15 may be formed within the interior void space 16 of composite scaffold 10. The microporous matrix 15 is supported and retained by support structure 5 and provide a support for cells to populate, proliferate. The microporous matrix 15 is resorbable or degradable and is designed to be rapidly replaced by neo tissue. A microporous matrix made from the materials described herein, on its own would not have the mechanical strength characteristics to be usable, both in terms of tensile strength and resistance to compression.
In embodiments, disclosed is a method of making a composite scaffold comprising constructing a three-dimensional support structure extending along a length dimension between first and second ends thereof and defining an interior surface within the support structure; and forming a microporous matrix within the interior surface, the microporous matrix having a multitude of interconnected pores 60 in fluid communication with exterior surfaces of the support structure. The microporous matrix is formed so that a plurality of the interconnected pores 60 are oriented relative to the dimensional characteristics of the support structure. For example, those pores closest to exterior surfaces of the composite matrix may be oriented substantially normal, or radially inward extending, relative to the closest exterior surface of the support structure. In addition, other of the plurality of interconnected pores 60 may be oriented towards the length dimension of the support structure in a manner that mimics the orientation of spacer elements 18, e.g. spacer yarns, separating the outer layers 12 and 14.
In embodiments, microporous matrix 15 may be implemented with a high surface area material such as any of a sponge, foam, or textured fibers or yarns, or any combination thereof. Methods for fabrication of the microporous matrix 15 may comprise any of lyophilization, particulate leaching, open cell extrusion, solvent casting, solid-state foaming, and cross-linking. In one embodiment, sponges/foams useful as the microporous matrix may comprise any of freeze-dried sponge, open cell extrusion foam and particulate leached sponge, or any combination thereof.
A material suitable to implement microporous 15 is collagen, including bovine type 1 collagen. Other materials that can be used for porous matrix 15, in place of or in addition to collagen, include hydrogels based on Polyethylene Glycol (PEG ), Polycaprolactone (PCL), or Poly (glycolide-co-caprolactone) (PGCL), or a combination thereof. A collagen solution can be infiltrated into support structure 5 with the help of a mold to hold the scaffold. The secondary scaffold material may also coat the exterior surfaces of support structure 5 in an encapsulating manner. The mold, with textile and collagen solution, may be placed into a shelf lyophilizer, also known as a freeze dryer that uses temperature-controlled shelves to freeze the contents of the
mold to a very cold temperature, e.g. down to -55C, which creates a crystalline structure within the collagen solution causing a matrix of interconnected pores to be formed within the collagen structure occupying the interior void space 16 of support structure 5. A vacuum is pulled in the lyophilizer chamber, and the shelf temperature gradually increased, providing energy to the frozen solvent, allowing the process of sublimation to occur. The sublimated solvent is collected in a separate condenser and fully removed from the inflammation. After a period of warming and vacuum, a highly porous, low density collagen matrix is formed within the textile.
The porosity of the collagen within the microporous matrix 15 can be influenced during this process in multiple ways. Bulk porosity can be increased or decreased by decreasing or increasing the collagen solution weight percentage, respectively. The size of the pores can be adjusted by changing the rate of freezing in the mold. Increasing the rate of freezing decreases the average size, and decreasing the rate of freezing increases the average size.
Since the total surface area of the pores is related to the pore size, e.g. a large quantity of small pores will have more surface area than fewer larger pores, increasing the rate of freezing increases decreases the average pore size therefor increasing the total surface area, while decreasing the rate of freezing increases the average size therefore decreases the total surface area of the microporous matrix. Figure 5D is a graph illustrating the relationship of temperature, pressure and time during the during the lypholization process.
Variations in mold material, including Delrin, Aluminum, Stainless Steel, or other materials, transfer heat differently and can result in different microporous matrix structures by altering crystallization in the collagen solution as it freezes. For example, a mold made of Delrin, a thermoplastic used in precision parts manufacturing, transfers heat more slowly causing larger pore sizes to form within the collagen solution. Conversely, a mold formed of aluminum transfers heat very quickly resulting in a microporous matrix with relatively small size pores. A mold made of stainless steel transfers heat more slowly than aluminum and results in larger pores than those generated with an aluminum mold, but smaller than those generated with a Delrin mold.
In addition, adjusting the thickness of the mold, between the bottom surface of the mold and the bottom of the cavity has a similar effect of increasing or decreasing heat transfer speed, which can result in different microporous matrix structures. In embodiments, or the molds shown in Figures 5A and 5B are made from stainless steel and have the cavity dimensions listed in Table 6 below, wherein the 5 x 260mm column of dimensions refers to the mold 50 illustrated in Figure 5A and the 23 x 30mm column of dimensions refers to the mold 57 illustrated in Figure 5B. Mold 50 defines a plurality rectangular cavities 52 and has clamps 54 with pins 55 securable at the ends thereof. Mold 57 includes an array of rectangular cavities 59 and threw holes 53.
Table 6
The mold illustrated in Figure 5A utilizes end clips made of Delrin, which are securable to the main mold body and which may be used to clamp the textile scaffolds during the lypholization process.
In an illustrative embodiment the cavity 52 of mold 50 have a substantially rectangular cross-sectional shape. Other cross-sectional shapes may be utilized to maximize the contact between surface area of the support structure five during the process of forming the microporous matrix therein. In particular, scaffolds having any of a D - shape, II - shape, O - shape, or C - shape may be utilized during the lypholization to maximize the surface area of the shape of the scaffold and further facilitate orientation of the pores with the microporous matrix the lypholization process. In particular, for a support structure five having a cylindrical or tubular shape, tube shaped molds, whether oriented horizontally or vertically may be utilized during the the lypholization process.
Alignment of pores relative to a dimension of the scaffold can be created via contact with the mold surfaces. As illustrated in the cross-sectional SEM photographs of Figures 6D-E, 6G- H, it is seen that pores within the microporous matrix 15 form, proximate the mold surface perpendicularly to the plane of contact with the mold. In embodiments, applicant has found that pores may be oriented between proximally 45° and 135° to the plane of contact with the mold. In embodiments, with a mold similar to that illustrated in Figure 5A, a substantial number of pores will orient normal to the contact surfaces with the mold interior towards the center of the support structure 5. Such orientation further facilitates the ingrowth of cells into the composite scaffold 10 more rapidly.
An alternative mold design utilizes a similar cavity as above, but with the addition of a securely fashioned and air-tight top lid. Vacuum, or pressure, or other means may be used to fill
the mold with collagen solution from one end, similar to injection molding, and release trapped gasses at another end, helping to further align the collagen fibers during the injection process.
An additional alternative mold design uses cavities that place the textile on its side, so that the faces of the textile are perpendicular to the bottom face of the mold. An additional alternative mold design may use cavities that have a “II” shaped cross-sectional profile or another shape, which will create a finished scaffold shaped more applicably for a specific type of implantation.
There are various methods to manufacture may be used to create a microporous matrix within the void space of the textile support structure, including salt leaching, gas extrusion, and other methods using either high pressure, or vacuum, and gasses.
The resorption and mechanical characteristics of the microporous matrix may be further modified by crosslinking. Generally, materials used for crosslinking have potential cyctotoxicity so being able to use lower levels is greatly beneficial. It is a benefit of the disclosed procedure that the use of the support structure 5 allows the microporous matrix 15 to utilize a low level of crosslinking. The 3D textile, infilled with a dry, highly porous and low-density collagen microporous matrix, is removed from the mold cavities and placed into a sealed chamber on a permeable shelf, such as a wire rack. A formaldehyde and ethanol solution is poured into a tray, and this tray is placed under the rack of scaffold, and the chamber door sealed. The tray fully encompasses the base dimensions of the chamber (L x W) and the vapor from the solution is used to crosslink the collagen within the 3D textile. After a set time, the tray is removed, and the product is moved into an aeration chamber, in which clean, dry air, or alternatively, another gas such as Nitrogen, is pumped through and out of the chamber, which effectively stops the crosslinking process. Crosslinking of the collagen can be increased by increasing the time in the chamber, increasing concentration of formaldehyde in the ethanol solution, or reducing the aeration. Likewise, crosslinking can be decreased by decreasing time in the chamber, decreasing concentration of formaldehyde in the ethanol solution.
Alternatively a chemical cross linking agent may be added to the collagen solution. These agents may include, but are not limited to, various concentrations of aldehydes such as glutaraldehyde, genipin, 1-ethyl-3-(3-dimethylaminoipropyl) carbodiimide (EDC), and EDC/N- hydroxysuccinimide (EDC/NHS). An additional alternative mode of crosslinking may come in the form of photochemically activated crosslinking, which may involve the use of UV or visible light to trigger a crosslinking process with or without a crosslinking initiator.
Composite Scaffold Mechanical Characteristics
The mechanical characteristics of the composite scaffolds 10 disclosed herein, result in a composite scaffold optimized for use in a wide array of medical procedures including to reinforce a suture repair, stand alone repair or reconstruction, or reconstruction using a tissue graft and for fixation purposes. Composite scaffolds 10 made in accordance with the description herein as well as Examples 1, 2 and 3 were tensile tested using a Mark-10 Tensile Tester with a crosshead speed of 20mm/min, with the results listed in Table 3.
Table 3
An advantage of the composite scaffold 10, and particularly, the support structure 5, as disclosed herein, is its ability to resist compression upon elongation. In embodiments, as can be seen from the values in Table 3 above, the width, height and cross-sectional area of the three- dimensional textile comprising support structure 5 resists compression upon substantial forces. In particular, for a support structure 5 having a cross-sectional area of approximately 9.92 mm2, a thickness (height) of approximately 2.17 mm and a width of approximately 4.57 mm, extension of the support structure 5 along its length axis by force of 35 N causes an approximately 13% extension of the length dimension of the support structure 5. In embodiments, the thickness dimension of the support structure changes less than approximately 31 % upon elongation of the length dimension by approximately 13%. In embodiments, the cross-sectional area changes less the approximately 35% upon elongation of the length dimension by approximately 13%. In embodiments, the width dimension of the support structure changes less than approximately 5% upon elongation of the length dimension by approximately 13%.
In embodiments, a length of a support structure 5, implemented with a three-dimensional textile scaffold as disclosed herein, may have an ultimate load at a percentage of elongation of the length dimension between approximately 30% and 125%. In embodiments, the scaffold may have a yield at a percentage of elongation of the length dimension between approximately 5% and 15%. In embodiments, the scaffold may have a tenacity of between approximately 0.073 grams-force/denier and 1.102 grams-force/denier. In embodiments, the scaffold may have a stiffness of approximately between 2.5 N/mm and 25 N/mm, wherein the stiffness defines an extent to which the scaffold resists deformation in response to an applied force. In embodiments, the scaffold may have a strain at failure of approximately between 20 % and 70 %. In embodiments, the scaffold may have a tenacity at failure approximately between 0.3 grams- force/denier and 2 grams-force/denier.
In an illustrative embodiment, the support structure 5, implemented with a three- dimensional textile scaffold 5 mm in width and 40 mm in length and having a thickness approximately 1 mm, or as disclosed herein, may have an ultimate load displacement of approximately between 5 mm and 50 mm, wherein the ultimate load displacement defines a change in displacement at an amount of load applied to the biomimetic scaffold beyond which the biomimetic scaffold will fail. Such test being done with a 40 mm gauge length and in accordance with the standards set forth by the American Society for Testing and Materials (ASTM). In the illustrated embodiment, the scaffold may have a yield displacement of approximately between 1
mm and 8 mm, wherein the yield displacement defines a change in displacement at which the biomimetic scaffold begins to deform. In the illustrated embodiment, the scaffold may have a yield force of approximately between approximately between 20 N and 70 N, wherein the yield force defines a force at which the biomimetic scaffold begins to deform. In the illustrated embodiment, the scaffold may have a stiffness of approximately between 2.5 N/mm and 25 N/mm, wherein the stiffness defines an extent to which the biomimetic scaffold resists deformation in response to an applied force. In the illustrative embodiment, the scaffold may have an ultimate strain of approximately between 20 % and 70 %, wherein the ultimate strain defines the deformation of the biomimetic scaffold due to stress. In the illustrated embodiment, the scaffold may have an ultimate load approximately between 100 N and 200 N wherein the ultimate load is defined as the amount of load applied to the biomimetic scaffold beyond which amount the scaffold fails. In the illustrative embodiment, the scaffold may have an ultimate strength approximately between 2.5 MPa and 20 MPa wherein the ultimate strength is defined as a capacity of the biomimetic scaffold to withstand loads tending to elongate the biomimetic scaffold. In the illustrative embodiment, the scaffold may have an ultimate stress approximately between 2.5 MPa and 20 MPa wherein the ultimate stress is defined as a maximum value of stress that the structure can resist beyond which maximum value the structure fails. In the illustrated embodiment, the scaffold may have a modulus of approximately between 2.5 MPa and 70 MPa, wherein the modulus defines measure of stiffness of the biomimetic scaffold with the void space. In illustrative embodiment, the scaffold may have a modulus of approximately between 150 MPa and 600 MPa, wherein the modulus defines measure of stiffness of the biomimetic scaffold without the void space, where the modulus is calculated using a cross-sectional area of only material comprising the composite scaffold.
According to embodiments, the composite scaffold disclosed herein provides greater support for a larger quantity of regenerated tissue through staggered degradation rates of the scaffold components. More specifically, the first and second support matrixes 5 and 15 of scaffold 10 have different degradation rates. In one embodiment, the second support matrix 15, e.g. the sponge, degrades 2 to 12 times faster than the first support structure 5 based on mass loss or molecular weight loss. For example, the sponge comprising the second support matrix may have a mass loss by 3 to 6 months following implementation whereas the textile weave comprising first support matrix may have mass loss at 12 months following implantation. Such difference in the rate of degradation enables the considerable tissue ingrowth facilitated by the interior void of the scaffold 10 to continue to be supported by the textile fabric for a longer period of time. As indicated, the parameter of material degradation may be measured via loss of mass or molecular
weight loss. In one embodiment, the composite scaffold may have a degradation profile of greater than or equal to 50% strength retention for at least approximately four weeks after implantation and a mass loss of 100% mass loss between approximately six and twelve months after implantation.
According to embodiments, the composite scaffold disclosed herein may have features which enhance usability and better performance once implanted. In embodiments, the scaffold 10 may have ends that narrow and transition into suture-like dimensions or are modified, e.g. stitched or knotted, to attach to conventional suture used in the procedures described herein. In embodiments, the support structure 5, e.g., the textile, has ends or edges that are modified to be heat set or embroidered or impregnated with other materials to facilitate better handling, better integration with the existing tissue and to further reduce dimensional distortion of the scaffold 10 under pressure, tensile, or shear forces. In embodiments selected sections of the scaffold 10 may be repeated, either randomly or with fixed rapidity to increase or decrease the density of the scaffold by increasing or decreasing the density of the textile, for example, by a change in the textile pattern of the first support structure 5. In embodiments, such repeat regions may be chosen to alter the surface finish of the scaffold by altering the parameters of lyophilization, smoothness or roughness, of the exterior surface of the scaffold to enhance acceptance of the scaffold once implanted.
In embodiments, the spacer elements18 may be located in only part of the interior space 16 of scaffold 10, e.g. a hollow lumen, as illustrated in Figure 2D. In other embodiments, the spacer elements 18 may have any of a regular or irregular repeating placement pattern within the interior space 16 between the layers 12 and 14 of the scaffold 10. In other embodiments, the spacer elements 18 themselves may be implemented with a textile, such as felt, or tissue or tissue derived materials, or as otherwise described herein.
According to embodiments, the composite scaffold could also be seeded with cells for a temporary pre-culture period to allow the cells to elaborate a collagen-rich extracellular matrix on the sponge and textile components. The scaffold could then optionally be decellularized to leave a matrix template having native extracellular matrix proteins on the textile structure and the scaffold subsequently implanted to repair a tendon or ligament in vivo.
Scaffold Pore Characteristics
Multiple samples of composite scaffolds manufactured in accordance with examples one and two and the processes described herein were tested to determine various behavioral
characteristics as described below. The microporous matrix in each sample composite scaffold has a multitude of interconnected pores opening to an exterior surface of the microporous matrix and the composite scaffold. Various characteristics of the pores within the microporous matrix, and, accordingly, the composite scaffold, are measurable by Mercury Intrusion Porosimtery (MIP) or gas adsorption. Mercury is a non-wetting liquid that will not actively infill into porous structures. However, by applying pressure, using MIP, mercury can be forced into the pores of the microporous matrix, with higher pressures allowing the mercury to enter smaller pores. By accurately monitoring a volume of mercury while step-wise increasing the applied pressure, pore size (diameter) and pore volume can be accurately measured. The pore size and volume measurements can be used to determine multiple properties of the microporous matrix and the composite scaffold generally.
Surface Area
An important characteristic of the disclosed composite scaffolds is the ratio of the scaffold surface area per unit weight of the scaffold. The disclosed composite scaffold, due to the extensive multitude of interconnected pores within the microporous matrix supported by the 3D textile support structure, has a large surface area onto which cell migration and subsequent neotissue development may occur. The total surface area of the interconnected pores and the exterior of the composite scaffold is more accurately measurable using MIP, instead of just geometric dimensions and image quantification. Surface area may be calculated from the known diameter of the pores, measured via MIP, by assuming the pores are spheres using the following formula:
A ~ 4 r
As such, the surface area parameter represents an amount of surface area of the composite scaffold per unit weight of the composite scaffold area, measurable in meters squared per gram (m2/g). Figure 8 is a graph 80 of test data showing the relationship of the cumulative total pore surface area relative to pore diameter, measured in micrometers, for a number of composite scaffold samples as well as a sample comprising only the 3D textile comprising support structure 5. In the samples of Figure 8, the 3D textile support structure 5, whether alone or populated with a microporous matrix 15, comprised PLLA fibers. All samples were produced in accordance with the methods and Examples 1 and 2 described herein. In embodiments, a disclosed composite scaffolds may have a surface area per weight unit which range from between approximately 0.3 m2/gram and 1.5 m2/gram. The disclosed composite scaffolds may have a
surface area per weight unit which range from between approximately 0.6 m2/gram and 1.2 m2/gram. The disclosed composite scaffolds may have a surface area per weight unit, from between approximately 0.71 m2/gram and 1.0 m2/gram.
The total surface area of the interconnected pores and the exterior of the composite scaffold is also more accurately measurable using gas adsorption, instead of just geometric dimensions and image quantification, such as with krypton gas. The Table 7 below illustrates two samples having a 5 mm width and a 40 mm length. The surface area of the composite scaffold is between approximately 0.3 m2/gram and 15 m2/gram, as measured by krypton gas adsorption for pores having a diameter less than 1 pm.
Table 7
Total Pore Volume
Another important characteristic of the composite scaffold is the high volume of void space due, in part, to the number, size, orientation and interconnectivity of the pores which collectively define void space within the microporous matrix. Such high total pore volume facilitates more rapid blood absorption, cell migration and subsequent neo-tissue development. The total volume of pores collectively forming the void space within the microporous matrix may be measured directly using MIP by monitoring the change in Mercury volume during the MIP process. As such, the pore volume parameter of the composite scaffold represents a total cumulative void volume per unit weight of the composite scaffold, e.g. cm3/g. Figure 9 is a graph 90 showing the relationship of the cumulative total pore volume as measurable in centimeters cubed per gram relative to pore diameter, as measured in micrometers for a number of composite scaffold samples as well as only the textile only support structure. In the samples of Figure 9, the textile support structure, whether alone or populated with a microporous matrix, comprises PLLA fibers. All samples were produced in accordance with the methods described herein. In embodiments, the disclosed composite scaffold may have a total pore volume which ranges from between approximately 3.0 cm3/gram and 9.0 cm3/gram. The disclosed composite scaffolds may have a volume which ranges from between approximately 3.5 cm3/gram and 7.0 cm3/gram. The disclosed
composite scaffolds may have a total pore volume which ranges from between approximately 4.0 cm3/gram and 5.0 cm3/gram.
Porosity
Another important characteristic of the composite scaffold is porosity, that is the measurement of the void space volume within the microporous matrix as a percentage of the measurable volume of the composite scaffold itself. Such calculation may be done using measurements taken during MIP. During the Ml P process, the mass of each sample is known, as is the occupied volume of the sample by monitoring mercury volume. At the lowest applied pressure during MIP, there should be no mercury infill into the scaffold, so bulk density of the composite scaffold can be calculated. At the higher applied pressures during MIP, the composite scaffold should be near-complete mercury infill. Accordingly, the scaffold skeletal density can be calculated as follows:
Porosity = 100 * 1 - (density at low pressure/density at high pressure)
In this manner, the measurable volume of the composite scaffold is not calculated geometrically but through relative densities. Figure 10 is a graph 100 of the relationship of the composite scaffold density in grams per cubic centimeter in relation to Mercury pressure, as measured in pounds per square inch absolute, i.e. in a vacuum, measured in micrometers, for a number of composite scaffold samples as well as only the textile only support structure. In the samples of Figure 10, the textile support structure, whether alone or populated with a microporous matrix, comprises PLLA fibers. All samples were produced in accordance with the methods described herein. In embodiments, the disclosed composite scaffold may have a porosity which ranges from between approximately 75% to 98%. In embodiments, the disclosed composite scaffold may have a porosity which ranges from between approximately 80% to 90%. In embodiments, the disclosed composite scaffold may have a porosity which ranges from between approximately 80% to 85%.
Permeability
Another important characteristic of the composite scaffold is the permeability of the microporous matrix which facilitates more rapid absorption of fluids, particularly blood, both during and after implantation, to accelerate the process of cell migration and subsequent neo-tissue development. The microporous structure, e.g. collagen, inside the textile support structure
facilitates a more uniform and well-defined pore structure compared to a collagen sponge alone, with a permeability of approximately 200% of the permeability of a collagen sponge by itself. This is due, at least in part, to the more uniform and well-defined structure of interconnected pores. Reproducible permeability values can be calculated from Mercury Intrusion Porosimetry (MIP) data using the Katz-Thompson equation set forth below:
Where: k (mD): air permeability
Pt (psia): pressure at which Hg starts to flow through pores
Dc (pm): diameter corresponding to Pt (Dc = 180/Pt)
Dmax (pm): diameter at which hydraulic conductance is a maximum hydraulic conductance: measure of the ease that a fluid flows through a porous material cp: porosity from MIP data (subtract inaccessible void space in fibers)
S(Dmax): fraction of connected pore space that is size Dmax and larger/ fraction of total porosity filled at Dmax
An explanation of how to calculate permeability using the above Katz-Thompson equation is set forth in a publication by Goa and Hu, entitled estimating permeability using median poor- throat radius obtained from Mercury intrusion precocity, J. Geophysics. Eng. (2013). In this manner, reproducible permeability values can be calculated from data collected during MIP. In embodiments, the disclosed composite scaffold may have a permeability which ranges from between approximately 1200 and 3000 millidarcy. In embodiments, the disclosed composite scaffold may have a porosity which ranges from between approximately from between approximately 1400 and 2600 millidarcy. In embodiments, the disclosed composite scaffold may have a porosity which ranges from between approximately from between approximately 1600 and 2000 millidarcy.
Total Surface Area/Scaffold Volume
Another important characteristic of the composite scaffold is the ratio of the total surface area/scaffold volume. The surface area per given sample is determinable from MIP. The skeletal density can be calculated as explained above with reference to the porosity parameter. Surface area is reported in units of square meters per sample weight unit (m2/g) and can be converted to meters cubed by multiplying by the sample mass. Scaffold volume is equal to the sample mass divided by the skeletal density. In embodiments, the disclosed composite scaffold may have a void space surface area to scaffold volume between approximately 5,000 cm2/cm3 and 16,000 cm2/cm3 . In embodiments, the disclosed composite scaffold may have a void space surface area to scaffold volume between approximately 7,000 cm2/cm3 and 14,000 cm2/cm3. In embodiments, the disclosed composite scaffold may have a void space surface area to scaffold volume between approximately 9,000 cm2/cm3 and 12,000 cm2/cm3.
Pore Size
Another important characteristic of the composite scaffold is median pore size of the interconnected pores within the void space of the microporous matrix 15, as measured in micrometers. The pores with the microporous matrix must be large enough to allow cell infiltration while not being so large that it slows cell proliferation and formation of neo-tissue prior to reabsorption of the microporous matrix following implantation. In accordance with the disclosure, a number of pores of a given diameter are effectively measured by tracking intrusion volume at a given pressure during MIP. From this, median pore size and pore size distribution are both reported. Figure 12 is a graph 120 illustrating graphically the relationship of the distribution of pore diameter, as measured in micrometers relative to the logarithmic differential volume as measured in cubic centimeters per grams. In embodiments, the microporous matrix may have a plurality of interconnected pores having a median pore size of between approximately 10 pm to 70 pm. In embodiments, the microporous matrix may have a plurality of interconnected pores having a median pore size of between approximately 12 pm to 50 pm. In embodiments, the microporous matrix may have a plurality of interconnected pores having a median pore size of between approximately 20 pm to 35 pm.
Another important characteristic of the composite scaffold is distribution of pore sizes within the void space of the microporous matrix of the composite scaffold, as measured in micrometers. Cumulative pore volume is determinable from MIP. The fractional contribution of pores over a certain size to the void space can be calculated as cumulative void space at a given pore size divided by total void space. The distribution of pore sizes within the void space of the
microporous matrix is also illustrated in Figure 12. As can be seen from Figure 12, the majority of the collective void space within a microporous matrix comprises pores having a size parameter greater than 10 pm. In embodiments, the microporous matrix has a multitude of interconnected pores collectively defining void space wherein at least approximately 99% of the void space comprises pores having a size dimension of 10 pm or greater. In embodiments, the microporous matrix has a multitude of interconnected pores collectively defining void space wherein at least approximately 95% of the void space comprises pores having a size dimension of 10 pm or greater. In embodiments, the microporous matrix has a multitude of interconnected pores collectively defining void space wherein at least approximately 80% of the void space comprises pores having a size dimension of 10 pm or greater.
Swelling and Absorbance
According to embodiments, the composite scaffold disclosed herein provides a measurably high absorptive capacity, e.g. capable of absorbing aqueous mediums, or wickability, to facilitate more rapid and greater quantity of absorbed biologic fluids and/or cells within the scaffold. In particular, the absorbance capacity of the composite scaffold can be measured from the following formula:
% Absorbance = (Sample wet mass - samples dry mass)/Sample dry mass*100
In embodiments, the disclosed composite scaffold has a measurable dry weight value representing a weight of the scaffold in a substantially dry state and a measurable dry volume value representing a volume of the scaffold in a substantially dry state, with an increase of between approximately 200% and 600% of the weight value of the scaffold from fluid absorption changing the dry volume value of the scaffold between approximately 0% and 10%. The percent volume change of the composite scaffold can be measured from the following formula:
% Volume Change = (Sample wet volume - sample dry volume)/Sample dry volume * 100
According to embodiments, the composite scaffold disclosed herein provides a reduced swelling profile, e.g. resists dimensional changes with increased absorption fluids. In particular, the percent swelling change of the composite scaffold can be measured from the following formula:
% Swell = (Sample wet mass - samples dry mass)/(Sample wet mass) * 100
In embodiments, the disclosed composite scaffold has a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state and a measurable dry length value representing a dimensional parameter of the composite scaffold in a substantially dry state, with an increase of between approximately 200% and 600% of the weight value of the composite scaffold from fluid absorption changing the dry length value of the composite scaffold by less than between approximately 0% and 3%. The percent length change of the composite scaffold can be measured from the following formula:
% Length Change = (Sample wet length - sample dry length)/Sample dry length * 100
In embodiments, the disclosed composite scaffold a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state and a measurable cross sectional profile value representing a dimensional parameter of the composite scaffold in a substantially dry state, with an increase of between approximately 200% and 600% of the weight value of the composite scaffold from fluid absorption changing the cross sectional profile value of the composite scaffold by between approximately 0% and 10%. The percent cross sectional profile change of the composite scaffold can be measured from the following formula:
% Cross sectional profile change = ((Sample wet width * sample wet height) - (Sample dry width * sample dry height)) I (Sample dry width * sample dry height)*100
Other relevant form are as followsulas:
% Density Wet = ((Sample wet weight/sample wet volume) I (sample dry weight/sample dry volume) * 100
% Thickness Change = (sample wet height - sample dry height)/ sample dry height * 100
% Weight Wet = sample wet weight/sample dry weight * 100
% of Sample Volume filled = (Sample wet mass - samples dry mass)/(Sample dry volume)
Composite scaffold devices are weighed throughout the manufacturing process, capturing both the mass of the textile alone, the mass after being coated with PEG 400, and the mass after adding collagen solution and subsequent lyophilization. The mass of the collagen microporous matrix in each device can be calculated as follows:
1TL(lSS( oiiagen — massscaffoid md'SStextile+PEG 400
The % dry weight of the collagen compared to the whole composite scaffold device can then be calculated:
Scaffold Density
Another important characteristic of the composite scaffold is scaffold density. According to embodiments, for the composite scaffold disclosed herein has a higher density or mass of the support matrix provides the primary and bulk structure of the disclosed scaffold, in comparison to the more porous matrix disposed therein. More specifically, the first and second support matrixes 5 and 15 of scaffold 10 have different densities or mass components relative to each other. In one embodiment, the first support structure 5, e.g., the textile, has a measurable mass or density which is greater than or equal to one times that of the mass or density of the second support matrix 15, e.g. the sponge, and, more preferably, between 2 to 5 times that of the mass or density of the second support matrix 15. In embodiments, the disclosed composite scaffold may have a maximum scaffold density of less than 0.5 g/cm3, and specifically between approximately 0.05 g/cm3 and 0.3 g/cm3
Methods of Manufacture
Methods for manufacturing the composite scaffold in accordance with the disclosure are as follows. A 5mm wide, 3mm tall, and 260mm long composite scaffold for ACL repair or augmentation made from a three-dimensional PLLA textile filled with a highly porous collagen matrix is manufactured, as follows. A three-dimensional (3D) textile which comprises the support structure is manufactured using the double pillar pattern illustrated in Figure 2A in accordance with the technique the warp knitting technique described. The resulting structure has top and bottom layers of 6 wales each. The corresponding wales top and bottom layers of the
interconnected by a series of knitted spacing yarns extending through the void space in the Z- direction, e.g. normal to the X-Y plane of the outer layers 12 and 14, and interconnecting the layers 12 and 14. The 3D textile is received as a continuous length textile, 5mm wide and 3mm tall and is ultrasonically scoured, e.g. washed, in solution of DI and I PA to remove particulate and yarn spin finish. Multiple washes, replacing solution in between washes, are used. The temperature of the wash solution may be room temperature, or up to 40C. The 3D textile is then air dried, and cut to length.
An alternative method of preparing the 3-D textile prior to coating with a hydrophilic solution involves wrapping the continuous length textile, not overlapping, around a frame, also known as a tenter frame, or suture rack, with moderate tension. The wrapped frame is then submerged in a distilled water and isopropyl alcohol solution, and washed either ultrasonically or in a shaker bath for agitation. Multiple washes, replacing solution between washes, may be used. The temperature of the wash solution may be room temperature, or up to 40C. The 3D textile is then air dried on the rack, under tension. The textile is then cut to length, while under tension, on the rack, creating uniform lengths. By utilizing the suture rack, washing under tension, and drying under tension, the textile is heat-set, reducing wrinkles, keeping top and bottom textile faces opposed, and tightening the knit structure, resulting in less elongation of the final textile under load.
The scoured and cut to length of 3D textile is then submerged in a solution of polyethylene glycol (PEG) and ethanol to increase hydrophilicity. The concentration of PEG in ethanol is specifically controlled to result in a controlled weight percentage of PEG on the 3D textile. The 3D textile is then air dried. An alternative method of preparing the 3-D textile prior to coating with a hydrophilic solution involves submerging the 3D textile in the PEG and Ethanol solution, after scouring, but before cutting to length. An additional alternative method involves submerging the 3D textile as wrapped on the frame, after scouring, but before cutting, in the PEG and ethanol solution. In the above-mentioned steps, multiple combinations of each alternative may be utilized to achieve the same outcome.
Next, a 0.6% collagen solution by weight is made up using low molarity acetic acid and powder-form Type-1 bovine collagen is blended and vacuum processed to remove trapped air bubbles. A different low molarity acid such as hydrochloric acid may be used to make the collagen solution. Additionally, an alternative process may remove trapped air bubbles, for example, by spinning the solution in a centrifuge.
Different weight percent collagen solutions can be used. Increasing the weight percentage of collagen increases the amount of collagen in the matrix. Decreasing the weight percentage of
collagen reduces the amount of collagen in the matrix. These changes will affect the final collagen matrix density, structural characteristics, and porosity when utilized with the lyophilization process described herein.
The stainless-steel mold 57 shown in Figure 5B is used to guide infill of collagen solution into the 3D textile and through the next step, lyophilization, to create the collagen sponge matrix structure. The cavities of the mold are filled with a small amount of collagen solution. Then, 3D textile lengths are placed into the mold, 3D textile faces parallel to the bottom of the cavity, and clamps are used on each end to secure the 3D textiles and to prevent movement. These clamps have an additive benefit, in the following step, Lyophilization, by creating areas on each end that are flat without porous collagen matrix, used for product handling and suture attachment.
Then, additional collagen solution is filled into the cavities with the textile, completely submerging the textile in collagen solution. Then, the mold with textile and collagen solution is vacuum processed to remove remaining air within the 3D textile to completely infill the textile with solution. The mold, with textile and collagen solution, are placed into a shelf lyophilizer, and the temperature brought down to -55C over a period of approximately 2 hrs. The textile, infilled with a dry, highly porous and low-density collagen matrix, is removed from the mold cavities and placed into a sealed chamber on a wire rack. A formaldehyde and ethanol solution is poured into a tray, and the tray placed under the rack of product, and the chamber door sealed. Vapor from the solution crosslinks the collagen within the textile. After approximately 2 hours, the tray is removed, and the product moved into an aeration chamber, in which clean, dry air is pumped through and out of the chamber, which effectively stops the crosslinking process. After a period of warming and vacuum, a highly porous, low density collagen matrix is formed within the 3D textile.
A 23mm wide, 3mm tall, and 30mm long composite scaffold for Rotator Cuff repair or augmentation made from a three-dimensional PLLA textile filled with a highly porous collagen matrix is manufactured, as follows. A 5mm wide, 3mm tall, and 260mm long composite scaffold for ACL repair or augmentation made from a three-dimensional PLLA textile filled with a highly porous collagen matrix is manufactured, as described hereafter. A three-dimensional (3D) textile which comprises the support structure is manufactured using the double pillar pattern illustrated in Figure 2A in accordance with the technique the warp knitting technique described. The resulting structure has top and bottom layers of approximately 25 wales each. The corresponding wales top and bottom layers of the interconnected by a series of knitted spacing yarns extending through the void space in the Z direction and interconnecting the layers.
The 3D textile is received as a continuous length textile, 5mm wide and 3mm tall and is ultrasonically scoured, e.g. washed, in solution of DI and IPA to remove particulate and yarn spin
finish. Multiple washes, replacing solution in between washes, are used. The temperature of the wash solution may be room temperature, or up to 40C. The 3D textile is then air dried, and cut to length. The scoured and cut to length of 3D textile is then submerged in a solution of PEG and ethanol to increase hydrophilicity. The concentration of PEG in ethanol is specifically controlled to result in a controlled weight percentage of PEG on the 3D textile. The 3D textile is then air dried.
Next, a 0.6% collagen solution by weight is made up using low molarity acetic acid and powder-form Type-1 bovine collagen is blended and vacuum processed to remove trapped air bubbles.
The stainless-steel mold shown in Figure 5B is used to guide infill of collagen solution into the 3D textile and through the next step, Lyophilization, to create the collagen sponge matrix structure. The cavities of the mold are filled with a small amount of collagen solution. Then, 3D textile lengths are placed into the mold, 3D textile faces parallel to the bottom of the cavity, and clamps are used on each end to secure the 3D textiles and to prevent movement. These clamps have an additive benefit, in the following step, Lyophilization, by creating areas on each end that are flat without porous collagen matrix, used for product handling and suture attachment.
Then, additional collagen solution is filled into the cavities with the textile, completely submerging the textile in collagen solution. Then, the mold with textile and collagen solution is vacuum processed to remove remaining air within the 3D textile to completely infill the textile with solution. The mold, with textile and collagen solution, are placed into a shelf lyophilizer, and the temperature brought down to -55C over a period of 2 hrs. A vacuum is pulled in the lyophilizer chamber, and the shelf temperature gradually increased, providing energy to the frozen solvent, allowing the process of sublimation to occur. The sublimated solvent is collected in a separate condenser and fully removed from the inflammation. After a period of warming and vacuum, a highly porous, low density collagen matrix is formed within the 3D textile.
The mold design may be such that the whole scaffold becomes encapsulated in the collagen gel this may have the benefit of shielding the body from the textile scaffold component with the more biocompatible collagen gel.
Medical Procedures
The composite scaffolds described herein may be utilized in a wide array of medical procedures including to reinforce a suture repair, stand alone repair or reconstruction, or reconstruction using a tissue graft and for fixation purposes. Reinforcement of a repair or reconstruction using the composite scaffold may be applicable to the knee, ankle, shoulder elbow
and hand, and non-musculoskeletal soft tissue. The knee may include any of ACL (anterior cruciate ligament), PCL (posterior cruciate ligament), LCL (lateral collateral ligament), MCL (medical collateral ligament), MPFL (medial patellofemoral ligament), ALL (anterolateral ligament), and Posterolateral Corner Injury (fibular collateral ligament, popliteus tendon, popliteofibular ligament). The ankle may include any of the ATFL (anterior talofibular ligament) and CFL (calcaneofibular ligament). The shoulder elbow and hand, may include any of the rotor cuff (supraspinatus, infraspinatus, subscapularis, and teres minor tendons), acromioclavicular ligament, UCL (ulnar collateral ligament), and flexor tendon. Non-musculoskeletal soft tissue may include any of the breast, abdominal wall, and pelvic floor. The composite scaffolds described herein may be utilized for fixation of permanent and re-absorbable materials, including sutures, suture anchors, tacks, and staples.
The physical dimensions and biomechanical characteristics of the composite scaffolds disclosed herein are optimized for use in a wide array of medical procedures including to reinforce a suture repair, standalone repair or reconstruction, or reconstruction using a tissue graft and for fixation purposes. Reinforcement of a repair or reconstruction using the composite scaffold may be applicable to the knee, ankle, shoulder elbow and hand, and non-musculoskeletal soft tissue. Such physical characteristics are measurably different than those of commercially available products such as hernia mesh and orthopedic suture tape and are more suitable for the above described procedures. For example, orthopedic suture tape exists, and is measurable as a three- dimensional entity, for all intents and purposes relative to surgery it is effectively two-dimensional with little value for regenerating the volume of tissue necessary to enhance or mimic the characteristics of tendons or ligaments. For surgical meshes and patches constructed of bioresorbable materials, which have broad applications and can be considered scaffolds, the resulting tissue plane that is formed following total resorption of the material can be quite thin and weak; this is due to a lack of thickness and/or sufficient void volume of suitable pore size for cellular ingrowth within the scaffold. Therefore, there is a clear need to create tissue scaffolds of sufficient thickness that regenerate thicker and stronger tissue planes following polymeric degradation.
In an exemplary embodiment, Figure12 and Table 4 below illustrates, over the number of samples, that a tendon augmented by the disclosed composite scaffold, is consistently stronger and capable of handling greater force over similar extension than the tendon alone.
Table 4
EXAMPLES
Example 1 - Manufacture of Textile Scaffold
A 75 denier 30 filament poly-L-Lactic Acid (PLLA) yarn was produced for use in manufacture of scaffold fabrics. A warp beam was produced for use in a Karl Mayer Double Needle Bar Machine to produce the fabric. A 5mm wide fabric of 6 wales across its width and a 23mm wide fabric with 27 wales across were produced, i.e. using a 22 gauge needle bed. The two surface layers were separated in the Z direction by spacer yarns to make fabrics 2mm thick. The fabric was scoured in an ultrasonic bath with a mixture of deionized water and iso propyl alcohol and dried.
Example 2- Manufacture of ACL Augmentation / Repair Device
A 0.6%collagen solution (by weight) was made up using low molarity Acetic Acid and powder-form Type-1 bovine collagen. This solution was blended and vacuum processed to remove trapped air bubbles. A stainless-steel mold, as shown in Figure 5A, its cavities filled with a small amount of collagen solution. The textile scaffold from Example 1 , a 26 cm long and 5mm wide sample, were placed into the mold, with textile faces parallel to the bottom of the cavity, and clamps used on each end to secure the textile and prevent movement. Additional collagen solution was filled into the cavities with the textile, completely submerging the textile in collagen solution. The mold with textile and collagen solution was vacuum processed to remove remaining air within the textile to completely infill textile with solution.
The mold was then placed in an SP Scientific Advantage Plus Lyophilizer and the samples lyophilized, the lyophilization process taking the interior of the Lyophilizer from room temperature to -55C over a period of 2 hrs. The textile, infilled with a dry, highly porous and low-density collagen matrix, was removed from the mold cavities and placed into a sealed chamber on a wire
rack. A formaldehyde and ethanol solution was poured into a tray, and the tray placed under the rack of product, and the chamber door sealed. Vapor from the solution crosslinks the collagen within the textile. After 2 hours, the tray was removed, and the product moved into an aeration chamber, in which clean, dry air was pumped through and out of the chamber, which effectively stops the crosslinking process. The final device was suitable for use in ACL augmentation or repair
Example 3 - Manufacture of Rotator Cuff Augmentation / Repair Device
Following the methodology of Example 2 a mold suitable to accommodate a 23mm wide fabric was used to impregnate 50mm by 23mm pieces of fabric from Example 1 , but instead using the mold of Figure 5B. The final device was suitable for use in rotator cuff augmentation or repair
Example 4- Manufacture of Matrix Material
A 0.6%collagen solution (by weight) was made up using low molarity Acetic Acid and powder-form Type-1 bovine collagen. This solution was blended and vacuum processed to remove trapped air bubbles. The solution was then lyophilized same as in Examples 2 and 3.
Example 5 - Demonstration of Tendon Augmentation
A Porcine profundus tendon was obtained from a local abbatoir. The composite scaffold device from Example 1 was doubled over the tissue and whip-stitched at one end with #2 suture. A tensile test machine was used to mimic the graft preparation table. The whip-stitched end secured in upper grip jaws of tensile tester. Pretension achieved by loading both ends of composite scaffold to appropriate force and securing lower grip jaws. The construct was cycled to 3.75mm extension and back to zero. The performance data are shown in Table 5 below, and demonstrated the ability of the composite scaffold pre tension to control the reinforcement provided by the scaffold.
Table 5
While the size of the composite scaffolds described herein may vary according to the intended application, it is contemplated that a scaffold may have a lengths up to 1000 mm and a width from 3 mm to 1000 mm to adopt to different soft-tissue sizes and applications. Further, the width may taper to suture width at the ends of the scaffold.
In embodiments, the composite scaffold may utilize a tubular spacer, whether warp or weft knit, which can be used as a “sheath” over autograft, allograft, or a repaired tendon or ligament. One method of producing this is to take a flat spacer fabric and then attach the opposing edges, by sewing, heat sealing, or other means, to create a tube, as illustrated in Figure 14. Alternatively, a customized circular knitter can be used to knit a tubular spacer fabric without a connecting seam. Another alternative method of making a tubular spacer is to weave the structure by method of 3D circular woven preform, method and structure is illustrated in Figure 15.
Any of the disclosed scaffolds or components thereof may be implemented using additive manufacturing techniques, including 3D printing, injection molding, casting. In embodiments, the textile component, which serves as the structure to hold the porous matrix, may be a 3D print a structure manufactured from an elastic or non-elastic material, which will then be infilled with the porous matrix. In other embodiments, both the support structure and the porous matrix can be 3D printed from one or multiple materials, either as separate but combined entities, or as a single entity that provides both strength, porosity, and resistance to compression. In still other embodiments, the scaffold comprises a composite structure with a textile outer cover extending at least partially thereover to provide strength and a 3D printed inner support structure to provide resistance to compression. Such scaffold may have either rectangular, tubular shape, customized
or other shaped profile. Braiding may be used as a cost effective method of producing a tubular structure. By braiding over a 3D printed inner support structure insert the required contiguous space for tissue ingrowth is provided. Polymer fibers braided longitudinally into an exterior braid structure may be provided to further modulate the tensile characteristics of the scaffold.
Implants For Specific Procedures
According to another aspect of the disclosure, the scaffolds described herein may be designed for specific applications such as rotator cuff repair, hernia repair and breast reconstruction, with reduced polymer density and/or increased the rate of absorbance, to enable faster tissue ingrowth, and less inflammation due to lower polymer density and faster absorption. As such implants having dimensional and behavioral characteristics may be specifically designed for rotator cuff, low polymer density rotator cuff, narrow soft tissue, (e.g. 2-3mm wide), hernia, breast reconstruction, meniscus, and achilles tendon repair procedures.
In embodiments, the support structure of a composite scaffold may be implemented with a knitted textile structure similar to those disclosed herein and may have a collagen matrix formed therein through lyophilization or other processes, as also described herein. The knit pattern influences polymer density: adding wales increases density, adding warps increases density, going from single ends to double ends add density, and adding yarns per wale increases density, while longer stitch length reduces density, and a larger gap between textile faces increases height of textile. One or both face patterns may have every two or three wales knitted together; two is more dense but stronger. Figures 22A, 23 and 24 are photographs of a pattern 220, 230, and 240, respectively, that may be utilized as scaffold faces of implants in accordance with the disclosure.
Polymer selection may influence absorbtion rate. Ratios of composite materials may also influence density and absorbtion rate. A polymer, such as any of Polypropylene, PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET, PDO, or PGS in various ratios, or as a copolymer in any combination thereof, or a copolymer can be extruded via a melt spinning technique or similar to create a fiber. The fiber may be multifilament or monofilament and may be knitted or otherwise formed into a textile structure having a 3/3 face design (3 wales stitched) or 2/2 face design (2 wales stitched) with a vertical fiber in the Z direction, featuring a short or long quality gap and either a single or double wale end, zero to two lay-ins, and between 5 to 30 wales.
Figure 25 is computer simulated sample scaffold 250 with a double baseline 5 wale panel, with 2 yarns per wale, and 1 lay-in sponge in accordance with the disclosure;
The final textile structure may be shaped and then infilled with lyophilization, casting or other process, with a porous matrix of a different absorbable material, such as collagen, Polyethylene glycol (PEG), Poly (Glycerol Sebacate) (PGS), Polycaprolactone (PLC), poly(lactic- co-glycolic acid) (PCLA), Polydioxanone (PDO) or chitosan or other polymeric or polymeric biologic materials, to form a scaffold which may be subsequently crosslinked via vapor or liquid phase, dehydrothermal (DHT), UV or other forms of crosslinking to increase in-vivo resistance to degradation. The resulting composite scaffold with microporous matrix supports tissue ingrowth and resists mechanical forces until the scaffold and microporous matrix is fully absorbed. Other relevant manufacturing technologies suitable for creating the use with the disclosed composite scaffolds include, but are not limited to warp knitting, weft knitting, weaving, braiding, nonwoven methods, electrospinning and 3D printing.
According to another aspect of the disclosure, the first and second support layer can be 3D printed, injection molded or cast to form a mechanical support structure as further described herein. The first and second layer can be manufactured simultaneously to create small pores while also maintaining mechanical strength. The first layer can be manufactured using 3D printing, injection molding or cast while the second layer may be implemented to define the interior space of the scaffold with small pores to promote tissue ingrowth.
According to another aspect of the disclosure, the first matrix may be implemented such that the design is shaped specific to a patient’s own anatomy. The shape may be tapered, conical, tubular, rounded, or rectangular, such that the first matrix represents the anatomical shape of the anatomy that is being repaired or replaced or reconstructed.
According to another aspect of the disclosure, the first matrix may be implemented such that the faces of embodiments may form various knitted, braided, woven or otherwise interconnected fibers with various patterns based on application and function of the composite scaffold for each category of utilization.
According to another aspect of the disclosure, the composite device may be constructed to reduce the overall density of the composite scaffold relative to other embodiments. The reduction of density may decrease the potential for an inflammatory reaction to the polymer
comprising the scaffold, and may increase the ability of tissue ingrowth and cell proliferation to occur.
According to another aspect of the disclosure, the composite device may be constructed to reduce the overall in-vivo absorption time of the composite scaffold relative to other embodiments. An increased rate of resorption may decrease the potential for an inflammatory reaction to the polymer comprising the scaffold, and may increase the ability of tissue ingrowth and cell proliferation to occur.
According to another aspect of the disclosure, any of the composite scaffolds embodiments described herein may comprise a microporous matrix having a multitude of interconnected pores and a three dimensional structure supporting the microporous matrix, wherein at least a portion of the three dimensional structure extends through the microporous matrix. Such portion of the support structure extending through the microporous matrix may be the disclosed spacer elements extending between layers of the support structure or may be integral portions of the support structure itself. In embodiments, the structure supporting the microporous matrix may have a generally geometric shape comprising any of a conical, tubular, rounded, tapered or rectangular shape, or a shape that generally mimics a shape of an anatomical structure, as described in the illustrated herein.
According to another aspect of the disclosure, the composite scaffold may provide mechanical reinforcement for meniscus repair, replacement or reconstruction. In embodiments, the composite scaffold comprises a support structure 180 which defines a void volume, such structure may be similar or different to the structure illustrated in Figures 18A-C, to allow adequate extracellular matrix deposition and new functional tissue regeneration. A porous material or hydrogel may be disposed of within a void volume of the support structure. The support structure reinforces and supports the porous material/hydrogel, enhances the tensile strength of the scaffold and resists compression as the scaffold is extended or subject to elongation forces. The porous material/ hydrogel has a porosity and void volume that allows adequate extracellular matrix deposition and new functional tissue regeneration. In embodiments, the void volume is contiguous or essentially contiguous along the long axis of the scaffold for a substantially linear implant, or one or more primary axes or planes of the scaffold for an irregularly shaped implant, which allows cells to fully migrate within the device and for new tissue to form with an orientation enabled by the support structure and microporous structure of the scaffold, while being protected from significant collapse, compression or excessive dilation during mechanical loading or
tensioning of the scaffold. Optionally, all or part of the scaffold may be hydrated with biologic fluids such as blood, bone marrow aspirate, platelet rich plasma, autologous or allogeneic cells to modulate or direct the immune response and further facilitate and accelerate healing and tissue regeneration. In some embodiments, the scaffold may have porous material/hydrogel encompassing both faces of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration. In some embodiments, the scaffold is shaped or trimmed appropriately to the application for which it is used in order to fit the anatomy of a patient, including but not limited to intrasubstance tears, radial tears, horizontal tears, flap tears, complex tears, and bucket-handle tears. In some embodiments, the scaffold provides mechanical reinforcement for meniscus repair, replacement or reconstruction including but not limited to arthroscopic meniscus repair with augmentation, meniscectomy, partial meniscectomy, and meniscus reconstruction.
According to another aspect of the disclosure, the composite device may provide mechanical reinforcement for rotator cuff repair. In embodiments, the composite scaffold comprises a support structure 190 which defines a void volume, such structure may be similar or different to the structure illustrated in Figures 19A-C, to allow adequate extracellular matrix deposition and new functional tissue regeneration. A porous material or hydrogel may be disposed of within a void volume of the support structure. The support structure reinforces and supports the porous material/hydrogel, enhances the tensile strength of the scaffold and resists compression as the scaffold is extended or subject to elongation forces. The porous material/ hydrogel has a porosity and void volume that allows adequate extracellular matrix deposition and new functional tissue regeneration. In embodiments, the void volume is contiguous or essentially contiguous along the long axis of the scaffold, which allows cells to fully migrate within the device and for new tissue to form with an orientation in the axial direction of the scaffold, while being protected from significant collapse, compression or excessive dilation during mechanical loading or tensioning of the scaffold. Optionally, all or part of the scaffold may be hydrated with biologic fluids such as blood, bone marrow aspirate, platelet rich plasma, autologous or allogeneic cells to modulate or direct the immune response and further facilitate and accelerate healing and tissue regeneration. In some embodiments, the scaffold may have porous material/hydrogel encompassing both faces of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration. In some embodiments, the scaffold may have porous material/hydrogel encompassing only one face of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration. In some embodiments, the scaffold is shaped appropriately to the application for which it is used in order to fit the anatomy of a patient. In some embodiments, the
scaffold provides mechanical reinforcement for rotator cuff repair, replacement or reconstruction including but not limited to arthroscopic rotor cuff repair with augmentation and reconstruction.
According to another aspect of the disclosure, the composite scaffold may provide mechanical reinforcement for breast repair or reconstruction. In embodiments, the composite scaffold comprises a support structure 200 which defines a void volume, such structure may be similar or different to the structure illustrated in Figures 20A-C, to allow adequate extracellular matrix deposition and new functional tissue regeneration. A porous material or hydrogel may be disposed of within a void volume of the support structure. The support structure reinforces and supports the porous material/hydrogel, enhances the tensile strength of the scaffold and resists compression as the scaffold is extended or subject to elongation forces. The porous material/ hydrogel has a porosity and void volume that allows adequate extracellular matrix deposition and new functional tissue regeneration. In embodiments, the void volume is contiguous or essentially contiguous along the long axis of the scaffold for a substantially linear implant, or one or more primary axes or planes of the scaffold for an irregularly shaped implant, which allows cells to fully migrate within the device and for new tissue to form with an orientation enabled by the support structure and microporous structure of the scaffold, while being protected from significant collapse, compression or excessive dilation during mechanical loading or tensioning of the scaffold. Optionally, all or part of the scaffold may be hydrated with biologic fluids such as blood, bone marrow aspirate, platelet rich plasma, autologous or allogeneic cells to modulate or direct the immune response and further facilitate and accelerate healing and tissue regeneration. In some embodiments, the scaffold may have porous material/hydrogel encompassing both faces of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration. In some embodiments, the scaffold may have porous material/hydrogel encompassing only one face of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration. In some embodiments, the scaffold may be coated in adhesion preventing material encompassing only face of the support, as to function as a barrier between bodily organs and the scaffold. In some embodiments, the scaffold is shaped appropriately to the application for which it is used in order to fit the anatomy of a patient to provide mechanical reinforcement for breast repair or reconstruction including but not limited to implant reconstruction, autologous reconstruction, flap reconstructions, nipple reconstruction, mastectomy, breast augmentation, breast reduction, breast revision, or other types of mammoplasty procedures.
According to another aspect of the disclosure, the composite scaffold may provide mechanical reinforcement for hernia repair. In embodiments, the composite scaffold comprises a
support structure 190 which defines a void volume, such structure may be similar or different to the structure illustrated in Figures 19A-C, to allow adequate extracellular matrix deposition and new functional tissue regeneration. A porous material or hydrogel may be disposed of within a void volume of the support structure. The support structure reinforces and supports the porous material/hydrogel, enhances the tensile strength of the scaffold and resists compression as the scaffold is extended or subject to elongation forces. The porous material/ hydrogel has a porosity and void volume that allows adequate extracellular matrix deposition and new functional tissue regeneration. In embodiments, the void volume is contiguous or essentially contiguous along the long axis of the scaffold, which allows cells to fully migrate within the device and for new tissue to form with an orientation in the axial direction of the scaffold, while being protected from significant collapse, compression or excessive dilation during mechanical loading or tensioning of the scaffold. Optionally, all or part of the scaffold may be hydrated with biologic fluids such as blood, bone marrow aspirate, platelet rich plasma, autologous or allogeneic cells to modulate or direct the immune response and further facilitate and accelerate healing and tissue regeneration. In some embodiments, the scaffold may have porous material/hydrogel encompassing both faces of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration. In some embodiments, the scaffold may have porous material/hydrogel encompassing only one face of the support structure, as to function as a scaffold for tissue ingrowth and cell infiltration. In some embodiments, the scaffold may be coated in adhesion preventing material encompassing only one face of the support, as to function as a barrier between bodily organs and the scaffold. In some embodiments, the scaffold is shaped appropriately to the application for which it is used in order to fit the anatomy of a patient. In some embodiments, the scaffold provides mechanical reinforcement for hernia repair including but not limited to inguinal hernias, incisional hernias, femoral hernias, umbilical hernias, epigastric hernia, hiatal hernia, or pelvic floor hernias.
Example 6: Knitting of a 3D Spacer Mesh with Dual Sponge (Symmetric Implant)
The following example describes the manufacture of a composite absorbable implant for any of rotator cuff repair, hernia repair, breast reconstruction, meniscal repair or other soft tissue repairs where weakness exists. A copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) may be formed into a three dimensional textile structure, in a manner similar or dissimilar as described herein, with two faces defining an internal open void space therebetween. The shapes of the faces can be any of a square, rectangular, circle or oval face or combination thereof depending on the application. The three dimensional textile structure may then have solvent cast within the void
space, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, in a manner similar or dissimilar as described herein, resulting in the three dimensional textile structure embedded within the casted sponge-like structure thereby creating a composite scaffold. The resulting sponge-like structure contains the textile structure in such a manner that the sponge structure extends beyond the textile structure faces so that the composite scaffold is generally symmetrical, allowing the composite scaffold to be implanted with either face in any direction with the functionality of the implant unchanged.
Example 7: 3D Spacer Mesh with Single Sponge (Asymmetric Implant)
The following example describes the manufacture of a composite absorbable implant for any of rotator cuff repair, hernia repair, breast reconstruction, meniscal repair or other soft tissue repairs where weakness exists. A copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) may be formed into a three dimensional textile structure with two faces, in a manner similar or dissimilar as described herein, defining an internal open void space therebetween. The shapes of the faces can be any of a square, rectangular, circle or oval face or combination thereof depending on the application. The three dimensional textile structure may then have solvent cast within the void space, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, in a manner similar or dissimilar as described herein, resulting in the three dimensional textile structure embedded within the casted sponge-like structure thereby creating a composite scaffold. The resulting sponge-like structure contains the textile structure in such a manner that the sponge structure extends beyond only a single face of the textile structure so that the composite scaffold generally asymmetrical allowing the composite scaffold to be implanted with a specific direction for the scaffold to be functional.
Example 8: 3D Mesh with Sponge (Sandwich)
The following example describes the manufacture of a composite absorbable implant for any of rotator cuff repair, hernia repair, breast reconstruction, meniscal repair or other soft tissue repairs where weakness exists. A copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) may be formed into a three dimensional textile structure, in a manner similar or dissimilar as described herein, with two planar faces defining an internal open void space therebetween. The shapes of the faces can be any of a square, rectangular, circle or oval face or combination thereof depending on the application. The three dimensional textile structure may then have solvent cast within the void
space, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, , in a manner similar or dissimilar as described herein, resulting in the three dimensional textile structure embedded within the casted sponge-like structure thereby creating a composite scaffold. The resulting sponge-like structure contains the textile structure in such a manner that the sponge structure envelopes the top and bottom planar faces and sides in their respective entireties so that the composite scaffold is generally symmetrical, allowing the composite scaffold to be implanted with either face in any direction with the functionality of the implant unchanged.
Example 9A: Dense sponge reinforced with fibers
The following example describes the manufacture of a composite absorbable implant for any of rotator cuff repair, hernia repair, breast reconstruction, meniscal repair or other soft tissue repairs where weakness exists. A structure can be casted via various methods using polymer or biologic polymer, such as collagen, PEG or chitosan in a manner similar or dissimilar as described herein, to create a three dimensional sponge. Adjusting the concentrations of inputs to the sponge structure may increase the density of the resulting three dimensional sponge. Further processing of the three dimensional sponge via additional casting, crosslinking, dissolution and recasting may also increase the density of the three dimensional sponge. To further reinforce the sponge, a copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) can be physically or chemically added to the three dimension sponge in the form of any of a fiber form, two dimensional textile form, or three dimensional textile form, resulting in a composite scaffold.
Example 9B: Dense sponge reinforced with fibers
The following example describes the manufacture of a composite absorbable implant for any of rotator cuff repair, hernia repair, breast reconstruction, meniscal repair or other soft tissue repairs where weakness exists. A structure can be casted via various methods using polymer or biologic polymer, such as collagen, PEG or chitosan in a manner similar or dissimilar as described herein, to create a three dimensional sponge. Adjusting the concentrations of inputs to the sponge structure may increase the density of the resulting three dimensional sponge. Further processing of the three dimensional sponge via additional casting, crosslinking, dissolution and recasting may also increase the density of the three dimensional sponge. To further reinforce the sponge, a copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) in the form of any of a fiber form, two dimensional textile form, or three dimensional textile form, can be configured into the mold, for example by
tensioning fibers in a mold, prior to casting, so that the sponge is effectively cast around the fiber patterns, the resulting in the composite scaffold.
Example 10: Low Density textile with sponge
The following example describes the manufacture of a composite absorbable implant for any of rotator cuff repair, hernia repair, breast reconstruction, meniscal repair or other soft tissue repairs where weakness exists. A copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) may be formed into a three dimensional textile structure, in a manner similar or dissimilar as described herein, with two parallel faces defining an internal open void space therebetween. The shapes of the faces can be any of a square, rectangular, circle or oval face or combination thereof depending on the application. One face may have less polymer present than another face, creating a more open face to the textile structure and an overall less dense structure. The three dimensional textile structure may then have solvent cast within the void space, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, in a manner similar or dissimilar as described herein, resulting in the three dimensional textile structure embedded within the casted sponge-like structure thereby creating a composite scaffold. The resulting sponge structure contains the textile structure in such a manner where the sponge structure takes up a majority of the scaffold volume and textile structure faces, improving the functionality of the sponge structure within the composite scaffold.
Example 11 : Shaped conical 3D spacer mesh with sponge
The following example describes the manufacture of a composite absorbable implant for any of rotator cuff repair, hernia repair, breast reconstruction, meniscal repair or other soft tissue repairs where weakness exists. A copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) may be formed into a three dimensional textile structure, in a manner similar or dissimilar as described herein, with two parallel faces defining an internal open void space therebetween. The shapes of the faces can be any of a square, rectangular, circle or oval face or combination thereof depending on the application. This textile structure can be cut or trimmed or otherwise separated and folded to create a conical shape comprising the textile structure. The three dimensional textile structure may then have solvent cast within the void space, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, in a manner similar or dissimilar as described herein, resulting in the three dimensional textile structure embedded within the casted sponge creating a composite scaffold which holds the folded textile structure shape in place. Another method of holding the shape in
place would be through additional stitching of the textile structure either before or after casting additional material. Another method of forming the textile structure would be to directly knit, braid or weave the structure. The sponge structure contains the textile structure in such a manner where the sponge structure extends beyond the textile structure faces so that the composite scaffold is symmetrical.
Example 12: Shaped tubular 3D space mesh with sponge
The following example describes the manufacture of a composite absorbable implant for any of rotator cuff repair, hernia repair, breast reconstruction, meniscal repair or other soft tissue repairs where weakness exists. A copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) may be formed into a three dimensional textile structure, in a manner similar or dissimilar as described herein, with two faces defining an internal open void space therebetween. The shapes of the faces can be any of a square, rectangular, circle or oval face or combination thereof depending on the application. This textile structure can be cut or trimmed or otherwise separated and folded or rolled to create a hollow cylindrical tube shape comprising a three dimensional textile structure with a void space down the center. The three dimensional textile structure may then have solvent cast within the void space, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, in a manner similar or dissimilar as described herein, resulting in the three dimensional textile structure embedded within the casted sponge creating a composite scaffold which holds the folded or rolled textile structure shape in place. Another method of holding the shape in place would be through additional stitching of the textile structure either before or after casting additional material. Another method of forming the textile structure would be to directly knit, braid or weave the structure. The sponge structure contains the textile structure in such a manner where the sponge structure extends beyond the textile structure faces so that the composite scaffold is symmetrical. Additional material can be placed within the tubular fabric.
Example 13: Crescent shaped 3D space mesh with sponge
The following example describes the manufacture of a composite absorbable implant for rotator cuff repair, hernia repair, breast reconstruction, meniscal repair or other soft tissue repairs where weakness exists. A copolymer or polymer (such as PLLA, PDLA, PDLLA, PLA, P4HB, PLC, PGA, PLGA, PTC, PET in various ratios or any combination thereof) can be formed into a three dimensional textile structure providing an open void space between two parallel faces. The shapes of the faces can be a square, rectangular, circle or oval face or combination thereof depending on the application. This textile structure can be cut or trimmed or otherwise separated
and folded or rolled to create a crescent moon shape comprising a three dimensional textile structure in the shape of a ‘C’. The three dimensional textile structure may have a solvent cast within, such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, so that the three dimensional textile structure is embedded within the casted sponge creating a composite scaffold and holding the textile structure shape in place. Another method of holding the shape in place is through additional stitching of the textile structure either before or after casting additional material. Another method of forming the textile structure would be to directly knit, braid or weave the structure. The sponge structure contains the textile structure in such a manner where the sponge structure extends beyond the textile structure faces so that the composite scaffold is symmetrical.
Alternative Manufacturing Methods
According to another aspect of the disclosure, alternative manufacturing methods_such as 3D printing, casting, and injection molding of a scaffold with a porous matrix made be utilized to achieve implants with varying mechanics and physical properties, as well as complex shapes for specific anatomy and tissue ingrowth requirement of procedures such as Soft tissues, cartilage, meniscus, rotor cuff repair and breast reconstruction. Such method may comprise any of 3D printing or injection molding of a polymer scaffold followed by formation of a microporous collagen matrix through lyophilization; 3D printing of a polymer scaffold and microporous matrix at same time, using the same or different materials; or 3D printing or injection molding of a polymer scaffold followed by dimensionally or mechanically manipulating, i.e. , drawing, the scaffold in order to align the polymer structure and improve mechanics, such as to increase stiffness, yield point, ultimate strength, etc. Other relevant manufacturing technologies suitable for use with the disclosed composite scaffolds include, but are not limited to, Injection Molding, Micro Molding, Stereolithography (SLA), Selective Laser Sintering (SLS), Fused Deposition Modeling (FDM), Digital Light Process (DLP), Multi Jet Fusion (MJF), Material Jetting (MJ), Direct Metal Laser Sintering (DMLS), Electron Beam Melting (EBM), and Drop on Demand (DOD).
As noted previously, a composite scaffold may comprise a first matrix and an optional second matrix which may be integrally formed with one another to maximize the surface area to volume ratio of the scaffold while still maintaining mechanical and structural integrity. According to embodiments, the first matrix may be implemented with the three-dimensional textile structure comprising first and a second support layers spaced apart to define an interior space or void therebetween. Multiple spacer elements extend between the first and second support layers to maintain the support layers separate. The first and second support layers may have different geometries, fibers, or material compositions. The first and second support layers and spacer
elements may be implemented as a three dimensional textile comprising multi-layer knitted or woven surfaces of multifilament fibers or monofilament fibers, or any combination thereof, formed of any combination of synthetic bioresorbable polymers, natural polymers and/or additives. The second matrix is disposed within the void space between and proximate the first and second support layers of the first support matrix. The second matrix may be implemented with a low- density, high surface area material comprising any of a sponge, foam, felt, textured fibers or yarns, collagen or tissue-derived material, or any combination thereof. The first and second matrices of the composite scaffold may have the same or different structure, composition, and bioabsorbable characteristics to facilitate optimal regeneration of functional tissue.
According to another aspect of the disclosure, the first matrix may be implemented with a three-dimensional printed (3D printed) structure composing first and second support layers spaced apart to define an interior space or void therbetween. The first and second support layers may have different geometries, diameters, or material compositions. The first and second support layers may be supported by spacer elements which may have different geometries, diameters, or material compositions. The first and second support layers and any spacer elements may be integrally formed with 3D printing using various technologies (FDM, SLS, SLA, etc.) which allow for lattice geometries to be formed, with varying lattice spacing which may change throughout, or the first and second support layers and any spacer elements may be separately 3D printed.
According to another aspect of the disclosure, the first matrix shape may be tapered, conical, tubular, rounded, or rectangular, such that the first matrix represents the anatomical shape of the anatomy that is being repaired or replaced.
According to another aspect of the disclosure, the second matrix is disposed within the void between and proximate the first and second support layers of the first support matrix. The second matrix may also be implemented using 3D printing at the same time as the first matrix, or in a secondary operation, and may be the same material or a different material. The first and second matrices of the composite scaffold may have the same or different structure, composition, and bioabsorbable characteristics to facilitate optimal regeneration of functional tissue.
According to another aspect of the disclosure, the first matrix may be implemented with injection molding or casting of the support structure comprising the first and second support layers which are spaced apart to define an interior space or void therebetween. The first and second support layers may have different geometries, diameters, or material compositions. The first and second support layers are supported by spacer elements which may have different geometries, diameters, or material compositions.
According to another aspect of the disclosure, the first matrix may be implemented by 3D printing, casting, or injection molding, and then mechanically drawn to improve mechanical strength. For example, polyesters are very low in strength prior to being oriented in the process used to make fibers. This is particularly true for resorbable polymers such as poly hydroxy butyrates and Poly caprolactones. A 3D printed scaffold can be produced that is a net like structure that when oriented provides strength and struts. An illustrative structure is shown in Figures 21A and 21 B. The structure 210A may be a two layer one with struts between the two layers, or there could be multiple layers. Upon uniaxial orientation the struts may be drawn and will increase in strength to provide the final structure 21 OB, shown in the post orientation state illustrate in Figure 21 B. Biaxial orientation would allow strength enhancement and opening up of the structure in two planes. The method used to orient the preformed structure could be similar to the method used for fiber manufacturer such as accelerating rollers. Textile processing technology such as stenters and tenters are also in existence that would allow stretching biaxially and uniaxially. Once the first matrix is oriented, a second microporous matrix, made from a collagen gel for example may be infused in the void space of the first matrix in a manner as described herein or using other current methodologies.
Example 14 - 3D printed support structure with cast and lyophilized sponge matrix
The following describes the manufacture of a composite absorbable implant. A polymer (such as PLLA, PDLA, PGA, P4HB) can be 3D printed (such as with SLS, SLA, or FDM) into a shaped porous scaffold which creates structural integrity while maintaining open space to resist compression and tension and mechanical forces. The scaffold can then be infilled (such as lyophilization or casting) with a porous matrix of a different absorbable material (collagen, PEG, PGS, PLC, PCLA, PDO or chitosan, or another absorbable polymer), which may be subsequently crosslinked. This composite scaffold with microporous matrix will support tissue ingrowth and resist mechanical forces until the scaffold and microporous matrix is fully absorbed.
Example 15 - 3D printed support structure, drawn and cast, with lyophilized sponge matrix
The following describes the manufacture of a composite absorbable implant. A polymer (such as PLLA, PDLA, PGA, P4HB) is 3D printed (such as with SLS, SLA, or FDM) into a shaped porous scaffold which creates structural integrity while maintaining open space to resist compression, tension and mechanical forces. The scaffold is then mechanically drawn or manipulated biaxially and uniaxially in such a way that the polymer's crystalline structure is aligned, improving the mechanical properties. The drawn scaffold is then infilled (such as with
lyophilization or casting) with a porous matrix of a different absorbable material (such collagen, PEG, PGS, PLC, PCLA, PDO or chitosan), which may be subsequently crosslinked. The resulting composite scaffold with microporous matrix will support tissue ingrowth and resist mechanical forces until the scaffold and microporous matrix is fully absorbed.
Example 16 - Injection molded support structure, then cast and lyophilize sponge matrix
The following describes the manufacture of a composite absorbable implant A polymer (such as PLLA, PDLA, PGA, P4HB) is injection molded into a shaped porous scaffold which creates structural integrity while maintaining open space to resist compression, tension and mechanical forces. The scaffold is then infilled (such as with lyophilization or casting) with a porous matrix of a different absorbable material (such as collagen, PEG, PGS, PLC, PCLA, PDO or chitosan), which may be subsequently crosslinked. The resulting composite scaffold with microporous matrix will support tissue ingrowth and resist mechanical forces until the scaffold and microporous matrix is fully absorbed.
Example 17 - 3D print of integral support and matrix
The following describes the manufacture of an absorbable implant. A polymer (such as PLLA, PLDA, PGA, PEG, P4HB) is 3D printed (such as with SLS, SLA, or FDM) into a scaffold matrix with small enough pores for tissue ingrowth, effectively creating an integral scaffold with both support and a porous matrix at the same time. The 3D printed material acts as both as mechanical support while also supporting tissue ingrowth. The scaffold itself can be made of the polymer but can be printed alongside a water soluble polymer (such as PGA) to provide structure during manufacturing or change the degradation rate of the absorbable implant. The absorbable implant may also be made alongside synthetic fibers incorporated during the additive process effectively creating more surface area and strength while maintaining flexibility.
Figures 26-29 illustrate conceptually how any of the disclosed scaffolds, illustrated in Figure 26 as scaffold 260, may be utilized for augmented ACL repair, stabilization or reconstruction. Specifically the scaffold 260 is bound to an allograft or autograft tendon, ligament, or tissue graft 280 and joined together at one or both ends. e.g. whip-stitched with suture, as illustrated in Figure 28A. One or both of scaffold 260 and tissue graft 280 may be pre-tensioned, as described herein. The combination of scaffold 260 and tissue graft 280 is then doubled over joined together at one end, e.g. whip-stitched with suture, and positioned into place, as illustrated in Figures 28B and 28C. In embodiments, scaffold 260 may be implemented as similar or
dissimilar to scaffold 270 of Figure 27 and may be comprises of a support matrix 292 having a microporous matrix 290 formed therein and about, as illustrated in Figure 29.
The present disclosure will be more completely understood through the following description, which should be read in conjunction with the drawings. In this description, like numbers refer to similar elements within various embodiments of the present disclosure. The skilled artisan will readily appreciate that the methods, apparatus and systems described herein are merely exemplary and that variations can be made without departing from the spirit and scope of the disclosure. The terms comprise, include, and/or plural forms of each are open ended and include the listed parts and can include additional parts that are not listed. The term and/or is open ended and includes one or more of the listed parts and combinations of the listed parts.
At various places in the present specification, values are disclosed in groups or in ranges. It is specifically intended that the description include each and every individual subcombination of the members of such groups and ranges and any combination of the various endpoints of such groups or ranges. For example, an integer in the range of 0 to 40 is specifically intended to individually disclose 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, and 40, and an integer in the range of 1 to 20 is specifically intended to individually disclose 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, and 20. Real numbers are intended to be similarly inclusive, including values up to at least three decimal places.
The foregoing description has been presented for purposes of illustration. It is not exhaustive and is not limited to the precise forms or embodiments disclosed. Modifications and adaptations will be apparent to those skilled in the art from consideration of the specification and practice of the disclosed embodiments.
As used herein, the indefinite articles “a” and “an” mean “one or more.” Similarly, the use of a plural term does not necessarily denote a plurality unless it is unambiguous in the given context. Words such as “and” or “or” mean “and/or” unless specifically directed otherwise. Further, since numerous modifications and variations will readily occur from studying the present disclosure, it is not desired to limit the disclosure to the exact construction and operation illustrated and described, and, accordingly, all suitable modifications and equivalents falling within the scope of the disclosure may be resorted to.
While several embodiments of the disclosure have been shown in the drawings, it is not intended that the disclosure be limited thereto, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Any combination of the above embodiments is also envisioned and is within the scope of the appended claims. Moreover,
while illustrative embodiments have been described herein, the scope of any and all embodiments include equivalent elements, modifications, omissions, combinations (e.g., of aspects across various embodiments), adaptations and/or alterations as would be appreciated by those skilled in the art based on the present disclosure. The limitations in the claims are to be interpreted broadly based on the language employed in the claims and not limited to examples described in the present application. The examples are to be construed as non-exclusive. Furthermore, the steps of the disclosed methods may be modified in any manner, including by reordering steps and/or inserting or deleting steps. It is intended, therefore, that the specification and examples be considered as illustrative only, with a true scope and spirit being indicated by the following claims and their full scope of equivalents.
While several embodiments of the disclosure have been shown in the drawings, it is not intended that the disclosure be limited thereto, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Any combination of the above embodiments is also envisioned and is within the scope of the appended claims. Therefore, the above description should not be construed as limiting, but merely as exemplifications of particular embodiments. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.
What is claimed is:
Claims
1. A composite scaffold comprising: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space; and a structure supporting the microporous matrix; wherein a surface area of the composite scaffold is between approximately 0.3 m2/gram and 15.0 m2/gram.
2. The composite scaffold of claim 1 wherein the surface area of the composite scaffold is between approximately 0.6 m2/gram and 1.2 m2/gram.
3. The composite scaffold of claim 1 wherein the surface area of the composite scaffold is between approximately 0.7 m2/gram and 1.0 m2/gram.
4. The composite scaffold of claim 1 wherein a volume of the void space is between approximately 3.0 cm3/gram and 9.0 cm3/gram.
5. A composite scaffold comprising: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space having a measurable volume; and a structure supporting the microporous matrix;
64
wherein the volume of the void space is between approximately 3.0 cm3/gram and 9.0 cm3/gram.
6. The composite scaffold of claim 5 wherein the volume of void space is between approximately 3.5 cm3/gram and 7.0 cm3/gram.
7. The composite scaffold of claim 5 wherein the volume of void space is between approximately 4.0 cm3/gram and 5.0 cm3/gram.
8. The composite scaffold of claim 5 wherein a surface area of the composite scaffold is between approximately 0.3 m2/gram and 1.5 m2/gram.
9. A composite scaffold comprising: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space having a volume; and a structure supporting the microporous matrix; wherein the void space volume is between approximately 75% and 98% of a measurable volume of the composite scaffold.
10. The composite scaffold of claim 9 wherein the void space volume is between approximately 80% and 90% of a measurable volume of the composite scaffold.
11. The composite scaffold of claim 9 wherein the void space volume is between approximately 80% and 85% of a measurable volume of the composite scaffold.
12. The composite scaffold of claim 9 wherein the composite scaffold has a surface area of between approximately 0.3 m2/gram and 1.5 m2/gram.
13. A composite scaffold having a volume and a surface area and comprising: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix;
65
wherein the composite scaffold has a permeability of between approximately 1200 and 3000 millidarcy.
14. The composite scaffold of claim 13 wherein the composite scaffold has a permeability of between approximately 1400 and 2600 millidarcy.
15. The composite scaffold of claim 13 wherein the wherein the composite scaffold has a permeability of between approximately 1500 and 2200 millidarcy.
16. The composite scaffold of claim 13 wherein a volume of the void space is between approximately 3.0 cm3/gram and 9.0 cm3/gram.
17. The composite scaffold of claim 13 wherein a surface area of the composite scaffold is between approximately 0.3 m2/gram and 1.5 m2/gram.
18. A composite scaffold comprising: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space having a void space volume; and a structure supporting the microporous matrix; wherein the multitude of interconnected pores have a tortuosity of approximately between 1 pm/pm and 50 pm/pm, wherein the tortuosity defines a ratio of actual flow path length to straight distance between first and second ends of the microporous matrix.
19. The composite scaffold of claim 18 wherein the multitude of interconnected pores have a tortuosity of approximately between 5 pm/pm and 30 pm/pm.
20. The composite scaffold of claim 18 wherein the multitude of interconnected pores have a tortuosity of approximately between 6 pm/pm and 20 pm/pm.
21 . A composite scaffold occupying a measurable volume and comprising: a microporous matrix having a multitude of interconnected pores collectively defining void space having a surface area; and a structure supporting the microporous matrix;
66
wherein the void space surface area to measurable volume is between approximately 5,000 cm2/cm3and 16,000 cm2/cm3
22. The composite scaffold of claim 21 wherein the void space surface area to measurable volume is between approximately 7,000 cm2/cm3 and 14,000 cm2/cm3.
23. The composite scaffold of claim 21 wherein the void space surface area to measurable volume is between approximately 9,000 cm2/cm3 and 12,000 cm2/cm3.
24. A composite scaffold comprising: a support structure defining an interior space; and a microporous matrix disposed within the interior space of the support structure, wherein the microporous matrix comprises a plurality of interconnected pores having a median pore size of between approximately 10 pm to 100 pm.
25. The composite scaffold of claim 24 wherein the microporous matrix comprises a plurality of interconnected pores having a median pore size of between approximately 12 pm to 70 pm.
26. The composite scaffold of claim 24 wherein the microporous matrix comprises a plurality of interconnected pores having a median pore size of between approximately 20 pm to 40 pm.
27. A composite scaffold comprising: a support structure defining an interior space; and a microporous matrix disposed within the interior space of the support structure, the microporous matrix having a multitude of interconnected pores collectively defining void space; wherein at least approximately 60% of the void space comprises pores having a size dimension of 10 pm or greater.
28. The composite scaffold of claim 27 wherein at least approximately 70% of the void space comprises pores having a size dimension of 10 pm or greater.
67
29. The composite scaffold of claim 27 wherein at least approximately 80% of the void space comprises pores having a size dimension of 10 pm or greater.
30. The composite scaffold of any of the preceding claims 1 through 29 wherein the composite scaffold has an elongation at tensile failure of between approximately 20% and 125%.
31 . A composite scaffold of any of the preceding claims 1 through 29 wherein the composite scaffold has an elongation at yield of between approximately 5% and 50%.
32. A composite scaffold of any of preceding claims 1 through 29 wherein the composite scaffold has a stiffness of approximately between 2.5 N/mm and 25 N/mm.
33. A composite scaffold of any of preceding claims 1 through 29 wherein the composite scaffold has an ultimate strain of approximately between 0.2 and 0.7.
34. A composite scaffold of any of the preceding claims 1 through 29 wherein the composite scaffold has an ultimate strength of approximately between 2.5 MPa and 30 MPa.
35. A composite scaffold of any of the preceding claims 1 through 29 wherein the composite scaffold has an ultimate stress of approximately between 2.5 MPa and 30 MPa.
36. A composite scaffold of any of the preceding claims 1 through 29 wherein the composite scaffold has a modulus of approximately between 2.5 MPa and 70 MPa, wherein modulus defines stress divided by strain of a cross-sectional area of the composite scaffold, including the void space.
37. A composite scaffold of any of the preceding claims 1 through 29 wherein the composite scaffold has a modulus of approximately between 150 MPa and 600 MPa, wherein modulus defines stress divided by strain of bulk material from which the composite scaffold is comprised, excluding the void space.
68
38. A composite scaffold of any of the preceding claims 1 through 29 wherein the scaffold has an ultimate load displacement of approximately between 5 mm and 50 mm.
39. A composite scaffold of any of preceding claims 1 through 29 wherein the scaffold has a yield displacement of approximately between 1 mm and 8 mm.
40. A composite scaffold of any of preceding claims 1 through 29 wherein the scaffold has a yield force of approximately between approximately between 20 N and 70 N.
41. A composite scaffold of any of preceding claims 1 through 29 wherein the scaffold may have a stiffness of approximately between 2.5 N/mm and 25 N/mm.
42. A composite scaffold of any of preceding claims 1 through 29 wherein the composite scaffold has an ultimate strain of approximately between 20 % and 70 %.
43. A composite scaffold of any of the preceding claims 1 through 29 wherein the scaffold has an ultimate load approximately between 100 N and 200 N.
44. The composite scaffold of any of claims 1 - 3 and 8 wherein the surface area of the composite scaffold is measured using mercury intrusion porosimtery.
45. The composite scaffold of claim 44 wherein the surface area of the composite scaffold includes surface area of pores approximately equal to or greater than 1 pm in size.
46. The composite scaffold of claim 18 wherein a volume of the void space is between approximately 3.0 cm3/gram and 9.0 cm3/gram.
47. The composite scaffold of claim 18 wherein a surface area of the composite scaffold is between approximately 0.3 m2/gram and 1.5 m2/gram.
48. The composite scaffold of claim 27 wherein a volume of the void space is between approximately 3.0 cm3/gram and 9.0 cm3/gram.
49. The composite scaffold of claim 27 wherein a surface area of the composite scaffold is between approximately 0.3 m2/gram and 1.5 m2/gram.
50. The composite scaffold of claim 27 wherein a surface area of the composite scaffold is between approximately 0.3 m2/gram and 1.5 m2/gram.
51. A composite scaffold occupying a measurable volume and comprising: a microporous matrix having a multitude of interconnected pores collectively defining void space having a surface area; and a structure supporting the microporous matrix; wherein the void space surface area to measurable volume is between approximately 5,000 cm2/cm3and 16,000 cm2/cm3
52. The composite scaffold of claim 51 wherein the void space surface area to measurable volume is between approximately 7,000 cm2/cm3 and 14,000 cm2/cm3.
53. The composite scaffold of claim 51 wherein the void space surface area to measurable volume is between approximately 9,000 cm2/cm3 and 12,000 cm2/cm3.
54. A composite scaffold comprising: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space; and a structure supporting the microporous matrix; wherein a surface area of the composite scaffold is between approximately 0.3 m2/gram and 15 m2/gram
55. The composite scaffold of any of claim 54 wherein the surface area of the composite scaffold is measured using gas adsorption.
56. The composite scaffold of any of claim 55 wherein the surface area of the composite scaffold is measured using krypton gas adsorption.
57. The composite scaffold of claim 54 wherein the surface area of the composite scaffold includes surface area of pores approximately equal to or less than 1 pm in size.
58. A composite scaffold comprising: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the composite scaffold having a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state and a measurable dry volume value representing a volume of the composite scaffold in a substantially dry state, wherein an increase of between approximately 200% and 600% of the weight value of the composite scaffold from fluid absorption changes the dry volume value of the composite scaffold between approximately 0% and 10%.
59. The composite scaffold of claim 58 wherein an increase of between approximately 300% and 600% of the dry weight value of the composite scaffold from fluid absorption changes the dry volume value of the composite scaffold between approximately 2% and 7%.
60. The composite scaffold of claim 58 wherein an increase of between approximately 300% and 600% of the dry weight value of the composite scaffold from fluid absorption changes the dry volume value of the composite scaffold between approximately 4% and 6%.
61. The composite scaffold of claim 58 wherein an increase of between approximately 300% and 600% of the dry weight value of the composite scaffold from fluid absorption changes a dry length value of the composite scaffold by between approximately 0% and 3%.
62. The composite scaffold of claim 58 wherein an increase of between approximately 300% and 600% of the dry weight value of the composite scaffold from fluid absorption changes a dry length value of the composite scaffold by between approximately 0% and 2%.
63. A composite scaffold comprising: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the composite scaffold having a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state and a measurable dry length value representing a dimensional parameter of the composite scaffold in a substantially dry state, wherein an increase of between approximately 200% and 600% of the weight value of the composite scaffold from fluid absorption changes the dry length value of the composite scaffold by less than between approximately 0% and 3%.
64. The composite scaffold of claim 63 wherein an increase of between approximately 300% and 600% of the dry weight value of the composite scaffold from fluid absorption changes the dry length value of the composite scaffold by between approximately 0% and 2%.
65. The composite scaffold of claim 63 wherein an increase of between approximately 500% and 600% of the dry weight value of the composite scaffold from fluid absorption changes the dry length value of the composite scaffold less than approximately 1%.
66. The composite scaffold of claim 63 wherein an increase of between approximately 300% and 600% of the dry weight value of the composite scaffold from fluid absorption changes the dry volume value of the composite scaffold between approximately 2% and 7%.
67. The composite scaffold of claim 63 wherein an increase of between approximately 300% and 600% of the dry weight value of the composite scaffold from fluid absorption changes the dry volume value of the composite scaffold between approximately 4% and 6%.
68. A composite scaffold comprising:
72
a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the composite scaffold having a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state and a measurable cross sectional profile value representing a dimensional parameter of the composite scaffold in a substantially dry state, wherein an increase of between approximately 300% and 600% of the weight value of the composite scaffold from fluid absorption changes the cross sectional profile value of the composite scaffold by between approximately 0% and 3%.
69. The composite scaffold of claim 68 wherein an increase of between approximately 300% and 600% of the dry weight value of the composite scaffold from fluid absorption changes the cross sectional profile value of the composite scaffold by between approximately 0% and 2%.
70. The composite scaffold of claim 68 wherein an increase of between approximately 500% and 600% of the dry weight value of the composite scaffold from fluid absorption changes the cross sectional profile value of the composite scaffold less than approximately 1 %.
71. The composite scaffold of claim 68 wherein an increase of between approximately 300% and 600% of the dry weight value of the composite scaffold from fluid absorption increases the cross sectional profile value of the composite scaffold by between approximately 0% and 2%.
72. The composite scaffold of claim 68 wherein an increase of between approximately 500% and 600% of the dry weight value of the composite scaffold from fluid absorption increases the cross sectional profile value of the composite scaffold less than approximately 1 %.
73. A composite scaffold comprising: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix;
73
wherein a smallest dimension of the composite scaffold is a thickness dimension approximately greater than or equal to 1 mm, and wherein the composite scaffold has a swelling profile measurable by a less than or equal to 10% change in measured wet thickness of the composite scaffold in comparison to a measured dry thickness of the composite scaffold.
74. A composite scaffold comprising: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; the composite scaffold having a measurable dry weight value representing a weight of the composite scaffold in a substantially dry state, wherein the microporous matrix is less than approximately 6% of the dry weight value of the composite scaffold.
75. A scaffold comprising: a three-dimensional support structure having a length dimension defined by first and second ends thereof and a thickness dimension, normal to the length dimension, defined by first and second outer layers separated by a space, and a plurality of spacer elements extending through the space and connecting the first and second outer layers; wherein the thickness dimension of the support structure changes less than approximately 10% upon elongation of the length dimension by approximately 5%.
76. A scaffold comprising: a three-dimensional support structure having a length dimension defined by first and second ends thereof and a cross-sectional area, normal the length dimension, at least partially defined by first and second outer layers separated by a space, and a plurality of spacer elements extending through the space and connecting the first and second outer layers; wherein the cross-sectional area changes less the approximately 35% upon elongation of the length dimension by approximately 13%.
74
77. A scaffold comprising: a three-dimensional support structure having a length dimension defined by first and second ends thereof and a width dimension, normal to the length dimension, at least partially defined by first and second outer layers, the first and second outer layers separated by a space and further defining a thickness dimension, normal to the length dimension and the width dimension, and a plurality of spacer elements extending through the space and connecting the first and second outer layers, wherein the width dimension changes less than approximately 5% upon elongation of the length dimension by approximately 13%.
78. A scaffold structure comprising: first and second outer layers having length dimensions defined by respective first and second ends thereof and defining an interior space therebetween, each of the first and second outer layers comprising a plurality of interconnected wales extending substantially parallel to the respective length dimensions; a plurality of spacer elements extending substantially normal to the respective length dimensions through the interior space and attached to each of the first and second outer layers proximate one of the plurality of wales, the plurality of spacer elements at least partially partitioning the interior space into a plurality of channels extending along the respective length dimensions of the first and second outer layers.
79. The scaffold structure of claim 78 wherein each of first and second outer layers have a corresponding number of wales and wherein the plurality of spacer elements are attached to corresponding wales of each of the first and second outer layers.
80. The scaffold structure of claim 78 wherein the plurality of spacer elements comprise spacer yarns.
81. The scaffold structure of claim 78 wherein a distance between spacer elements along a wale of the first or second outer layers is between approximately 100 pm and 2500 pm.
75
82. The scaffold structure of claim 78 wherein a distance between wales in the first outer layer or the second outer layer is between approximately 200 pm and 5000 pm.
83. The scaffold structure of claim 78 wherein the plurality of spacer elements have a length extending between the first and second outer layers between approximately 100 pm and 5000 pm.
84. The scaffold structure of claim 78 wherein the wales of one of the first and second outer layers comprise a pillar stitch and an axial lay-in yarn.
85. A scaffold structure of any of the preceding claims 75 through 84 wherein the scaffold has an elongation at tensile failure of between approximately 20% and 125%.
86. A scaffold structure of any of the preceding claims 75 through 84 wherein the scaffold has an elongation at yield of between approximately 5% and 50%.
87. A scaffold structure of any of preceding claims 75 through 84 wherein the scaffold has a stiffness of approximately between 2.5 N/mm and 25 N/mm.
88. A scaffold structure of any of preceding claims 75 through 84 wherein the scaffold has an ultimate strain of approximately between 20 % and 70 %.
89. A scaffold structure of any of the preceding claims 75 through 84 wherein the scaffold has an ultimate stress of approximately between 2.5 MPa and 30 MPa.
90. A scaffold structure of any of the preceding claims 75 through 84 wherein the scaffold has a yield stress of approximately between 2.5 MPa and 30 MPa.
91 . A scaffold structure of any of the preceding claims 75 through 84 wherein the scaffold has a modulus of approximately between 2.5 MPa and 70 MPa, wherein modulus defines stress divided by strain of a cross-sectional area of the scaffold, including the void space.
92. A scaffold structure of any of the preceding claims 75 through 84 wherein the scaffold has a modulus of approximately between 150 MPa and 600 MPa, wherein
76
modulus defines stress divided by strain of bulk material from which the scaffold is comprised, excluding the void space.
93. A scaffold structure of any of preceding claims 75 through 84 wherein the scaffold may have a stiffness of approximately between 2.5 N/mm and 250 N/mm.
94. A scaffold structure of any of preceding claims 75 through 84 wherein the scaffold has an ultimate strain of approximately between 20% and 70%.
95. A scaffold structure of any of preceding claims 75 through 84 wherein the scaffold has a tenacity between approximately 0.07 grams-force/denier and 1.10 grams- force/denier.
96. A scaffold of any of the preceding claims 75 through 84 wherein the scaffold has a tenacity at failure of approximately between 0.3 grams-force/denier and 2 grams- force/denier.
97. A scaffold of any of the preceding claims 75 through 84 at least part of the wherein at least part of the scaffold is coated with a hydrophilic solution.
98. A scaffold of claim 97 wherein the hydrophilic solution comprises Polyethylene glycol (PEG).
99. A scaffold of claim 97 wherein the scaffold comprises monofilament, multifilament, or textured yarns, or any combination thereof, knitted into a three- dimensional structure.
100. A scaffold of any of the preceding claims 75 through 84 wherein the scaffold comprises any combination of bioresorbable polymers, natural polymers and/or additives.
101. The scaffold of claim 100 wherein the scaffold comprises any of homopolymers, copolymers, or polymer blends of any of the following: polylactic acid, polyglycolic acid, polycaprolactone, polydioxanone, polyhydroxyalkanoates, polyanhydrides, poly(ortho esters), polyphosphazenes, poly (amino acids),
77
polyalkylcyanoacrylates, polypropylene fumarate, trimethylene carbonate, poly(glycerol sebacate), poly(glyconate), poly(ethylene glycol), poly(vinyl alcohol) and polyurethane, or any combination thereof.
102. A scaffold structure of any of preceding claims 75 through 84 wherein the composite scaffold may have a cross sectional area of approximately between 3 mm2 and 3000 mm2 wherein the cross sectional area defines an area of a two-dimensional shape of the scaffold at a point perpendicular to the length of the scaffold, and wherein the wherein the cross-sectional area changes less than approximately 10% at a elongation percentage of 5%.
103. A scaffold comprising: a three-dimensional support structure having a length dimension defined by first and second ends thereof and a thickness dimension, normal to the length dimension, defined by first and second outer layers separated by a space, and a plurality of spacer elements extending through the space and connecting the first and second outer layers; wherein the void space surface area to measurable volume is between approximately 500 cm2/cm3 and 7,000 cm2/cm3
104. A composite scaffold comprising: a microporous matrix having a multitude of interconnected pores collectively defining void space opening to an exterior surface of the microporous matrix; and a structure supporting the microporous matrix; wherein the composite scaffold has a density of approximately between 0.05 g/cc and 0.75 g/cc, wherein the density is defined as the mass per unit volume of the composite scaffold.
105. The composite scaffold of claim 104 wherein the composite scaffold has a density of approximately between 0.10 g/cc and 0.50 g/cc.
106. The composite scaffold of claim 104 wherein the composite scaffold a density of approximately between 0.15 g/cc and 0.25 g/cc.
78
107. A composite scaffold comprising: a three-dimensional support structure having a length dimension defined by first and second ends thereof and defined by first and second outer layers separated by an interior space, a plurality of spacer elements extending through the space and connecting the first and second outer layers; a microporous matrix disposed in the interior space and having a multitude of interconnected pores collectively defining void space between first and second ends of the support structure.
108. The composite scaffold of claim 107 wherein at least approximately 60% of the void space comprises pores having a size dimension of at least 10 pm or greater.
109. The composite scaffold of claim 107 wherein a volume of the void space is between approximately 3.0 cm3/gram and 9.0 cm3/gram.
110. A composite scaffold of any of the preceding claims 104 through 109 wherein composite scaffold may have a cross sectional area of approximately between 3 mm2 and 250 mm2, and wherein the cross-sectional area changes less than approximately 17% at a strain percentage of 13%.
111. The composite scaffold of claim 107 wherein a surface area of the composite scaffold is between approximately 0.3 m2/gram and 1.5 m2/gram.
112. A composite scaffold comprising: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space; and a structure supporting the microporous matrix; the composite scaffold having a substantially rectangular cross-section defined by exterior sides, and wherein a plurality of the interconnected pores proximate one of the exterior sides have a largest dimension oriented to the one exterior side.
79
113. The composite scaffold of claim 112 wherein the plurality of the interconnected pores have a largest dimension oriented between approximately between 45° and 135° relative to the one exterior side.
114. The composite scaffold of claim 112 wherein the plurality of the interconnected pores have a largest dimension oriented between approximately between 60° and 120° relative to the one exterior side.
115. The composite scaffold of claim 112 wherein the plurality of the interconnected pores have a largest dimension oriented between approximately between 75° and 105° relative to the one exterior side.
116. A composite scaffold of any of the preceding claims 104 through 112 wherein the composite scaffold has an ultimate strain of between approximately 0.2 and 1.25.
117. A composite scaffold comprising: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space; and a structure supporting the microporous matrix; wherein the volume of the void space is between approximately 3.0 cm3/gram and 9.0 cm3/gram.
118. The composite scaffold of claim 117 wherein the volume of void space is between approximately 3.5 cm3/gram and 7.0 cm3/gram.
119. The composite scaffold of claim 117 wherein the volume of void space is between approximately 4.0 cm3/gram and 5.0 cm3/gram.
120. A composite scaffold of any of the preceding claims 104 through 112 wherein the composite scaffold has an ultimate stress of approximately between 2.5 MPa and 30 MPa.
80
121. A composite scaffold of any of the preceding claims 104 through 112 wherein the composite scaffold has an yield stress of approximately between 2.5 MPa and 30 MPa.
122. A composite scaffold of any of the preceding claims 104 through 112 wherein the composite scaffold has a modulus of approximately between 2.5 MPa and 70 MPa, wherein modulus is calculated using a cross-sectional area of material comprising the composite scaffold and the void space.
123. A composite scaffold of any of the preceding claims 104 through 112 wherein the composite scaffold has a modulus of approximately between 150 MPa and 600 MPa, wherein modulus is calculated using a cross-sectional area of only material comprising the composite scaffold.
124. The composite scaffold of any of the preceding claims 104 through 119 wherein the structure supporting the microporous matrix comprises a three-dimensional textile structure.
125. The composite scaffold of any of the preceding claims 104 through 119 wherein the microporous matrix comprises any of a sponge, foam, or textured fibers or yarns, or any combination thereof.
126. The composite scaffold of claim 125 wherein the microporous matrix comprises any of a freeze-dried sponge, open cell extrusion foam, particulate leached sponge, or any combination thereof.
127. The composite scaffold of claim 125 wherein the microporous matrix comprises any of a sponge, foam, or textured fibers or yarns, or any combination thereof disposed within the scaffold by any of knitting, weaving, lyophilization, particulate leaching, open cell extrusion, solvent casting, solid-state foaming, and cross-linking.
128. The composite scaffold of any of the preceding claims 104 through 119 wherein the microporous matrix comprises one of collagen and hydrogel.
81
129. The composite scaffold of claims 104 through 119 wherein the scaffold comprises monofilament, multifilament, or textured yarns, or any combination thereof, knitted into a three-dimensional structure.
130. The composite scaffold claims 104 through 119 wherein the scaffold comprises any combination of synthetic bioresorbable polymers, natural polymers and/or additives.
131. The composite scaffold of claim 130 wherein the scaffold comprises any of homopolymers, copolymers, or polymer blends of any of the following: polylactic acid, polyglycolic acid, polycaprolactone, polydioxanone, polyhydroxyalkanoates, polyanhydrides, poly(ortho esters), polyphosphazenes, poly (amino acids), polyalkylcyanoacrylates, polypropylene fumarate, trimethylene carbonate, poly(glycerol sebacate), poly(glyconate), poly(ethylene glycol), poly(vinyl alcohol) and polyurethane, or any combination thereof.
132. A composite scaffold occupying a measurable volume and comprising: a microporous matrix having a multitude of interconnected pores collectively defining void space having a surface area; and a structure supporting the microporous matrix; wherein the void space surface area to measurable volume is between approximately 5,000 cm2/cm3and 16,000 cm2/cm3
133. The composite scaffold of claim 132 wherein the void space surface area to measurable volume is between approximately 7,000 cm2/cm3 and 14,000 cm2/cm3.
134. The composite scaffold of claim 132 wherein the void space surface area to measurable volume is between approximately 9,000 cm2/cm3 and 12,000 cm2/cm3.
135. A method of ligament or tendon injury repair with a composite scaffold comprising:
A) providing a composite scaffold comprising:
82
i) first and second layers spaced apart to define an interior space therebetween and a plurality of spacer elements extending through the interior space and attached to the first and second layers; and ii) a microporous matrix having a multitude of interconnected pores disposed within the interior space, and
B) pre-tensioning the composite scaffold along a length dimension thereof;
C) attaching the composite scaffold to an allograft or autograft tendon or a damaged or torn ligament or tendon.
136. A method of making a composite scaffold comprising:
A) constructing a three-dimensional support structure extending along a length dimension between first and second ends thereof and defining an interior surface within the support structure; and
B) forming a microporous matrix within the interior surface, the microporous matrix having a multitude of interconnected pores in fluid communication with exterior surfaces of the support structure, wherein a plurality of the interconnected pores are oriented relative to the dimensional characteristics of the support structure.
137. The method of claim 136 wherein the plurality of interconnected pores are oriented radially inward into the interior space from exterior surfaces of the support structure.
138. The method of claim 136 wherein the plurality of interconnected pores are oriented towards the length dimension of the support structure.
139. The method of claim 136 wherein the support structure has an exterior profile and B) comprises:
B1) disposing the support structure into a solution filled mold having a cross- sectional profile which at least partially mimics the exterior profile of the support structure, and
B2) changing the temperature of the mold to cause crystallization of the solution within the interior space of the support structure.
83
140. The method of claim 136 further comprising:
C) at least partially covering the support structure with a hydrophilic substance.
141. The method of claim 136 wherein A) comprises:
A1) knitting a scaffold comprising first and second layers spaced apart to define an interior space therebetween but attached together by a plurality of spacer elements extending through the interior space.
142. The method of claim 140 wherein at least partially covering the three- dimensional support structure with a hydrophilic substance occurs before disposing a microporous matrix within the interior space.
143. The method of claim 140 wherein the hydrophilic substance at least partially comprises polyethylene glycol (PEG).
144. The method of claim two wherein the microporous matrix comprises one of collagen and hydrogel.
145. The method of claim 136 wherein the support structure comprises a scaffold comprises any combination of synthetic bioresorbable polymers, natural polymers and/or additives.
146. The method of claim 145 wherein the scaffold comprises monofilament, multifilament, or multifilament and textured yarns, or any combination thereof, knitted into a three-dimensional structure.
147. The method of claim 136 wherein the microporous matrix comprises any of a sponge, foam, or textured fibers or yarns, or any combination thereof.
148. The method of claim 136 wherein the microporous matrix comprises any of a freeze-dried sponge, open cell extrusion foam, particulate leached sponge, or any combination thereof.
84
149. The biomimetic scaffold of claim 136 wherein B) comprises forming a microporous matrix by any of lyophilization, particulate leaching, open cell extrusion, solvent casting, solid-state foaming, and cross-linking.
150. A composite scaffold comprising: a support structure having an exterior profile defining an interior space and extending along a length dimension between first and second ends thereof a microporous matrix disposed within the interior space having a multitude of interconnected pores opening exteriorly of the support structure; wherein a plurality of the interconnected pores are oriented relative to the dimensional characteristics of the support structure.
151. The composite scaffold of claim 150 wherein the plurality of interconnected pores are oriented radially inward into the interior space from exterior surfaces of the support structure.
152. The composite scaffold of claim 150 wherein the plurality of interconnected pores are oriented towards the length dimension of the support structure.
153. The composite scaffold of claim 150 wherein the support structure has a substantially rectangular shaped cross-sectional exterior profile.
154. The composite scaffold of claim 150 wherein the support structure has a substantially circular shaped cross-sectional exterior profile.
155. A composite scaffold of any of preceding claims 1 through 29 wherein the scaffold has a yield force of approximately between approximately between 20 N and 270 N.
156. A composite scaffold of any of the preceding claims 1 through 29 wherein the scaffold has an ultimate load approximately between 100 N and 600 N.
157. A composite scaffold of any of preceding claims 1 through 29 wherein the scaffold may have a stiffness of approximately between 2.5 N/mm and 85 N/mm.
85
158. A composite scaffold of any of the preceding claims 1 through 29 wherein the composite scaffold has a modulus of approximately between 140 MPa and 600 MPa, wherein modulus defines stress divided by strain of bulk material from which the composite scaffold is comprised, excluding the void space.
159. A composite scaffold of any of the preceding claims 1 through 29 wherein the support structure has a generally geometric shape comprising any of a conical, tubular, rounded, tapered or rectangular shape.
160. A composite scaffold of any of the preceding claims 1 through 29 wherein the support structure has a shape that generally mimics a shape of an anatomical structure.
161. A method of making a composite scaffold comprising:
A) constructing a three-dimensional support structure defining an interior surface within the support structure;
B) modifying the three-dimensional support structure, and
C) forming a microporous matrix within the interior surface.
162. The method of claim 161 wherein (A) comprises constructing the three- dimensional support structure by an additive manufacturing method.
163. The method of claim 162 wherein the three-dimensional support structure comprises one or more polymers and wherein the additive manufacturing method comprises injection molding of a polymer support structure.
164. The method of claim 162 wherein the additive manufacturing method comprises three dimensional printing of a support structure.
165. The method of claim 161 wherein the three-dimensional support structure comprises one or more polymers and (B) comprises dimensionally or mechanically manipulating the support structure to align the polymer in the support structure to improve any of a stiffness, yield point, or ultimate strength behavioral characteristics thereof.
166. The method of claim 161 wherein (C) comprises forming a microporous matrix by an additive manufacturing method.
86
167. The method of claim 166 wherein the additive manufacturing method comprises three dimensional printing of the microporous matrix.
168. The method of claim 161 wherein (A) comprises constructing the three- dimensional support structure by an additive manufacturing method and (C) comprises forming a microporous matrix by an additive manufacturing method.
169. The method of claim 168 wherein one of (A) and (C) comprises utilizing an additive manufacturing method comprising any of Injection Molding, Micro Molding, Stereolithography (SLA), Selective Laser Sintering (SLS), Fused Deposition Modeling (FDM), Digital Light Process (DLP), Multi Jet Fusion (MJF, Material Jetting (MJ), Direct Metal Laser Sintering (DMLS), Electron Beam Melting (EBM), and Drop on Demand (DOD) methods.
170. The method of claim 161 wherein constructing the three-dimensional support structure and forming a microporous matrix are not performed substantially simultaneously.
171. The method of claim 161 wherein the three-dimensional support structure and the microporous matrix comprise substantially different materials.
172. The method of claim 161 wherein the three-dimensional support structure has a generally geometric shape comprising any of a conical, tubular, rounded, or rectangular shape.
173. The method of claim 161 wherein the three-dimensional support structure has a generally tapered shape.
174. The method of claim 1 wherein the three-dimensional support structure has a shape that generally mimics a shape of an anatomical structure.
175. A method of making a composite scaffold comprising:
A) constructing a three-dimensional support structure defining an interior surface within the support structure;
B) modifying the three-dimensional support structure to improve a behavioral characteristics thereof, and
87
C) forming a microporous matrix within the interior surface.
176. The method of claim 175 wherein the three-dimensional support structure comprises one or more polymers and (B) comprises dimensionally or mechanically manipulating the support structure to align the polymer in the support structure.
177. The method of claim 175 wherein the behavioral characteristics of the support structure comprises any of a stiffness, yield point, or ultimate strength behavioral characteristics thereof.
178. A method of making a composite scaffold comprising:
A) constructing a three-dimensional support structure defining both an exterior support matrix and a microporous matrix interiorly of the exterior support matrix; and
B) modifying the three-dimensional support structure to improve a behavioral characteristics thereof.
179. The method of claim 178 wherein the three-dimensional support structure comprises one or more polymers and (B) comprises dimensionally or mechanically manipulating the support structure to align the polymer in the support structure.
180. The method of claim 178 wherein the behavioral characteristics of the support structure comprises any of a stiffness, yield point, or ultimate strength behavioral characteristics thereof.
181. The method of claim 178 wherein the three-dimensional support structure has a generally geometric shape comprising any of a conical, tubular, rounded, or rectangular shape.
182. The method of claim 178 wherein (A) comprises constructing the three- dimensional support structure by one of an additive manufacturing method and injection molding.
183. The method of claim 178 wherein (A) comprises constructing the three- dimensional support structure by any of an additive manufacturing, Injection Molding, Micro Molding, Stereolithography (SLA), Selective Laser Sintering (SLS), Fused Deposition Modeling (FDM), Digital Light Process (DLP), Multi Jet Fusion (MJF, Material
88
Jetting (MJ), Direct Metal Laser Sintering (DMLS), Electron Beam Melting (EBM), and Drop on Demand (DOD).
184. A composite scaffold comprising: a microporous matrix having a multitude of interconnected pores opening to an exterior surface of the microporous matrix and collectively defining void space; and a three dimensional structure supporting the microporous matrix; wherein at least a portion of the three dimensional structure extends through the microporous matrix.
185. The composite scaffold of claim 184 wherein the three dimensional structure supporting the microporous matrix has any of a generally geometric shape comprising any of a conical, tubular, rounded, tapered or rectangular shape.
186. The composite scaffold of claim 184 wherein the support structure has a shape that generally mimics a shape of an anatomical structure.
89
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063060453P | 2020-08-03 | 2020-08-03 | |
PCT/US2021/044354 WO2022031709A1 (en) | 2020-08-03 | 2021-08-03 | Composite scaffold for the repair, reconstruction, and regeneration of soft tissues |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4188469A1 true EP4188469A1 (en) | 2023-06-07 |
Family
ID=80118488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21854425.2A Pending EP4188469A1 (en) | 2020-08-03 | 2021-08-03 | Composite scaffold for the repair, reconstruction, and regeneration of soft tissues |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4188469A1 (en) |
AU (1) | AU2021322190A1 (en) |
CA (1) | CA3187896A1 (en) |
IL (1) | IL300329A (en) |
WO (1) | WO2022031709A1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5653418B2 (en) * | 2009-05-22 | 2015-01-14 | ソフト ティシュー リジェネレイション, インコーポレイテッド | Mechanically responsive scaffold for ligament and tendon regeneration |
CA2767714C (en) * | 2009-07-10 | 2017-09-26 | Bio2 Technologies, Inc. | Resorbable three-dimensional tissue scaffold fabricated from bioactive glass fibers bonded by bioactive glass |
US8535388B2 (en) * | 2011-11-23 | 2013-09-17 | Timothy Ganey | Bone graft |
US20170273775A1 (en) * | 2016-03-25 | 2017-09-28 | Biorez, Inc. | Complex braided scaffolds for improved tissue regeneration |
-
2021
- 2021-08-03 AU AU2021322190A patent/AU2021322190A1/en active Pending
- 2021-08-03 CA CA3187896A patent/CA3187896A1/en active Pending
- 2021-08-03 EP EP21854425.2A patent/EP4188469A1/en active Pending
- 2021-08-03 IL IL300329A patent/IL300329A/en unknown
- 2021-08-03 WO PCT/US2021/044354 patent/WO2022031709A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2022031709A1 (en) | 2022-02-10 |
AU2021322190A1 (en) | 2023-03-02 |
IL300329A (en) | 2023-04-01 |
CA3187896A1 (en) | 2022-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11622847B2 (en) | Composite scaffold for the repair, reconstruction, and regeneration of soft tissues | |
US20210161645A1 (en) | Composite scaffold for the repair, reconstruction, and regeneration of soft tissues | |
CN103590177B (en) | The method manufacturing the mesh grid for prosthetic appliance | |
McCullen et al. | Fiber-reinforced scaffolds for tissue engineering and regenerative medicine: use of traditional textile substrates to nanofibrous arrays | |
EP0751751A1 (en) | Three-dimensional bioremodelable collagen fabrics | |
EP4188469A1 (en) | Composite scaffold for the repair, reconstruction, and regeneration of soft tissues | |
MXPA96003990A (en) | Bio remodelable collagen fabrics, three-dimensional |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230228 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |